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INTRODUCTION TO ACCESS,
COST, AND QUALITY
The United States healthcare system is complex and sometimes controversial. Despite
attempts to improve quality of healthcare and access to it, costs in the United States (US) are
high and continuing to rise. Projections suggest US health expenditures could exceed $4
trillion by the year 2020, or approximately 20% of the US gross domestic product.1
Conservative models have estimated that waste accounted for nearly 20% of total US
expenditures in 2011, or approximately $500 billion.2 Despite spending more than other
countries on healthcare, the US falls short on improving overall health and wellbeing as a
nation.
A 2017 study by the Commonwealth Fund ranked the US last (11th out of 11) in overall health
care among other industrialized countries. Despite spending the most per capita, the US
ranked 5th in care process, 10th in administrative equity and last 11th in access, equity, and
health care outcomes.3 A 2016 report by the Centers for Medicare and Medicaid Services
(CMS) showed that the annual National Healthcare Expenditures (NHE) for the year reached
$3.3 trillion dollars, an average of over $10,300 per person.4 The CMS report also shows that
the US had spent 17.9% of its gross domestic product (GDP) on healthcare in 2016, which far
exceeds the amount spent by any other country in the world.4 The following chapters will
discuss how cost, access, and quality are impacted in interactions between patients, payers,
and providers.
Access, cost, and quality are three major factors used to evaluate healthcare systems.5
Countries maintaining a good balance between these components have more effective
healthcare systems. Optimizing the balance can be difficult because changes or
improvements to one may come at the expense of the others.
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SECTION 1
ACCESS
Access to care is fundamental in allowing patients to achieve successful outcomes. Access
may be defined as reaching necessary providers and being able to pay for the care needed.
Patient-centered medical homes (PCMH) and neighborhoods focus on the needs of patients
as a central component to delivery of care. This may include multidisciplinary team-based
care, email communication directly with providers, and flexibility through extended hours or
seven-days a week appointment options. PCMH provide key components for coordination of
patient care and are usually a component of Accountable Care Organizations (ACOs)
discussed in Section 2.
Providers must be prepared for patient-centered collaborative care. Successful patient
outcomes must be achieved regardless of the patient’s health literacy, health status, and
socioeconomic considerations. Studies have shown that a positive relationship exists
between health literacy levels and an individual’s knowledge of available health services and
payment, and results in improved overall health outcomes.1 Individuals who understand their
payer coverage are more likely to successfully navigate their financial benefits. Providers,
including pharmacists, can help bridge the literacy gaps that may exist between patients and
payers.
Pharmacists can clinically and financially assist patients with low health literacy.
Community pharmacists are an easily accessible source of clinical knowledge. They may
assist patients transition home after an inpatient stay, including navigating new providers
and understanding the care necessary for a new diagnosis. The ability to consider the
economic, social and cultural issues of the patient population they serve will likely increase
pharmacists’ success and satisfaction with their profession.
Ultimately, pharmacists have the clinical knowledge to meet heightened demands for
patient-centered care and contribute to the growing need for access, cost, and quality-minded
health care providers. They will have interactions with different types of providers. These
interactions range from providing education, recommending drug therapy, or answering
questions. In general, interactions are for the ultimate benefit of the patients and are aimed
at improving patient care.
3
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CHAPTER 1
WHO PROVIDES THE CARE?
Author: Trish Devine PharmD
A multitude of healthcare professionals provide patient care. With nearly 18 million workers,
healthcare providers/professionals are considered among the largest groups of employees in
the US and they comprise the fastest growing sector of the US economy.1 Furthermore, they
constitute one of the most gifted, well-educated, highly-compensated, and diverse groups of
employees in the nation.2 In this section, the similarities and differences between the most
frequently encountered healthcare professionals will be covered. While many of these
providers have traditionally been considered providers of either inpatient or outpatient care;
however, many provide direct patient care in both settings.
PHYSICIANS
Physicians are at the center of the healthcare setting and play one of the biggest roles in
providing care to patients.1 Physicians diagnose conditions, examine patients, order and
evaluate diagnostic tests, and prescribe medications.3 Physicians must complete many steps
in their training in order to practice. First, they must graduate from an accredited medical
school with either a Doctor of Medicine (MD) or Doctor of Osteopathic Medicine (DO) degree.
Most complete at least four years of undergraduate study then complete four additional years
of medical school to earn this degree. After completing their degree, prospective physicians
complete a residency where they gain on-the-job training and may become specialized in
certain areas. These residencies typically take between three and eight years.1 After they
complete the residency, physicians then take an examination to become licensed to provide
direct patient care in a particular state.1
There are many different types of physicians. Generally, physicians are categorized as MDs
or DOs. MDs practice allopathic medicine, which focuses on using medical treatment as
active intervention to treat and counter an illness or disease.2 Most MDs are specialists in one
particular area, such as cardiology, emergency medicine, oncology, surgery, or urology. DOs
practice osteopathic medicine, which focuses on preventative measures and treating the
whole patient with a special emphasis on the musculoskeletal system of the body.4 Most DOs
are primary care providers (also known as “generalists”), which means they practice family
medicine, general medicine, general internal medicine, or general pediatric medicine.2
5

Psychiatrists and ophthalmologists are medical doctors (MD or DO) who are sometimes
confused with psychologist and optometrist respectively. Psychiatrists specialize in mental
health, including substance use disorders, are qualified to assess both the mental and physical
aspects of psychological problems and can prescribe medication for treatment. Clinical
psychologist have a masters or doctorate degree in psychology and specialize in emotional
and behavior mental health diseases. In most states, they are only allowed to use talk therapy
as treatment. A few states allow psychologists to prescribe some psychiatric medications if
they have met the required training.5 Patients must be seen by a psychiatrist or other medical
doctor to receive medication treatment. Ophthalmologists are medical doctors who
specialize in eye and vision care whereas optometrist complete an undergraduate degree and
four years at a college of optometry obtaining a doctor of optometry (OD) degree. The scope
of practice varies by state but in general an optometrist are licensed to provide primary vision
care, nonsurgical management of eye diseases including medication treatment.6
DENTISTS
Dentistry is a branch of medicine that is involved with the study, diagnosis, prevention, and
treatment of diseases, disorders, and conditions of the oral cavity and structures in the jaw
area. Dentists are doctors specializing in oral health who have earned either a Doctor of
Dental Medicine (DMD) degree or a Doctor of Dental Surgery (DDS) degree. Dentists
primarily work in private outpatient practice but some work in the inpatient setting.7
PHYSICIAN ASSISTANTS
Another important component of the inpatient care team is the physician assistant (PA). PAs
must be associated with and practice under the direction of a physician. The supervision does
not need to be direct and the physician may either be on or off site.1,8 They may examine
patients, diagnose illnesses and injuries, and prescribe medications according to the laws of
the state where they practice. Most PAs complete two to three years of training and receive a
master’s degree.2 After completing a PA program, a PA must become licensed in order to
practice. PAs become certified (PA-C) by passing a national certifying examination and are
licensed in the state which they practice.3,9
NURSES
Often considered the front line of inpatient care, nurses are the largest group of healthcare
professionals.9 There are many different types of nurses and the level of care they can deliver
depends on their degree. The first type of nurse is a Licensed Practical Nurse (LPN). These
nurses provide for the basic needs of patients and are asked to take vital signs (such as blood
6

pressure, heart rate, pulse, etc.), assist with activities of daily living (ADLs), make
observations, and keep records. They typically have a high school diploma, followed by
completion of a one year nursing program and passage of a state licensing exam.1
Another type of nurse is a registered nurse (RN). RNs must also be licensed in the state in
which they provide care and obtain their level in one of three ways: a 2-3 year hospital diploma
program, a 2-3 year associate’s degree in nursing (ADN) from a community college, or a 4 year
Bachelor of Science degree in nursing (BSN) from a college or university. After becoming
licensed and depending on their level of practice and expertise, nurses may do all or any of the
following: administer medications, record progression of a patient’s condition, provide
patient education, perform medical procedures, and assist physicians.9
Nurses can specialize in specific fields of nursing. It may take more schooling or training
depending on the speciality. Some of the areas of speciality include but not limited to:
neonatal, critical care, dialysis, pain management and pediatric nursing.10
ADVANCED PRACTICE NURSES
If a registered nurse decides to receive advanced training and education beyond the level of
an RN, they may become an advanced practice nurse (APN).1 There are four different types of
APNs: nurse practitioner (NP), clinical nurse specialist (CNS), certified nurse midwife
(CNM), and certified nurse anesthetist (CNA). APNs, as outlined by state laws, are typically
allowed to provide direct patient care and often serve as an intermediary between doctors and
RNs.8
Comprising the largest group of the APNs, nurse practitioners (NPs) are registered nurses
who obtain a master of science in nursing (MSN) degree.1 Working closely with physicians
under collaborative practice agreements but not necessarily always under their direct
supervision, NPs can do many things that a physician can do.8 These duties include
evaluating patients, diagnosing and treating common conditions, providing patient education
and resources, and prescribing most types of medications depending on the laws in their
respective states.2,8 Along with becoming certified (NP-C), nurse practitioners can also
specialize in certain areas, including geriatrics, pediatrics, or family care. NPs and PAs are
often favorably viewed by patients due to their increased accessibility and amount of time
they spend with their patients. Both NPs and PAs are cost-effective alternatives to physicians
in regards to treating common conditions and educating patients about different disease
states.1
7

MEDICAL ASSISTANTS
Some of the fastest growing healthcare-related occupations are the medical assistant (MA),
certified medical assistant (CMA) and registered medical assistant (RMA).11 MAs are
normally found on the “front lines” of physicians’ offices and routinely perform
administrative tasks including scheduling appointments, greeting patients, answering phone
calls, ordering supplies, and filing medical records. Some may also assist the healthcare
professional with clinical duties, such as preparing patients for surgery/examination,
recording vital signs, taking medication histories, collecting and preparing lab specimens,
and calling prescriptions into pharmacies. MAs may receive formal training by attending
vocational-technical high schools or community colleges. Others may attend colleges or
universities where they receive either a one-year certificate or a two-year associate’s degree.
Still others may have a high school degree or equivalent and receive on-the-job training.
A medical assistant may become certified by passing a national exam. Medical assistants have
quickly become crucial members of healthcare teams and their roles are expected to expand
with the proliferation of physician’s offices.11
PHARMACISTS
Pharmacists are the health professional most accessible to the public. They have been
traditionally perceived as engaged only in the community setting, dispensing medications,
counseling patients, and providing medical advice and expertise. However, pharmacists have
also been working in hospitals, nursing homes, medical industries and other settings for many
years. Roles of the pharmacists have evolved over the years to provide high quality care for
patients and the general public. Pharmacists work closely with other members of medical
teams to enhance patient care, making drug recommendations based on evidence-based
medicine and therapeutic guidelines, monitoring lab results and patient-specific responses
to therapies, and educating patients and their families on disease states and their
medications.12 Pharmacists also participate in health promotion through health-related
campaigns, community group education, and health fairs.12
All pharmacists, regardless of setting, must receive a doctor of pharmacy (PharmD) degree
from an accredited institution and licensed in their state to practice pharmacy.13 After
graduation, a prospective pharmacist gains licensure by successfully completing the North
American Pharmacist Licensure Examination (NAPLEX) and the Multistate Pharmacy
Jurisprudence Exam (MPJE) or an equivalent state-level law exam.8
After receiving licensure, pharmacists may pursue residency programs. Residents are
8

exposed to different facets of practice and learn about the many career paths available to
pharmacists today. During a one-year residency (Post-Graduate Year 1 or PGY1), pharmacy
residents are generally trained in a variety of areas within the residency setting. Most
pharmacy residency programs are hospital based; however, there is an increasing number of
residency opportunities in community and managed care areas. Usually a second year of a
residency program (Post-Graduate Year 2 or PGY2) is specialized in a certain area, such as
pediatrics, ambulatory care, critical care, infectious diseases, cardiology, and many others.8
In addition to residencies, pharmacists can obtain disease-specific multidisciplinary
certification. Pharmacists can voluntarily become certified in certain disease states, such as
diabetes, asthma, anticoagulation, and dyslipidemia.12 For example, a pharmacist can become
a “Certified Diabetes Educator” in order to help diabetic patients learn about and understand
their condition, as well as help them to manage the condition and their medications.
Certifications can be obtained through national programs that involves didactic, professional
diabetes patient experience and exams. This type of certification is also available to other
healthcare professionals.
More specifically, pharmacists can become board-certified in a specialty practice area of
pharmacy through The Board of Pharmacy Specialties’ (BPS) post-licensure certification
program. BPS board certification is considered the gold standard when it comes to
determining a pharmacist’s qualifications and capabilities within a specialty area. The BPS
currently offers eight distinct specialty areas, including: Ambulatory Care, Critical Care,
Nuclear, Nutrition Support, Oncology, Pediatric, Pharmacotherapy, and Psychiatric
pharmacy.14 Pharmacists must practice at least three to four years in the speciality area and
pass a speciality certification examination to become a board-certified pharmacy specialist
(BCPS) and must be recertified every seven years.15 Becoming BPS board certified enables
pharmacists affirm their knowledge and skills to provide more comprehensive patient care in
a specific area, be recognized for their expertise by other healthcare professional, employers,
patients and insurers. With more opportunities to provide direct patient care in inpatient and
outpatient settings, pharmacists are seeing their roles expanding and are moving closer to
being recognized as providers rather than just “drug experts.”
ALLIED HEALTH PROFESSIONALS
An allied health professional is someone who has received special training and earned a
certification or degree in a science related to healthcare and has responsibility for the delivery
of health or related services. This does not include anyone who has received a degree in
medicine, dentistry, veterinary medicine, optometry, podiatry, chiropractic, pharmacy,
9

psychology, or equivalent. Allied health professionals can be divided into two categories:
technicians/assistants and therapists/technologists. Technicians and assistants generally
receive less than two years of postsecondary education and require supervision. Examples are
physical therapy assistants, medical laboratory technicians and respiratory therapy
technicians. Therapists and technologists receive more advanced training and education and
are responsible for evaluation, diagnosis and development of treatment plans and can
practice independently from a physician in some states.16
Therapists & Technologists
Occupational therapists (OTs) work with individuals who have conditions that are mentally,
physically, emotionally or developmentally disabling. A master’s degree is the typical
minimum requirement for entry into this field.17
Physical therapists (PTs) help injured or ill people improve their movement and manage their
pain. These therapists are often an important part of the rehabilitation and treatment of
patients with chronic conditions, illnesses, or injuries. A Doctor of Physical Therapy (DPT)
degree and license is required to practice. 17
Respiratory therapists (RTs) care for patients who have trouble breathing, from a chronic
respiratory disease, such as asthma or emphysema, or emergency care, such as heart attack or
drowning. Patients range from premature infants with undeveloped lungs to elderly patients
with diseased lungs. Respiratory therapists typically need an associate’s degree, though some
have bachelor’s degrees, and a state license is required in all states except Alaska. 17
Speech therapists or pathologists assess, diagnose, treat, and help to prevent communication
and swallowing disorders in patients. Speech, language, and swallowing disorders result from
a variety of causes, such as a stroke, brain injury, hearing loss, developmental delay,
Parkinson’s disease, cleft palate, or autism. Speech-language pathologists typically need at
least a master’s degree and must be licensed in most states. 17
Audiologists diagnose, manage, and treat a patient’s hearing, balance, or ear problems.
Audiologists need a doctoral degree and all states require a license. 17
Dietitians and nutritionists are experts in the use of food and nutrition to promote health and
manage disease. They advise people on what to eat to lead a healthy lifestyle or achieve a
specific health-related goal. Most dietitians and nutritionists have a bachelor’s degree and
have completed supervised training through an internship. Many states require dietitians
and nutritionists to be licensed. 17
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Social workers help people solve and cope with problems in their everyday lives. Social
workers may work with children, people with disabilities, and people with serious illnesses.
Their work varies based on the type of client. There are child and family, clinical, school,
healthcare, and mental health social workers. Social workers assess clients’ situations, and
support networks to determine their needs. They help clients adjust to changes and
challenges in their lives, such as illness, divorce, or unemployment by providing community
resources, such as food stamps, child care, and healthcare to assist and improve a client’s
well-being. Most social workers need a bachelor’s degree in social work, while clinical social
workers must have a master’s degree and 2 years of post-master’s experience in a supervised
clinical setting. Clinical social workers must also be licensed in the state in which they
practice.18
Counselors provide support and advice to people. There are many different kinds of
counselors, including substance abuse and behavioral disorder counselors who advise people
suffering from alcoholism, drug addiction, eating disorders, or other behavioral problems.
Genetic counselors assess individual or family risk for a variety of inherited conditions. They
provide information and support to other healthcare providers or to individuals and families
concerned with the risk of genetic disorder and birth defects. Most positions require a
bachelor’s degree, though educational requirements can vary from a certification to a
master’s degree depending on the employer. 17
ADVANCED PRACTITIONERS
Centers for Medicare and Medicaid Services (CMS) and the US Department of Justice’s Drug
Enforcement Administration (DEA) use different terminology to identify non-physician
healthcare providers such as nurse practitioners, clinical nurse specialists, and physician
assistants who are authorized to dispense controlled substances by the state in which they
practice. The term “mid-level practitioner” is used by the DEA, while CMS uses “nonphysician practitioner.” There is a movement to change this nomenclature, as the descriptor
“mid-level” does not represent the advanced degrees earned by these health care providers.
Patients may feel they will not receive high quality care if they are seen by a “mid-level or nonphysician practitioner” instead of by an advanced practitioner or their actual degree title.19,20
HOSPITALISTS
Society of Hospital Medicine defines a hospitalist as a physician, nurse practitioner or
physician assistant who is engaged in clinical care, teaching, research, and/or leadership in
the field of hospital medicine. Hospitalists coordinate the care of patients' in hospital. They
11

organize the communication between different providers caring for a patient, and serve as the
point of contact for other doctors and nurses for questions, updates, and provides safe
transitions of care within the hospital and from the hospital to the community. Hospitalist
are the main point person for patients and family members to contact for patient care
questions. 22
CREDENTIALING AND PRIVILEGES
Each medical staff member who provides medical services in a hospital setting and for health
insurance holders must meet the credentialing and privileging standards of a nationally
recognized accrediting/certifying body such as the Joint Commission, the American
Association for Ambulatory Health Care, or the Centers for Medicare and Medicaid
Services. Medical staff includes physicians (MDs and DOs), dentists, physician assistants
and nurse practitioners, and those defined by the hospital’s policies and procedures manual
and bylaws.23
Credentialing is the primary source verification of a healthcare practitioner’s education,
training, work experience, and license. A variety of resources are used to verify this
information, including but not limited to direct communication with educational and
training institutions, past and current hospital affiliations and employers, peer reference
letters, certification boards and licensing agencies.23
Privileging is granting approval for an individual to provide specific aspects of patient care
within a specific institution. Examples of privileges include admitting, prescribing, and
performing procedures. In some instances, healthcare providers may be credentialed,
trained, and licensed to provide certain care but may have their practice limited by the
privileges granted within a hospital.23 For example, a physician assistant specializing in
pediatrics may only be granted privileges to the pediatric unit and would not be able to admit
a patient to other areas of the hospital. Healthcare providers go through similar processes at
all hospitals where they want to practice and each hospital makes an independent decision
regarding privileges.6, 24
INTERPROFESSIONAL EDUCATION AND HEALTH CARE TEAMS
According to the World Health Organization (WHO), “inter-professional education occurs
when students from two or more professions learn about, from, and with each other to enable
effective collaboration and improve health outcomes. Once students understand how to work
inter-professionally, they are ready to enter the workplace as members of the collaborative
practice team. This key step moves health systems from fragmentation to a position of
12

unity.”25
Interprofessional healthcare teams are composed of an array of healthcare professionals who
bring their specialized knowledge, experience and skills to work together to provide optimal
care for patients. Many organizations interprofessional healthcare teams consist of a nurse,
pharmacist, physician, social worker and therapist. Members of an Interprofessional team
communicate and work together, as colleagues, to provide quality, individualized care for
patients.26
In the United States, an Inter-Professional Education Collaborative (IPEC) was formed in
2009, with five health professional associations represented allopathic and osteopathic
medicine, dentistry, nursing, pharmacy, and public health to promote a more consistent
approach to inter-professional education (IPE) and improve population health outcomes. By
2017, fourteen additional health care professional associations became members
representing over 20 professions including podiatry, physical therapy, occupational therapy,
psychological medicine, veterinary medicine, physician assistant, optometry, allied health
and social work.27 IPEC developed four interprofessional collaborative practice competency
domains for future health professionals in training. The four domains with their general
competency statement are:
Values/Ethics for interprofessional Practice- Work with individuals of other professions to
maintain a climate of mutual respect and shared value.
Roles/Responsibilities- Use the knowledge of one’s own role and those of other professions to
appropriately assess and address the healthcare needs of the patients and populations served.
Interprofessional Communication- Communicate with patients, families, communities, and
other health professionals in a responsive and responsible manner that supports a team
approach to the maintenance of health and the treatment of disease.
Teams and Teamwork- Apply relationship-building values and the principles of team
dynamics to perform effectively in different team roles to plan and deliver patient-centered
care that is safe, timely, efficient, effective, and equitable.27
The accreditation council for pharmacy education has included Interprofessional Education
in its Standards. Schools of pharmacy must include IPE in their curriculum for
accreditation.28 In an effort to enhance quality and meet the evolving needs of patients,
interprofessional team based delivery of health care is used.
13

Interprofessional teams’ goal is to provide patient-centered care. There is evidence that
shows including patient preferences into patient care improves outcomes.29
Interprofessional or multi-disciplinary teams have been a part of health care delivery in
hospitals for a long time. Accountable Care Organizations and Patient-Centered Medical
Homes are beginning to utilize interprofessional teams to improve patient care and decrease
health care costs.6 Interprofessional team practice arrangements vary from inpatient to
outpatient teams as well as from patient to patient depending on individual needs. The central
goal of an integrated health care practice is to provide the most effective, accessible, and
efficient care to the patient, based upon clinical and patient-focused outcome measures or
assessments.30

14

GLOSSARY
Medical Provider Credentialing
A detailed process that reviews doctors’ qualifications and career history including their
education, training, residency and licenses, as well as any specialty certificates.
Medical Provider Privileges
Defines a physician's scope of practice and the clinical services he or she may provide.
Patient-Centered Care
Identify, respect, and care about patients’ differences, values, preferences, and expressed
needs; relieve pain and suffering; coordinate continuous care; listen to, clearly inform,
communicate with, and educate patients; share decision-making and management; and
continuously advocate disease prevention, wellness and promotion of healthy lifestyles,
including a focus on population health.
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CHAPTER 2
HEALTHCARE SETTINGS
Author: Carriann Smith, BS, PharmD
Healthcare is provided in a variety of settings usually categorized as inpatient or outpatient.
Table 2-1 displays examples of inpatient and outpatient facilities and more details are
provided in this chapter. Examples of facilities that provide inpatient services include
hospitals and nursing homes. Various facilities that provide outpatient care include
physician offices and urgent care centers.

Healthcare Settings
Inpatient
●
●
●
●
●

Hospitals
Mental institutions
Nursing homes
Long-term acute care facilities
Long-term skilled nursing
facilities
● Inpatient rehabilitation centers

Outpatient
●
●
●
●
●
●
●
●
●

Physicians' offices
Urgent care centers
Emergency departments
Home health agencies
Outpatient surgery centers
Rehabilitation centers
Dialysis centers
Sports medicine clinics
Chemotherapy centers

Table 2-1. Examples of inpatient and outpatient facilities
While these general distinctions exists, a facility may function as an inpatient or outpatient
setting depending on the type of treatment being given and admission status of an individual
patient. For example, inpatient facilities, such as hospitals, may have outpatient offices and
provide outpatient services, such as surgeries, rehabilitation, and ambulatory clinics, without
admittance to the hospital.1 Determining whether someone is admitted as an “inpatient” or
seen at the facility as an “outpatient” impacts how bills will be submitted and paid.
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INPATIENT CARE
Not everyone who goes to the hospital is considered an inpatient. Based on various factors,
such as the prescriber’s judgement of the situation, seriousness of the condition, and medical
necessity for hospital services, the physician will choose whether or not to order admission
for a patient.1 The decision to admit may not be immediate. A patient in a hospital bed may be
considered an observational outpatient (sometimes termed “obs”) to allow physicians time to
run tests and/or make further evaluations before they decide whether to fully admit as an
inpatient or discharge to home or another facility. Patients can only be considered
observational (i.e., outpatient) for less than 24 hours before a decision must be made on
whether they will be admitted. This observation may or may not include an overnight stay and
the observation can occur anywhere in the hospital, including the ED.1
A patient will typically be admitted if the patient is expected to need at least two days of
hospital care that can be provided by the facility.1 If the physician determines that the patient
does not need to be admitted, they will discharge the patient from their care. However, if the
physician has ordered admission, the hospital must then formally accept the order and admit
the patient as an inpatient. Hospitals may only allow physicians to have admitting privileges
excluding other practitioners.2
Types of Institutions
Hospitals
Hospitals are commonly recognized as the provider for acute care services. Hospitals can be
classified in a number of different ways, including type of service provided, ownership, and
average length of stay.3 Type of service includes two main types of hospitals: general and
specialty.3 General hospitals, such as Massachusetts General Hospital, provide a wide range
of services with few limits. These services include surgeries, labor and delivery, and
treatment of most of acute disorders or illnesses. Specialty hospitals, such as Peyton Manning
Children’s Hospital or MD Anderson Cancer Center, focus on specific types of patients or
specific illnesses or diseases.3
There are two primary types of hospital ownership: public and private. Public hospitals may
be owned by the federal, state, or local government.4 The federal government owns and
operates federal hospitals, such as the Veterans Administration (VA).5 The VA consists of
hospitals, clinics, and nursing homes that provide care and services solely for retired United
States armed forces veterans.5 Other examples of federal hospitals and networks include
Indian Health Services, which provides healthcare for Native Americans.4 Facilities owned
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and funded by state governments typically include long-term facilities for psychiatric
patients and those with chemical dependency and addictions. Local governments, such as
counties, also fund and operate hospitals. These hospitals are usually general hospitals that
are open to anyone, regardless of insurance or their ability to pay for care.5 Often thought of
as “safety-net” hospitals, these facilities often focus on providing services to underserved
populations at reduced costs.
Private hospitals typically only provide care to patients who are part of their private network,
except for emergencies.5 Private hospitals are named because of their private source of
funding. They are not government operated and may be either non-profit or for-profit.4,5 Nonprofit hospitals are frequently affiliated with charitable organizations or religious
denominations.4 As a non-profit hospital, the government does not require them to pay taxes.
Profits are reinvested in operating expenses, hospital improvement, or donated to the
community rather than given to shareholders or private investors.3 For-profit hospitals are
owned by private corporations. A portion of their profits are used for operations and making
improvements and some of their profits are disbursed to owners and investors via dividends.3
Hospitals may also be classified by how long patients are expected to stay in the facility.
Short-term hospitals, also known as acute care hospitals, care for their patients for an average
of less than thirty days.6 Patients are admitted for short-term needs, such as routine surgery
or an acute illness like pneumonia, receive the care they need, and are discharged home. Long
term acute care hospitals provide care for patients who need to stay for an average of thirty or
more days.3
Long Term Acute Care Facilities (LTAC)
In the past, patients would stay in a general hospital for their entire acute critical illness
episode, including time needed for recovery.7 With the advent of LTAC facilities, patients
who need additional care are transitioned to these facilities.8 Patients moved to LTAC
facilities typically do not need as much intensive care as they previously received for their
injury or condition from an acute care hospital, but they still have needs for ongoing care that
they cannot receive outside of a facility.7 Some of the services typically offered at LTAC
facilities include respiratory therapy, head trauma treatment, and intensive pain
management.8 With the additional time and care, patients have been shown to have
experienced improvement in their conditions and fewer re-admittances for similar or related
conditions.8 LTAC hospitals have proven to be successful in reducing costs and improving
patient outcomes.
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RS was admitted to an inpatient facility following a serious motor vehicle accident. RS had
damage to several internal organs and is still on a ventilator. He has been transferred to a
LTAC facility until he can be weaned from the ventilator and begin rehabilitation.
Nursing Facilities
Nursing facilities, more commonly known as nursing homes, provides long term nursing care
without the level of medical attention or specialty provided at LTAC facilities.8 This type of
long term care may involve around-the-clock nursing, custodial care or both. Skilled care is
care administered when direct medical attention is needed and provided by a licensed
medical professional in a certified facility. Custodial care may be performed by someone
without professional medical skills either at home or in a facility. Custodial care provides
assistance with activities for daily living (ADLs), like eating and bathing, and not direct
medical treatments.
Inpatient Rehabilitation Centers
Sometimes when patients are past their acute illness they still need functional assistance but
not medical assistance. This functional therapy is provided by occupational therapists,
physical therapists, or speech language pathologists. The goal of these therapies is to assist
the patient in returning to as much of their normal functioning as quickly as possible.
OUTPATIENT CARE
Physician Offices and Integrated Care Models
As often portrayed on TV, physician offices traditionally featured a physician, a nurse, and
office staff. While some of these sole practitioner offices still exist today, integrated care
offices are becoming more common. These primary care practice models have multiple
physicians and other practitioners, such as pharmacists, physician assistants, nurse
practitioners, and social workers to meet the needs of their patients.
In the spirit of providing value based care, there has been increased interest in healthcare
delivery models that are more patient-focused. These models include Patient-Centered
Medical Homes (PCMHs). These practices represent a primary care delivery model focused
on comprehensive, coordinated, and integrated management of all aspects of a patient’s
health.9
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Emergency Departments
Emergency departments (EDs) and various outpatient clinics may be part of a hospital or
health system. Many patients with limited resources use the ED for nonurgent care, resulting
in around 10 million nonurgent visits per year.
Urgent Care Centers
Urgent care centers are walk-in clinics that offer a variety of services during convenient
hours. Although they are not quite as equipped for emergencies as EDs, urgent care centers
can be used when doctors’ offices are closed and are much cheaper than EDs.
Retail Clinics
Often seen in pharmacies and grocery stores, retail clinics are operated for patient
convenience. Physicians are not required and they are staffed by nurse practitioners or
physician assistants.
Ambulatory Surgery Centers
Some minor surgeries don’t require an overnight stay. Approximately two-thirds of surgeries
performed in the last 10 years were outpatient surgeries.9
Other Outpatient Models
Other models of outpatient care include community health centers, charitable clinics, local
government health departments, home health, hospice, telemedicine, and
complementary/alternative medicine.
Why are Patients Increasingly Seeking Outpatient Services?
Since the 1980s, the volume of outpatient services delivered has grown considerably.
Advances in medicine and technology have enabled us to provide more advanced treatments
in outpatient settings. The introduction of the Medicare Prospective Payment System in 1983
changed the way hospitals were reimbursed for inpatient hospitalizations and encouraged
shorter lengths of stay.3 This provided incentive to continue treatment in outpatient settings
without payment restrictions.10
Increased use of outpatient services and fewer doctors pursuing primary care practice
provides an opportunity for pharmacists to increase their involvement in the primary care
setting. Residencies are now available and the Board of Pharmacy Specialties offers a
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specialty certification in ambulatory care pharmacy practice. Similar to outpatient care,
ambulatory care includes all health-related services in which patients walk to seek their
care.11
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CHAPTER 3
ROLES OF AMBULATORY CARE PHARMACISTS
Author: Jessica Wilhoite, PharmD, BCACP
Ambulatory care pharmacists may practice in a variety of settings, but similar skill sets are
utilized throughout different practices. This section will review general pharmacy services
which will be helpful in learning how they are applied in specific ambulatory care settings.
MEDICATION HISTORY AND RECONCILIATION
Before managing a new patient, pharmacists should obtain a comprehensive list of
medications the patient is currently taking, which is referred to as the patient’s medication
history.1 A medication history should include both prescription and over-the-counter
medications, such as herbal products and nutritional supplements. Vaccines and injectable
drugs may also be added to the list. It is important to note the route, frequency, and time that
the patient is taking the medications. Additionally, any drug allergies and adverse reactions
to drugs should be recorded.1,2
A medication history can be obtained in several ways. You may be able to consult a patient on
what medications they are taking, particularly if they carry a list of their medications with
them and are able to say what they are or are not taking. However, speaking with the patient
is not always possible or the patient may be confused about their medications.2 In these
instances, there are several other options. The patient’s regular community pharmacy may
have a list of prescriptions filled recently by the patient, which may indicate the patient is
currently taking those medications. Prescribers may also be contacted to determine what the
patient has been prescribed and should be currently taking. If the patient is coming from a
hospital, it may be possible to obtain from the hospital the patient’s prescriptions at
discharge.1,2
After this information has been acquired and documented, the process of medication
reconciliation may begin. The Joint Commission defines medication reconciliation as:
“the process of comparing a patient's medication orders to all of the medications that
the patient has been taking. This reconciliation is done to avoid medication errors
such as omissions, duplications, dosing errors, or drug interactions. It should be done
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at every transition of care in which new medications are ordered or existing orders are
rewritten. Transitions in care include changes in setting, service, practitioner, or level
of care.”2
In medication reconciliation, a pharmacist looks for discrepancies in the patient’s drug list.
During this exercise, the pharmacist may find several possible errors: inappropriate drug
therapy, duplicate therapy, drug-drug interactions, drug-disease state interactions, or
incorrect doses.1,2
Medication reconciliation is an important process in patient care. Table 3-1 includes
medication history discrepancies that may lead to issues in patient care.

Discrepancy

Result

A medication is listed in the
patient’s history that the patient
is no longer taking

This medication may continue to be dispensed to the
patient
● Could lead to duplicate therapy or drug
interactions

The incorrect strength of a drug
is listed

The patient may be getting too high or too low of a
dose
● Could lead to adverse side effects (dose too
high) or inadequate therapy (dose too low)

The patient’s medication list may
be incomplete and does not
include all the medications the
patient is taking

The pharmacist may not be able to identify all
possible drug interactions
● Meds not listed may interact with other meds

How the patient is taking the
medication may be incorrectly
listed

If the patient is taking the medication more or less
than listed, the patient may be getting too much or
too little of the drug
● Could lead to adverse side effects or

Medications may be added that interact with
medications not listed
● Could cause drug adverse effects or decrease
the effectiveness of drug therapy
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Discrepancy

Result
inadequate therapy
If the patient is taking the medication at a different
time of day than listed, the pharmacist may be
unable to identify inadequate therapy or side effects
related to the time of day
● Could decrease effectiveness of drug therapy
or side effects (e.g. if a sedating drug were
given in the morning)
The pharmacist may not be able to identify if the
medication interacts with other medications the
patient is taking
● Certain drugs need to be separated from one
● another and taken at different times

The incorrect dosage form of a
medication is listed

The patient may be getting inadequate drug therapy
● Example: If an immediate release formulation
is given instead of an extended release
formulation, patient may not be getting
enough drug

Table 3-1. Medication history discrepancies
By obtaining a thorough medication history and carefully checking through it, pharmacists
can help to reconcile these and other errors that may have gone unnoticed.
MEDICATION THERAPY MANAGEMENT
Medication therapy management (MTM) involves a scope of activities with the goal of
optimizing health outcomes for patients and helping patients manage their medications.
Pharmacists and other healthcare professionals providing patient care are included in this
process (Figure 3-1). Many patients may be eligible for MTM; however, patients who benefit
most from MTM services include elderly patients, patients taking multiple medications, and
patients with multiple or complex disease states.4 These patients may have more difficulty
managing their medications and pharmacists can help with this task.
27

In ambulatory care, MTM services are generally provided via one-on-one patient
appointments.4 Patients may be referred to an ambulatory care pharmacist by their health
plan, physician, or other healthcare providers. Medication therapy management services are
generally done in person but may also be provided over the phone. Although both in-person
and phone appointments are possible, face-to-face interactions allow the pharmacist to
visually observe the patient for potential health problems. Regardless of the type of visit, an
MTM appointment typically includes a medication therapy review, developing an action
plan, and referral to other health care providers.3,4

Figure 3-1. The MTM process3

Medication Therapy Review
Pharmacists review patient information and drug therapies to identify any medicationrelated problems.4 After obtaining an accurate medication history, the pharmacist can
identify if problems or side effects experienced by the patient are related to their drug
therapy.5 During this time, the pharmacist may also address patient adherence and identify
barriers that may be preventing patients from taking medications as they should. Any issues
the patient is experiencing could stem from incorrect use of the medications rather than the
drug therapy itself; therefore, it is the pharmacist’s responsibility to identify the source of
medication-related problems.
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Developing a Plan
After the pharmacist has identified drug-related problems, a plan for resolving the issues
is then developed.4 During this process, the pharmacist works with the patient and the
physician/healthcare provider to determine possible options for fixing the drug-related
problems. These options may include discontinuing therapy that is ineffective for the patient
or is causing side effects the patient cannot tolerate, adding drugs onto inadequate drug
therapy, or adjusting doses. Medications that are discontinued may also be replaced with
medications that can provide the same type of therapy. In other cases, drugs may be added
onto current drug therapy if the patient has a health concern not being managed. The drug
dose may also be adjusted according to the needs of the patient. Any type of drug therapy
changes should be discussed and explained to the patient.4
Referral
Medication therapy management services include referral to other healthcare providers as
deemed appropriate.4 These providers should be consulted if a patient’s care goes beyond the
extent of the pharmacist’s scope of practice. In these instances, the patient should be referred
to the appropriate provider.4

Situations that may require referral to another health care provider
The patient is experiencing a medical problem outside of the pharmacist’s scope of
practice
The patient is experiencing any type of medical emergency
The patient needs medication adjustments unable to be made by the pharmacist
Table 3-2. Situations requiring referral.
DRUG INFORMATION SERVICES
Another service commonly provided by ambulatory care pharmacists is providing drug
information.6 As experts in medication knowledge, pharmacists are able to provide accurate
drug information to both patients and healthcare providers. Pharmacists utilize primary
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literature and medication databases to provide accurate drug information. Educating
patients on their disease states and medications enables patients to better manage their
health, and providing drug information to healthcare providers can help them to care for
patients more effectively.6
DISEASE STATE MANAGEMENT
Many medications are used to treat chronic disease states. Pharmacist responsibilities
include managing patient medications which translates into managing chronic disease.
Disease state management may be accomplished through patient visits with a pharmacist and
can occur in a variety of settings including, but not limited to: physician offices, pharmacistmanaged disease state clinics, or community pharmacies. In pharmacist-managed clinics,
the pharmacist is independently responsible for providing primary care via protocol with a
physician, which includes ordering lab tests, modifying drug therapy, and following up with
patients.14 Helping patients with their medication regimens can help to optimize disease state
outcomes, such as:
● In one smoking cessation group clinic, pharmacists were able to assist patients in
quitting smoking, with 47.6% of patients smoke-free at 3 months and 52.4% of patients
smoke-free at 6 months.19
● A pharmacist-managed spirometry clinic resulted in pulmonary drug regimen
changes in 80% of patients, with referral to physicians or further diagnostic testing in
27.4% of patients.18
● A study on pharmacist-managed hypertension clinics resulted in 81% of patients
reaching their blood pressure goals versus only 12% of patients who did not meet with
a pharmacist.21
Pharmacy services in ambulatory clinics may focus on a single disease state, such as diabetes,
or may be focused around multiple conditions related to a high risk medication, such as
warfarin.7 Medication management services can be expanded further when pharmacists
work in collaboration with other healthcare professionals.
Collaborative Drug Therapy Management
Collaborative drug therapy management (CDTM) has been defined as a formal partnership
between a pharmacist and physician or group of pharmacists and physicians to allow
pharmacists to manage a patient’s drug therapy.8 CDTM agreements allow pharmacists to
expand their scope of practice by allowing them to perform services they would not be allowed
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to perform without a CDTM agreement. CDTM can help improve patient outcomes, increase
patient satisfaction, and lower costs.

Potential Problem
Medication adverse events
Limited patient access to healthcare
practitioners
High healthcare costs

Pharmacist Intervention
Pharmacists may identify drug interactions,
resolve side effects, identify inappropriate
medications or doses
Pharmacists may help provide care to
patients, lessening patient load for
physicians
Pharmacists can reduce costs by optimizing
medication use
● Can identify unnecessary or
inappropriate medications
● Ensuring patient adherence to
medications can help prevent
hospital admissions

Table 3-3. CDTM Benefits9
Ambulatory care pharmacists utilize CDTM agreements to work collaboratively with
physicians to enhance patient care. Based on the pharmacist’s scope of practice in their state,
responsibilities of a pharmacist under CDTM agreements may include implementing or
modifying drug therapy, ordering and evaluating drug-therapy related laboratory tests, and
administering medications such as immunizations. However, these responsibilities may
vary depending on the legal agreement and scope of practice.8,9
ADMINISTRATION
In some clinics, particularly those providing services to underserved populations, ambulatory
care pharmacists may be asked to assist with developing drug formularies and monitoring
prescribing habits. A formulary is a list of medications and related drug information that is
continually updated and reviewed by physicians, pharmacists, and other healthcare
professionals.10,11 For health plans, a formulary includes all the prescription medications
covered by the plan. Hospitals also have drug formularies, which include drugs that the
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hospital carries. Formularies are developed by identifying the most medically appropriate
and cost-effective drug therapy options. Pharmacists play a key role in this process by
continually reviewing primary literature and guidelines on medications to determine the
most appropriate drug therapies to include in formularies and relaying findings to physicians
and other healthcare professionals.10,11
PREVENTATIVE CARE / WELLNESS SCREENINGS
In addition to helping patients manage existing chronic disease, pharmacists may also help to
prevent disease. For example, an annual wellness visit (AWV) may serve as an annual health
screening for patients. Medicare Part B covers the patient’s cost and provides reimbursement
for the practitioner providing this service. AWV occur in a physician office and during these
visits, patients are assessed to determine if they have risk factors for certain disease states
and may be referred to health education or other preventive services.12, 13

Figure 3-3. Elements of an AWV12

DIRECT PATIENT CARE
Direct patient care is one of the primary services performed by ambulatory care pharmacists.
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CDTM agreements facilitate pharmacist-independent and team-based patient care
services.14 Table 3-4 outlines the pharmacist’s role in various clinic types, which can be
provided by pharmacist-independent or team-based care.
Pharmacist-Independent Care
Ambulatory care pharmacists may be independently responsible for providing patient care,
generally when working collaboratively under a physician.14 This is most commonly seen in
disease state management with CDTM in place. When a pharmacist is working
independently to care for a patient, responsibilities may include completing medication
histories, physically assessing the patient, ordering lab tests, adjusting medications, and
following up with the patient.15 Additionally, based on the collaborative agreement in place,
pharmacists may also authorize refills of certain medications and provide immunizations.15
Team-Based Care
Ambulatory pharmacists may also work as a member of a team with other healthcare
professionals to provide care for a patient.14 In this setting, pharmacists may meet with the
patient at the same time as other healthcare providers. During shared appointments,
pharmacists are able to address medication questions and concerns brought up by the patient
or the other healthcare providers.15 Pharmacists may still have independent responsibilities
in this setting, such as obtaining medication histories and performing medication reviews.14

Clinic Type
Diabetes9,16

Anticoagulation17
(primarily warfarin)

Pharmacist Role
Help patients set self-management goals
o Blood pressure and A1C targets
o Investigate barriers to achieving these goals
● Adjust medications to help achieve these goals
● Provide diet and exercise education
●

Adjust warfarin doses
● Assess for drug interactions or diet changes that may affect
warfarin therapy
● Interpret INR results to see if dose adjustments need to be
made to keep patients in therapeutic range
●

33

Clinic Type
Pulmonary18

Smoking
Cessation19

Pharmacist Role
Provide spirometry tests to evaluate patient pulmonary
functions
● Identify respiratory problems related to inadequate
medication therapy
● Counsel on proper inhaler and nebulizer use
●

Instruct on both prescription and over-the-counter
medications to help quit smoking
● Provide strategies and tips in quitting
● Follow up with patient to ensure no relapse
●

Heart Failure20

●

Ensure patient is not taking medications that may worsen
heart failure
● Inform patient’s primary care provider of any inappropriately
prescribed drugs

Hypertension21

●

Behavioral Health9

●

HIV22

●

Hepatitis C23

●

Take patient’s blood pressure
● Suggest adjustments to patient’s medications based on blood
pressure results
● Diet and lifestyle counseling
Help to adjust or initiate psychiatric medications
o Disease states include depression, schizophrenia, and
bipolar disorder
o Consider special populations such as geriatrics and
pediatrics

Help to optimize treatment regimens
o Analyze patterns of resistance to the HIV virus
● Ensure patients have access to medications
Manage drug interactions
● Assess appropriateness of treatment regimens based on
patient genotypes

Table 3-4. Pharmacist’s role based on clinic type
34

CARE COORDINATION
Transitions of Care
Transitions of care refers to the movement of a patient from one setting of care (hospital,
ambulatory care practice, long-term care, home health, rehabilitation facility) to another.24
Transitions of care may also apply to patients who are leaving a healthcare setting to go
home. When patients leave one healthcare setting and move to another, it is important that
they are receiving continuous care. Care should be coordinated between all healthcare
professionals providing care to the patient. When patients are transferred from one setting to
another, adverse events may occur, often caused by medication errors. Recent studies have
shown that 54% of patients experienced medication errors upon hospital admission; a
significant percentage of these errors (39%-45%) were found to be potentially harmful to the
patient.25 Patients who are admitted to a care facility, such as a hospital, may leave with a
different prescribed medication regimen than what they had previously. If these changes are
not adequately communicated between healthcare providers, the patient may end up
receiving inappropriate and/or duplicate drug therapy. This is why it is important for
healthcare providers to effectively communicate any changes in drug therapy.24,25
Pharmacists may play a significant role in facilitating a patient’s transition of care in
collaboration with other health care providers such as, physicians, nurse practitioners,
clinical nurse specialists, or physician assistants.24,26 Obtaining a patient’s complete
medication history in order to accurately perform medication reconciliation is important in
reducing medication errors.27 The patient’s medication list should be reconciled again upon
discharge to another healthcare facility and should be available for the next healthcare
providers taking care of the patient. Patient adherence to new drug regimens is also important
and can be improved through disease state education and medication education. Educating
the patient about their condition, medication, how to take the medication, and potential side
effects can improve medication adherence rates. Disease state education can help a patient
understand their new diagnosis and the risks involved can help motivate patients towards
better adherence. Immediate patient follow-up is another task in which pharmacists can
help.26 Care transition pharmacists make contact with the patient within a few days of
discharge from the inpatient setting. This quick initial contact can help answer questions the
patient may have and help them to better manage their new diagnosis effectively. In addition
to these services, pharmacists can also integrate MTM services and medication counseling
services. In some practices, pharmacists are able to continue following the patient if the
patient’s chronic conditions match those in which the pharmacist manages at the clinic.
Pharmacists provide a unique, medication-specific approach to transitions of care, which has
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been shown to decrease hospital admissions, readmissions, and ED visits.24,27

CASE 3-1

Dr. Jones is a local physician whose patient population consists largely of

diabetic and atrial fibrillation patients. Many of his patients appear not to be
adequately managed in their disease states. Additionally, Dr. Jones has a

high patient load which prevents him from seeing his patients as often as he
should, resulting in poor outcomes, trouble managing appointments, and
difficulty bringing in new patients. Due to poor performance scores, Dr.

Jones is at risk for facing penalties and/or not receiving full reimbursement
amounts with his payers.

What are opportunities for ambulatory care pharmacists in this
scenario? What services could be provided?
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SECTION 2
COST
There are many reasons healthcare costs so much in the United States, but the answers
usually fall into two categories: costs due to the healthcare system itself and costs due to the
nature of disease and society.1 Costs caused by the healthcare system can be attributed to
insurance used as insulation, lack of transparency, and lack of standardization and
coordination.1 Insurance was originally designed to protect against high, catastrophic costs
that could lead to medical bankruptcy or significant financial loss. Insurance as insulation
attempts to assist consumers with even low cost expenses, increasing the cost of insurance
because providers can no longer calculate costs based solely on the risk of catastrophic
events. This more extensive coverage relies heavily on private negotiations and opaque
contracts to control costs.
The American healthcare system is a private, competitive, market-driven system with
limited government regulation, price controls, and salary caps. Many other countries have
centralized negotiation programs where companies compete for contracts by offering lower
prices.2 In the United States, private and government payers may negotiate prices with
healthcare administrators without involvement of the patient or healthcare provider.
Therefore, price does not equal cost or reimbursement for a particular healthcare service or
product. This lack of transparency allows for variable prices for similar services and further
impacts competition. Prices for drugs, office visits, and procedures are typically higher in the
United States than any other country. These costs support innovation, advanced technology,
attractive facilities, and higher salaries of healthcare providers. A 2013 Gallup Poll suggests
that Americans have more positive feelings about their personal healthcare than the
country’s healthcare.3 Approximately 2/3 of Americans rate their personal healthcare
coverage as excellent or good and about 1/3 give the country’s healthcare coverage a high
rating.3 59% of respondents indicated they were satisfied with the cost of their own
healthcare.3
Costs related to the nature of disease and society include costs of chronic disease care, end of
life care, unhealthy behaviors, and health literacy.1 According to the Agency for Healthcare
Research and Quality (AHRQ), in 2013, 5% of the US population account for 48.7% of
spending with an estimated annual mean expenditure of $43,253.4 The lack of incentive for
preventive care and unhealthy lifestyles leads to an increase of chronic disease. The
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expectation of insurance payment for chronic disease management is part of the systemic
costs of increased perception of insurance as insulation. Attitudes toward prevention and
healthy lifestyle are part of the costs related to the nature of disease and society. Societal
views on extensive end of life care contributes significantly to healthcare spending, especially
as the baby boomer population ages. Other factors that impact the cost of care will be
discussed later.
Until the early twentieth century, insurance for routine healthcare did not exist. The first
modern group health insurance plan was formed in 1929. A group of teachers in Dallas, Texas
negotiated a contract with a local hospital for services in exchange for a fixed monthly fee.5
This arrangement led to the startup of organizations such as Blue Cross and Blue Shield
which offered similar insurance programs. Offered only by some employers, insurance was
generally purchased by the patient consumer and having insurance was uncommon. This
changed during World War II when the federal government imposed wage freezes. At the
time, employers could not raise salaries but could offer benefits to employees and employers
competed for workers by offering better benefits packages. A key component was new or
improved health insurance plans. This led to major demand and growth for private employerbased health insurance and by the late 1950s the majority of Americans had some amount of
healthcare coverage. However, those who were unemployed, self-employed, or employed by
small employers were unable to afford the care they needed. In response, Medicare and
Medicaid were created in 1965 providing public funding for healthcare coverage for the
elderly and indigent.5 Each of these coverage options may use one or more payment
structures, including fee for services, network negotiations, capitated payments, or salaried
providers.
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CHAPTER 4
FROM INSURANCE BASICS TO PLAN
SELECTION
Author: Carriann Smith, BS, PharmD
By purchasing insurance, plan members are buying protection from a large debt in the event
of a catastrophic need for medical care. However current practice in using insurance to cover
non-catastrophic expenses causes higher premiums or decreases the amount available to pay
for covered expenses.
On average, a three day hospital stay can cost about $30,000 and a reasonable question might
be how health insurance companies pay for the large bills.1 The insurance company’s job is to
spend money to benefit the most members without having to raise premiums or deny
additional services. This includes using profits to pay competitive salaries to employees. The
business of health insurance in the United States relates as much to finance as it does to
healthcare. Plan members pay for insurance through regular premiums and insurance
companies invest that money to pay for illnesses that happen to anyone in the group. Proper
investing and money management provides the best coverage to cost ratio for beneficiaries.
Insurance is paid via premiums, deductibles, co-payments, and co-insurance amounts.
Premiums are a monthly payment to ensure the member stays covered under a plan (like a
basic phone bill without usage charges). Many insurance plans require patients to pay a
deductible at the beginning of each year of coverage, typically January 1. A deductible is the
total amount a member must spend on their care per policy period (generally one year) before
insurance will begin to cover their portion. Therefore, beneficiaries pay for coverage but the
insurance doesn’t work right away. Depending on the plan, deductibles may only apply to
certain types of care. For instance, if the deductible does not apply to prescriptions, the
patient does not have to pay the deductible first for prescriptions.
Once a patient has met their deductible, they may continue to have to pay a portion of their
bills until they have reached their out-of-pocket maximum. Having beneficiaries paying some
of their own costs, cost sharing, has been shown to engage them in keeping costs low. It also
helps to keep the costs of premiums down by decreasing insurance company spending. The
patient will pay a portion of costs through co-pays, which are flat fees, and co-insurance,
which is a percentage of total charges. Insurance will cover the remainder of the bill.
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Health insurance plans negotiate prices and have out-of-pocket maximums to help prevent
members from going bankrupt despite having insurance. Once the out-of-pocket maximum is
reached, insurance will cover 100% of a member’s healthcare costs for the rest of the year.1
RELATIONSHIPS BETWEEN PAYERS AND PROVIDERS
Fee-For-Service (FFS)
Before the 1970s, Medicare and private insurance primarily offered insurance, called
indemnity insurance, that used a fee-for-service model. Fee-for-service means that each item
or expense would be itemized to one or more bills. Providers would be paid a specified amount
for each service amount established by each insurer. In the fee-for-service model, the patient
chooses their own providers and has no restrictions on the use of specialty services. Providers
who receive reimbursement directly from payers may then charge the patient what the
insurance did not cover. This is referred to as balanced billing because the patient is billed for
the remaining balance. 2

Patient receives
care

Payor pays
patient

Patient pays
provider with
money received

Payor pays
provider

Patient pays
differences or
provider loses that
portion

Provider bills the
payor

Figure 4-1. Fee for service model

In 1973, President Richard Nixon signed a law to help control the rising healthcare costs.3
With this law, a model for a managed care organization (MCO) was initiated.4 An MCO is a
private insurance company with agreements in place with selected healthcare administrators
and providers. This agreement is settled before patient care is delivered and outlines
negotiated prices and payment arrangements. MCOs lower costs for patients by limiting their
healthcare provider options to only those with an agreement. There are several types of
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MCOs, including: Health Management Organizations (HMOs), Preferred Provider
Organizations (PPOs), and Point of Service (POS) plans.3 The options described below
outline the financial agreements between healthcare providers or administrators and payers
in managed care coverage. This is important to help patients understand their coverage and
to help providers understand how they will be reimbursed.
HEALTH MAINTENANCE ORGANIZATION (HMO)
Healthcare providers within an HMO network are usually paid by salary or a capitated (per
person, per year) amount, allowing the HMO to exert more connection and possibly control
over the providers and their healthcare decisions. Therefore, patients can only receive
healthcare services from providers in the HMO network.3 If a patient uses a provider that is
not an HMO provider, their insurance plan will not pay for any services from that provider
and the patient is responsible for all associated costs.
Under an HMO plan, a patient is usually required to choose a primary care provider (PCP)
who serves as a gatekeeper for their care.2 As gatekeeper, the PCP provides primary care and
is the only provider who can refer the patient to specialists for care beyond the PCP’s scope of
practice.2

Patient
identifies a
primary care
provider
within the
HMO network

Provider gets
paid either a
salary or a
capitated
amount
because the
patient is now
identified as
being under
their care

Patient goes
to provider
and pays a
copay if
applicable

Provider cares
for the patient

If patient
needs to see a
specialist they
must be
referred by the
primary care
provider

Figure 4-2. Health maintenance organization model
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PREFERRED PROVIDER ORGANIZATION (PPO)

Patient goes to any provider

In a PPO, a patient has a preferred in-network list of providers from which to choose. If a
patient chooses to see a provider who is out-of-network, it is more expensive than seeing a
provider that is in-network but there will be some coverage from the insurer. In-network
providers offer services at discounted rates in exchange for increased business from that
insurance company. High deductibles may be options within PPOs (Figures 4-3 and 4-4),
which can be offset by putting money into a tax-free account referred to as a Health Savings
Account (HSA).

In
Network

Out of
Network

Patient will likely
pay a copay for
in network
providers

Coinsurance %
more likely

copay at

Policy and contract
terms determine
payment
to provider

Patient receives an
explanation of
benefits (EOB)

Terms of policy
and contract
determine
payment to
provider

Provider bills the
patient for their
coinsurance amount

Patient receives an
explanation of
benefits (EOB)

Patient pays
time of visit

Figure 4-3. PPO plan without a high deductible
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Enroll in plan
through an
employer
group or
through an
individual plan

Put money
into a Health
Savings
Account. Most
do monthly
contributions
from their
paycheck

Some
employers pay
money into
the Health
Savings
Account since
employers
save money
when their
employees
choose this
plan

Pay the full
cost of care
when you
need it until
you reach a
high
deductible

Once you
satisfy the
deductible,
plan operates
like other
plans, usually
a PPO

Figure 4-4. PPO plan with a high deductible
POINT OF SERVICE (POS)
A POS may be considered a combination of an HMO and PPO.3 In these plans, a patient is
typically required to choose a primary care provider (PCP) similar to an HMO. The PCP
coordinates the patient’s care and can refer them for additional services. At this point, the
patient can choose to receive point of service (POS) care from a less expensive in-network or
more expensive out-of-network provider.3 The out-of-network providers are more expensive
because they are reimbursed on a fee-for-service basis.
In summary, managed care attempts to limit healthcare costs by steering patients toward
specific providers and controlling the number and variety of paid for services. A lack of
provider knowledge of costs, limited patient knowledge about the care they need, and thirdparty negotiations have made it difficult for patients embrace manage care. A trend toward a
new structure, called accountable care, integrates healthcare providers to consider cost
versus benefit with a focus on outcomes and value to patients.
ACCOUNTABLE CARE
The intent of the Patient Protection and Affordable Care Act (PPACA) was to shift from
paying providers for the amount of care, fee-for-service, to paying providers based on the
quality and value of the care they provide. The goal of pay-for-performance is to improve
patient outcomes, enhance the quality of patient care, and reduce overall system costs.2,5
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Instead of having payers lead the decisions, the PPACA directed health care providers to be
accountable for their patient care. This was done through changes to reimbursement for
providers. New payment structures are based on measures of improving clinical outcomes,
increasing overall patient satisfaction with the provider, minimizing adverse events, or
decreasing length of stay and treatment times.6
Accountable Care Organizations
The PPACA established a new model to encourage and support accountable care: the
accountable care organization (ACO). ACOs consists of groups of physicians, hospitals, and
other health care providers. The ultimate goals of ACOs are to increase the use of evidencebased quality measures, actively engage patients in their care, and coordinate patient care
between providers.5 Coordinated care is intended to provide patients with the right care,
avoid unnecessary duplication, and improve patient outcomes.7
Medicare provides coverage to individuals who are at least 65 years old or those of any age
who are permanently disabled. A new payment model, the Medicare Shared Savings Program,
offers financial incentives to certain ACOs. Providers must meet different criteria but if they
are successful and improving outcomes while cutting costs, they received a portion of the
money saved back. To help measure success and determine reimbursement, ACOs are
required to submit information to the Centers for Medicare & Medicaid Services (CMS) on
quality measures which together comprise four domains: Patient/Caregiver Experience,
Care Coordination/Patient Safety, Preventative Health, and At-Risk Populations.8 Looking
at the domains, it is easy to see how the focus on both the patient experience and clinical care
connects to providing value based care.
Accountable Care and Pharmacists
The sustainability of ACOs is dependent on how well they can control costs through
coordinated care while improving healthcare quality. Pharmacists are in a position to help
ACOs succeed. The pharmacist’s role in accountable care will continue to include optimizing
treatment choices, considering cost, ensuring medications are being prescribed and used
properly, reducing medication-related adverse events, and helping other providers manage
chronic disease states.5,9
For example, think about a patient who has high cholesterol. The outcome of treatment is to
lower the cholesterol. Lowering cholesterol may be done by changes in diet and exercise and
by medications. This patient in self-employed and has a fee-for-service plan. Each time the
physician meets with the patient and orders a lab test, it will be paid for by the insurance
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company and the patient will pay a portion of the cost. If the physician is concerned the
patient is at risk of a heart attack, they may be very aggressive may order frequent tests,
prescribe new medications, and schedule regular appointments because each item will be
paid. The physician is free to make clinical judgment without any review.
The patient changes jobs and now has employer coverage using a health maintenance
organization (HMO). The physician the patient had been seeing is not in network, so he must
go to a different provider. After making an appointment with the new physician, the patient
learns this will be his primary care provider who will decide what additional care the patient
needs. This is the gatekeeper and the name appears on the patient’s insurance card. This
physician is focused on maintaining the patient’s health and limiting the use of expensive
laboratory tests and medications to reduce cost for the HMO and the patient. This physician
recommends more extensive exercise and nutrition. The physician makes recommendations
based on the guidelines and policies provided by the HMO. The physician’s payment and
employment is based on following the HMO criteria and managing cost and risk to the HMO.
The patient now retires and enrolls in Medicare. The patient changes physicians to one that
takes Medicare. This physician is part of an accountable care organization (ACO). This
physician knows that his reimbursement is based on the patient achieving his cholesterol goal
and staying out of the hospital. He implements a diet, exercise and medication plan that fits
nationally recognized guidelines and the physician’s clinical experience. The physician
considers the costs of care and balances that with maximizing the benefits for the patient.
The physician considers what quality measures exist for patients with high cholesterol and
set goals for the patient that match this goal. If this and other patients meet their quality
measures for cholesterol management, the physician will receive the remainder of his
reimbursement.
This is a simplified approach to understanding the difference between payment structures to
clearly delineate how healthcare providers may be impacted. It is not likely that a provider
would change their treatment by the type of insurance coverage but different settings are
likely to place different emphasis on treatment options. There is certainly overlap between
what drives different providers and their use of quality measures, national guidelines, payer
guidelines, and clinical experience.
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Figure 4-5. Transition from Fee for Service to Accountable Care.
PATIENT TO PAYER CONNECTIONS
Fundamental knowledge of insurance terminology is necessary for navigating patient to
payer interactions. The primary purpose of health insurance is to help protect an individual
from financial risks of medical expenses, which can often be very high, and to help avoid
significant financial loss.1 Health insurance in the United States usually includes both
medical insurance (doctor and hospital coverage) as well as prescription coverage. A common
misconception is the belief that insurance will pay for all health care expenses that occur.10
Health insurance plans identify services or expenses that are covered or eligible for insurance
payment.11 It may also list items that are excluded, where an individual will pay any expenses
incurred without insurance help. When a health care provider or patient submits these
expenses to the insurance company for processing (send in the bill), the expenses are referred
to as claims. Additional vocabulary such as deductible, coinsurance, etc. is defined in the
glossary.
Types of Insurance Coverage
Figure 4-6 below provides an overview of the primary types of health insurance coverage
available in the US.11 Health insurance may be purchased privately, either individually or as
part of a group, or publicly, through state or federal government. Employer coverage, a form
of group coverage, is the most common type of private insurance.11
Employers who offer health insurance plans to their employees generally offer better
coverage at a cheaper rate than if the employee were to purchase it on their own as an
individual policy. Employers may also choose to cover a portion of the premium for each
employee. The employees then pay their portion of the premium through paycheck
deductions.11
Others are not able to obtain employer health insurance. These individuals may not work
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enough hours to qualify for employer coverage, are unemployed or work for a small employer
who does not offer regular group coverage. These individuals can purchase private coverage
through the health insurance marketplace (online) or from private agents.

Figure 4-6. An overview of the types of insurance coverage available to Americans

IN-DEPTH LOOK AT THE MARKETPLACE
Marketplace
The Patient Protection and Affordable Care Act, PPACA, created a new, private insurance
marketplace in all 50 states and the District of Columbia.12 Some states created their own
marketplace and others utilize the federal health insurance marketplace. These marketplaces
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include a central online location, called the Small Business Health Options (SHOP)
Exchange, that enable individuals and small groups to shop for private health insurance
plans.12.13 Here, small businesses, currently defined by the federal government as 100 or fewer
employees, can set up accounts to allow individuals to compare available plans specifically
selected by the small employer.13 In the SHOP, individuals have fewer options than on the
individual marketplace, but the employer pays a portion of the premium.13
People who select insurance plans through the individual health insurance marketplace may
be eligible for tax credits to help cover their premium. These credits are based on the person’s
income.14 Some individuals may also choose to self-pay for medical bills, rather than pay for
insurance coverage. However, this choice will result in penalty taxes the individual will be
required to pay, unless they qualify for a tax exemption.14
Marketplace exchanges support individual access and comparison of health insurance
coverage. Resources are available to help individuals navigate the exchanges. HealthCare.gov
offers a wide variety of information regarding navigation and utility of the federal health
insurance marketplace. Individuals can apply online, by phone, via a paper application, or
with in-person help using a tool on HealthCare.gov, which enables individuals to enter their
location information, and select the type of coverage they are searching.14,15
Function and Navigation
Individuals can enroll in plans during yearly open enrollment periods (OEP) that is set by the
federal government.14 During this timeframe, individuals may browse and enroll in a health
insurance plan for the following year. Enrollment outside of the OEP cannot occur unless the
patient, also known as a beneficiary, qualifies for a special enrollment period.14 Special
enrollment periods occur over a 60 day period following particular life events that result in a
change of family status, such as marriage, childbirth, or after the loss of prior health
coverage.14
HealthCare.gov offers screening tools to help individuals determine if they are eligible for
either Medicaid, Children’s Health Insurance Program (CHIP), or a special enrollment
period. Both Medicaid and CHIP are discussed later in this chapter.
Marketplace Plans
The federal health insurance marketplace categorizes insurance plans into four “metals”:
Bronze, Silver, Gold, and Platinum. Although a common misconception, the “metals” do not
reflect or categorize plans according to quality or amount of care provided by each plan.7 Each
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metal level reflects the cost of monthly plan premiums and the portion of costs for care or
services, such as hospital visits or prescriptions, that the patient will be expected to pay.7
“Metal” categories are defined in Figure 4-7.16
“Metal” Federal Health Insurance Marketplace Categories
Bronze

• Health plan covers approximately 60% of total average costs
• Beneficiary covers approximately 40% of total average costs

Silver

• Health plan covers approximately 70% of total average costs
• Beneficiary covers approximately 30% of total average costs

Gold

• Health plan covers approximately 80% of total average costs
• Beneficiary covers approximately 20% of total average costs

Platinum

• Health plan covers approximately 90% of total average costs
• Beneficiary covers approximately 10% of total average costs

Figure 4-7. “Metal” insurance plans for the federal health insurance marketplace
Catastrophic health plans, often referred to as a ‘fifth category’ within the marketplace, exist
for individuals under 30 years of age or those who have a hardship exemption.16 Hardship
exemptions are a set of specific criteria, such as being homeless, experiencing domestic
violence, or facing substantial medical debt, that enable an individual from having to obtain
health insurance coverage for a particular period of time.16,17 Catastrophic plans focus their
benefits on high medical costs such as serious injury or hospitalization rather than
outpatient, chronic care.17 Under these Catastrophic plans, health insurance companies pay
less than 60% of the total average costs of care, placing more payment responsibilities on the
patient.16 These plans are an option for younger individuals who are healthier and do not
utilize their insurance coverage on a regular basis.17 Individuals under hardship exemptions
are eligible, regardless of age or income, to purchase a Catastrophic health plan, but are not
required.17
Public/Government Insurance Coverage Options
Individuals who have a very limited income and significant medical need may obtain health
insurance through the state government Medicaid program. Medicaid is a collection of
programs available for different levels of need. Medicaid provides health insurance options
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for low-income families and children, pregnant women, the elderly, and people with
disabilities. Low income in most states is defined as at or below 133 percent of the federal
poverty level.18 Some states have expanded their Medicaid programs to cover all adults below
138% (133%+/-5%) levels.18 Medicaid recipients typically don’t pay a premium and copays are
low to nonexistent since coverage is funded by the state and federal government.
Although each state administers their own program, the federal government provides some
financial support to assist with Medicaid funding. The federal government also sets
minimum guidance standards, such as criteria for enrollment and evaluation of claims,
Medicaid programs must follow to ensure some consistency of coverage between state
programs.18 Therefore, though all states must meet minimum standards, Medicaid benefits
vary between states based on individual state budgets and overall population need.
Individuals who are over 65, disabled for 24 months or longer, have End Stage Renal Disease
(ESRD), and/or ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease) qualify for
another government program called Medicare.19 It is important to note that individuals may
qualify for both Medicaid and Medicare. Table 4-8 describes the different types of Medicare
programs available to patients.19

Types of Medicare
Medicare Part A & B
(“Original Medicare”)

Original Medicare is a fee-for-service health plan that has two
parts: Part A (Hospital Insurance) and Part B (Medical Insurance).
After the member pays a deductible, Medicare pays its share of the
Medicare-approved amount, and the member pays their share
(coinsurance and deductibles).

Medicare Part C
(“Medicare
Advantage”)

Medicare health plan that contracts with Medicare and uses
managed care arrangements with providers to provide Part A and
Part B benefits to Medicare patient. Medicare Advantage Plans
include Health Maintenance Organizations, Preferred Provider
Organizations, Private Fee-for-Service Plans, Special Needs Plans,
and Medicare Medical Savings Account Plans. Patients choose
either Medicare Advantage or Original Medicare. Most Medicare
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Advantage Plans offer prescription drug coverage.
Medicare Part D

A separate program that helps pay for prescription medications for
people with Medicare. All Medicare Part D plans are offered
through private insurance or prescription benefit companies, there
is no “original” Medicare Part D plans offered by the federal
government. There are two ways to get Medicare prescription
drug coverage: through a stand alone Medicare Prescription Drug
Plan or a Medicare Advantage Plan that includes medication
coverage.

Table 4-8. Types of Medicare
Other examples of government-funded programs include federal coverage through the
Department of Defense for military members and their families and coverage for veterans
through the Veterans’ Administration (VA).19 Government-funded coverage may also be
referred to as public health coverage.
Fee for Services versus Managed Care Organizations
As discussed earlier in this chapter, there are three primary forms or categories of health
insurance plans:
1. fee-for-service
2. health maintenance organizations
3. preferred provider organizations.10,11
Traditional fee-for-service plans are often the most expensive coverage options but offer
patients the most flexibility when choosing health care providers.11 Health maintenance
organizations (HMOs) offer lower co-pays for patients than traditional fee-for-service plans
and cover most costs for preventative care, but patients are only allowed to use a limited
number of health care providers and facilities except in emergency situations.11,20 HMOs
require their patients to select a primary care provider in order to receive coverage.11,20,21
Additionally, HMOs may require referrals from a single primary care provider, also known as
a gatekeeper, to see providers outside of the plan’s network.20 Point-of-service options may
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also be offered by some HMOs and allow patients to receive care outside the preferred
network, but at a higher, out-of-pocket cost through higher premiums.20
Preferred provider organizations (PPOs) offer lower co-pays than traditional fee-for-service
plans and provide more flexibility to patients when selecting health care providers or
facilities.20 PPOs typically provide the most coverage for providers within network but allow
patients to receive care out-of-network at higher costs and usually do not require referrals for
such care.21,22 Unlike HMOs, PPOs do not require patients to choose a primary care
provider.11,22
Comparing and Selecting Health Insurance Plans
Ultimately, selecting a health care insurance plan requires evaluation by the individual
seeking coverage. They must first understand the types of coverage available to them, such as
private or public. Based on the type of coverage, different forms of reimbursement (HMO,
PPO, fee-for-service) may impact a patient’s choice.20,21,22 A patient’s current health status,
health behaviors, and financial situation must also be considered when selecting insurance
plans. Acceptance of risk should also be taken into consideration.21 Like a warranty plan for
an appliance, paying for more insurance coverage decreases the risk that an individual would
have to pay out of pocket for unplanned medical expenses. Alternatively, if patients do not
wish to pay for coverage they may not need, they may want to reduce the amount of coverage
they select. Patients not expecting to go to the doctor may select a plan with lower monthly
premiums but less coverage.14.16 However, a healthy patient wishing to avoid the expense of
unexpected healthcare services may choose to pay higher premiums under a private
insurance plan to ensure better coverage.
Less coverage may be defined in different ways: it may mean the insurance plan covers fewer
expenses or that the insurance company covers the same number of expenses but the patient
must pay more out of pocket.14,16 Paying a higher cost share may mean a patient pays 30%
instead of 20% of the medical cost, for example.14,16 Insurance plans may also have different
coverage for different levels of care, referring to the location of where care was received.14 For
instance, a patient with a fever and flu symptoms would likely pay much more for a visit to the
ED than an urgent care. The same visit would cost even less at a physician’s office.
In choosing a plan, the patient should be aware of how networks function. Based on the plan
they choose, they may have little to no coverage at certain providers who are out of
network.20,21,22 If there is a certain provider or service needed, the patient should make sure it
is covered under their intended plan. By limiting the number of providers that a patient can
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receive care from allows the insurance company to reduce expenses and pass that savings on
to the patient.20,21,22 For example, seeing a primary care physician for a physical may be
covered, whereas seeing a renal specialist for the same physical may not be covered. This
helps direct patients to the most appropriate provider for their care need.
Some plans may offer tax-exempt Health Savings Accounts (HSAs) or Flexible Spending
Accounts (FSAs).23 These accounts enable patients to deposit and save money, tax-free, to
help pay for future medical expenses. Typically, a percentage of a patient’s paycheck will be
directly pulled and deposited into the accounts.23 This is a great way to save money and
manage healthcare costs. Since the accounts are commonly used with high-deductible
policies, patients typically pay higher costs upfront and track their expenses more carefully.23
It is important to determine if the plan includes prescription drug coverage, especially if the
patient is currently taking prescription medications. Patients should consider a health
insurance company’s formulary when selecting plans to better determine their prescription
coverage needs and/or costs.24,25,26 Medications or brands not on the formulary can be much
more expensive or may not be covered at all. Sometimes the plan will place formulary
restrictions on certain medications and only cover them after the patient has completed a
step therapy or other type of prior authorization, discussed later in this chapter, to prove the
medication is medically necessary.24,25,26
Ultimately, premiums, deductibles, and benefits must be weighed and balanced. Patients who
need high cost prescriptions may purchase a different plan than a person who primarily needs
support for wellness and emergency care.
Explanations of Benefits
Explanations of benefits are sent to patients by the insurance company to explain their health
insurance coverage. These explanations of benefits (EOBs) outline what claims were covered,
the negotiated contracted price for the medication, the amount owed by the patient, the
amount paid by the insurance company and the reason for any claim rejections, where the
insurance company refuses to cover a particular medication and/or therapy.
Fees for Not Having Health Insurance
As set in the PPACA, individuals may be subject to penalties should they not have health
insurance coverage. Individuals who can afford health insurance but choose not to purchase
coverage are required to pay a fee called the Individual Shared Responsibility Payment, also
known as a penalty, fine, or individual mandate.25,28 Individuals without coverage are
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required to pay the fee for any month they, their spouse, or their tax dependents do not have
health insurance coverage that qualifies as minimum essential coverage.28 Payments are
required upon filing for federal tax returns for the year coverage was not held.28 Fees are
calculated per person as a percentage of an individual’s household income. HealthCare.gov
provides resources to estimate mandated fees.
Exemptions for the Individual Shared Responsibility payment may be available for qualifying
individuals. An individual must meet one of the following criteria, (see Figure 4-9), to be
exempt, which prevents them from holding minimum health insurance coverage:26

Have no affordable coverage options due to the fact that the minimum required costs for
the annual premium rises more than 8% above the household income17
Have gap in health coverage lasting less than 3 consecutive months17
Qualify for an exemption for at least one various reason, such as having a hardship that
prevents an individual from obtaining coverage or belonging to a group explicitly exempt
from the health insurance coverage requirement17
Figure 4-9. Criteria for exemptions for Individual Shared Responsibility payment

Simply holding insurance coverage may not enable an individual to avoid penalties. Under
the PPACA, health insurance coverage must meet minimum comprehensive benefit
standards.13 Figure 4-10 outlines these essential health benefit standards.29
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Essential Health Benefits

Ambulatory Patient Services
(outpatient care, non-hospital admittance)
Emergency Services
Hospitalizations
(surgery, overnight stays, etc.)

Mental Health/Substance Use
Disorder Services
(counseling, psychotherapy, etc.)
Laboratory Services

Pregnancy, Maternity, and
Newborn Care

Prescription Drugs

Rehabilitative/Habilitative Services/Devices
(help gain or recover mental/physical skills)

Pediatric Services
(oral, vision, etc.)

Preventative/Wellness Services and
Chronic Disease Management

Figure 4-10. Essential Health Benefits
All marketplace plans meet minimum standards.12,28,29 Most plans obtained through
employer, government, or state programs also meet minimum standards.28 Providers should
advise patients who wish to purchase insurance outside of these programs to ensure all
coverage requirements are being met. HealthCare.gov can be used to help identify whether a
plan meets minimum standards.
Pharmacists in different practice settings may assist patients and providers in making the
most of their insurance benefits including plan and benefit selection. While this chapter has
focused on medical (hospital and office visit) benefits. The next chapter will focus on
pharmacy benefits (outpatient prescription) benefit.
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GLOSSARY
Annual Limit
The maximum amount a member’s insurance company will pay for healthcare in a year.
These caps may be placed on particular services such as hospitalizations as dollar limits or
number of services such as number of therapy appointments. After the annual limit is
reached, the member must pay all associated healthcare costs for the rest of the year.
Beneficiary
A patient who is insured under a specific insurance policy. This could be the primary
cardholder or any dependents.
Benefits
The health care items or services covered by a health insurance plan. Covered benefits are
defined in the health insurance plan's coverage documents such as the policy or certificate.
Claim
A request for payment (bill) that the member or their healthcare provider submits to the
health insurer for healthcare products or services.
Coinsurance
The percent the patient pays (for example, 20%) of the allowed amount for a covered
healthcare service or product.
Copayment
A fixed amount (for example, $15) paid for a covered healthcare service, usually when the
service is provided.
Covered Expense
A healthcare service or product that is covered as part of the specific insurance plan. A
covered expense does not mean it is covered at 100%, but instead that some amount of
coverage will be provided.
Deductible
The amount the patient must pay towards a covered health care product or service before the
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health insurance plan begins to pay. For example, if the deductible is $1,000, the plan won’t
pay anything until the member has paid $1,000 for covered services. If a covered expense is
NOT subject to deductible, then the patient will not have to pay the deductible first.
Dependent
A child or other patient that benefits from the insurance policy but is not the cardholder. One
type of beneficiary.
Excluded Services
Health care services that the health insurance or plan doesn’t pay for or cover. This may also
be referred to as non-covered.
Flexible Spending Account (FSA)
An arrangement set up through the employer to allow employees to designate money from
their paycheck to be used for healthcare before taxes are taken out. This makes the use of
these funds tax free. The member decides how much of their pre-tax wages are taken out of
their paycheck and put into an FSA. Unlike an HAS, there is no carry-over of FSA funds at the
end of the plan year.
Formulary
A list of prescription drugs covered by a prescription drug plan or another insurance plan
offering prescription drug benefits.
Health Savings Account (HSA)
A savings account that can be set up at a bank for patients enrolled in a High Deductible
Health Plan. The funds contributed to the account aren't subject to federal income tax at the
time of deposit. Funds must be used to pay for qualified medical expenses. Unlike a Flexible
Spending Account (FSA), funds roll over year to year if they are not spent.
Lifetime Limit
The maximum amount that an insurance company will pay during a person’s lifetime. After a
lifetime limit is reached, the insurance plan will no longer pay for covered services. The
PPACA eliminated lifetime limits from most insurance plans.
Member
A member is a patient who benefits from an insurance plan. Member is another word for
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beneficiary. Member is more likely to be used with managed care plans.
Network
The list of all facilities, providers and suppliers the health insurer or plan has contracted with
to provide health care services.
Out-of-Pocket Maximum
The most the member will have to pay for covered services in a policy period (usually one
year). After reaching this amount, the health plan will pay 100% for covered essential health
benefits until the annual or lifetime limit is reached. The calculation towards out-of-pocket
maximum includes the yearly deductible and may also include any cost sharing after the
deductible. It doesn’t have to count premiums, out-of-network cost-sharing, or non-covered
expenses.
Preauthorization
A decision by the health insurer or plan that a health care service, treatment plan,
prescription drug or durable medical equipment is medically necessary. Sometimes called
prior authorization, prior approval or precertification. Your health insurance or plan may
require preauthorization for certain services before the member receives them, except in an
emergency. Preauthorization is not a guarantee that the health insurance or plan will cover
the cost.
Premium
The amount that must be paid to keep coverage under a health insurance or plan. The member
and/or employer usually pay it monthly, quarterly or yearly.
Readmission
When a patient returns to the hospital shortly after being discharged this is considered a
readmission. This is usually counted if it is within 30 days of the discharge. It may count if it
is for the same condition or another condition.
Reimbursement
Reimbursement is the amount a payer provides to the health care provider in response to a
claim. For managed care plans, reimbursement amount may be based on the terms of the
contract. Usual, customary and reasonable amounts may apply to fee for service plans.
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Referral
A written order from a primary care doctor for the member to see a specialist or get certain
medical services. In many Health Maintenance Organizations (HMOs), a referral is
necessary receiving medical care from anyone except the primary care doctor. Without
getting a referral first, the plan may not pay for the services.
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CHAPTER 5
PRESCRIPTION INSURANCE
Author: Carriann Smith, BS, PharmD
When patients are choosing health insurance, pharmacy or outpatient prescription benefits
are usually part of the health insurance package. Medicare Part D is the exception that focuses
only on outpatient pharmacy benefits. In this chapter, more detail will be provided on
prescription benefits. While prescription benefits are only part of a health insurance package,
they may be the most used component of a person’s plan and careful consideration should be
given to what they cover.
PHARMACY BENEFIT MANAGERS
Functioning as a third-party administrator of prescription drug programs, pharmacy benefit
managers (PBMs) are companies (not individuals) often hired to help design, manage, and
maintain formularies for insurance companies.1,2 However, PBMs may also be utilized to
form contracts with pharmacies, negotiate discounts and rebates with medication
manufacturers, and process payment for prescription medication claims. PBMs can help
maintain or reduce pharmacy costs of insurance plans, while providing value and flexibility
to patients. Some PBMs may offer additional resources that provide patients with
information, such as lower-cost therapeutic alternatives, medication therapy management,
and mail order services.1,2
Pharmacists are often employed by PBMs to provide high quality medication therapy
management for members within an insurance plan while considering the
pharmacoeconomic implications as well.1,2 Managed care pharmacists perform a variety of
roles including medication distribution and dispensing, patient safety monitoring, clinical
program development, business operations, analysis of therapeutic outcomes, and formulary
management.1,2
FORMULARIES
Most health insurance plans utilize a formulary, which is a list of particular medications that
ensures drug products are used in a rational, safe, and cost-effective manner. Formularies can
be either open or closed.3 Insurance plans with open formularies pay for all medications, even
those not on the formulary. Closed formularies only provide coverage for medications that are
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listed on the health insurance plan’s formulary.3
Formularies are typically developed by pharmacy and therapeutics (P&T) committees, which
are made up of primary care and specialty physicians, pharmacists, nurses, legal experts, and
other health care professionals.3 As mentioned previously, the goal of this committee is to
provide a formulary that represents the optimal therapy for patients based on evidence-based
efficacy and safety information. Additionally, elements such as cost and ease of delivery are
considered when determining which medications should be on a formulary, which are
discussed further in Chapter 6.4
PRIOR AUTHORIZATIONS
Health insurance plans have implemented prior authorizations (PAs) to ensure efficacious
and safe medications are being covered, optimizing patient outcomes. A PA requires
physicians to provide explanations and/or documentations to justify the use of specific
medications for a patient.4 Insurances use this information to determine whether they will
approve or deny coverage of the medication. This helps ensure medications are administered
according to recommended therapeutic guidelines and provides better control over costs for
health insurance plans.4 PAs may also be used to limit the use of high risk medications or
institute other quality measures set by different quality organizations.4
For example, a patient presents a prescription for Crestor® to their community pharmacy,
which submits a claim to the patient’s health insurance plan. Unfortunately, the brand name
medication is not covered by their insurance plan and the claim is rejected or unpaid. Since
brand name medications are not on the formulary, the patient may choose to have their
prescriber submit a PA to their insurance plan. The prescriber may then do one of two things:
1. Deem the generic medication for Crestor® (rosuvastatin) equally effective for the
patient’s condition
2. Deem the generic medication to be non-equivalent and not effective for the patient’s
condition
Should the prescriber choose option 2, they must request pre-approval from the insurance
plan to cover the brand medication. Thus, the provider submits the appropriate
documentation and/or explanation (to the insurance plan) that Crestor® is medically
necessary and more beneficial/effective, than the generic medication, for their patient. The
patient’s insurance will then review the prescriber’s request for pre-approval and will
determine whether or not the medication will qualify for coverage under the patient’s health
insurance plan.
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In this example, the brand name medication was deemed medically necessary by the patient’s
insurance, and a PA for medication coverage was granted. It is important to note that had the
patient’s insurance found no medical need for the brand name medication, the patient would
then face several options:
1. Try the generic medication under physician approval
2. Try a different medication under physician approval
3. Pay cash for the full cost of the brand name medication not covered by their insurance
plan
Other options may exist based upon the particular situation and patient factors.
Guidelines and administrative policies for PA’s may vary between insurance plans and
companies. Although prior authorizations may be time consuming and frustrating for
consumers and health providers, they can help minimize overall health care costs by helping
avoid inappropriate medication use and promote utilization of evidence-based medication
therapy.4
Prior authorizations can be implemented in a variety of ways. Some prior authorizations
require additional clinical patient information, such as diagnosis and laboratory results,
before a providers is allowed to prescribe that medication.4 Figure 5-1, identifies common
types of prior authorizations that may be utilized.4,5

Types of Prior Authorization
Indication
Prescriber Coverage for
Particular Medication
Quantities outside FDAApproval
Non-step Therapy

• Off-label
• One indication vs. another

• Specialist vs. Primary Care Physican
• Duration of therapy
• Days supply
• Maximum daily dose limits
• Utilizing second-line, more complex, and/or more
expensive options/alternatives before first line options

Medications outside of patient’s health insurance plan’s formulary
High misuse or abuse potential medications
Figure 5-1. Types of prior authorizations
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In another example, a patient presents a prescription to their community pharmacist for a
migraine medication, which they have been prescribed to take four times daily. However,
their insurance company rejects the submitted claim. According to their formulary, the
insurance plan will only cover (or pay) for the migraine medication to be taken three times
daily. The patient may then choose to have their prescriber submit a PA to their insurance
plan. Should the prescriber provide appropriate documentation and/or explanation that
proves taking the migraine medication four times daily is medically necessary, the insurance
plan may issue a PA for coverage of medication costs.
EXCEPTION AND APPEALS PROCESS
Prior authorizations may also be referred to as exceptions. Insurance plans can evaluate
coverage based on individual patient cases to determine whether or not coverage exceptions
will be made.4 Patients may also request an exception when an insurance plan executes a
change to their formulary and their medication is no longer covered.16
Insurance plans differ on the amount of time it takes them to review an exception. Some
plans, such as Medicare Part D, offer expedited requests based on prescriber
recommendations for the patient’s overall health.5 In the event that coverage exceptions or
PAs are denied, patients may complete an appeal to request further evaluation or reevaluation of their original exception.5 Because certain exceptions must be initiated by the
payer, completed by the prescriber, and reviewed by the payer, the response time can vary. If
possible, pharmacists can assist patients by suggesting an alternative medication to avoid this
lengthy process.
HOW TO READ AN INSURANCE CARD
Although insurance cards may look different, they often contain similar information needed
to complete claim submissions for payment. In order to submit a claim to an insurance plan,
a patient’s member identification, BIN, Group, and PCN number are necessary. Should a
member’s coverage be expired or not active until a later date, submitted claims will not be
reviewed for coverage. Help phone numbers are typically found on the back of an insurance
card and may be utilized for various issues, such as when insurance card components are
missing or claims are rejected. Figure 5-2 defines common components of an insurance card,
whereas Figures 5-3 and 5-4 are examples of what an insurance card may look like.6,7
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Components of an Insurance Card
Member
Identification
Number
Group Number

BIN Number
PCN Number
Plan Type
Phone Numbers
Effective Date

• Used to identify the individual covered or “holding” the
insurance
• Numbers may be similar for other covered under the original
card holder

• Used to track specific benefits of the insurance plan
• Helps identify the individual covered under the insurance
plan
• Unique six digit number that identifies the third party
processor
• Third party processors may contract with multiple companies,
which utilize the same BIN number
• Help identify different plans via utilization of numbers or
letters
• May have either HMO, PPO, HAS, Open, or other
words/labels to describe the type of network the insurance
plan maintains
• Help lines, information, questions, etc.
• Date the coverage became active

Figure 5-2. Components of an insurance card

Figure 5-3. Sample insurance card6
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Figure 5-4. Sample insurance card7

SUBMITTING CLAIMS
Pharmacy claims are generally transmitted at the point of sale. Generally, when a patient
brings a prescription to the pharmacy, a pharmacist, technician, or intern will either access
their insurance information stored within their pharmacy computer (entered from prior
transactions) or enter/update their insurance card information. The pharmacy’s computer
system will transmit the patient’s claim electronically to the insurance company or pharmacy
benefit manager. This digital information will be processed electronically and information
will be sent back to the pharmacy to determine whether or not the patient is currently
enrolled under the entered insurance plan, if the prescription is covered under the plan, what
amount the patient owes for the prescription, and what amount of reimbursement the
pharmacy can expect to receive for the prescription. Although the information can be viewed
within the pharmacy’s computer system, the amount owed by the patient and saved by the
insurance is typically printed along with the patient prescription label, which are packaged
with the medication and distributed to the patient.
If a prescription is not covered, the pharmacy staff can communicate with the patient and
prescriber to help determine what steps should be taken. Patients may decide to pay cash or a
discount price (using eligible discount cards or coupons), but most often patients will choose
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to work with the physician and/or pharmacist to determine alternative therapies which may
be covered through the insurance or available at cheaper costs for the patient. If a prior
authorization process is required, the pharmacy staff will communicate that to the
prescriber’s office and/or staff electronically. At this point, the prescriber will need to
complete the prior authorization process with the patient’s insurance company before the
pharmacy can re-submit a claim. Most prior authorizations are completed within 72 hours.
LOWER COST SUPPORT/ASSISTANCE
Inability to afford medications is a major cause of non-adherence.8 Uninsured patients
lacking prescription and/or health insurance entirely and in need of assistance paying for
their medications have several options. Many pharmacies offer free or discounted
prescriptions for products such as vitamins, antidiabetic agents, antihypertensive
medications, and antibiotics. Underserved medical clinics may also provide limited
medications at no cost.
Patient assistance programs are available for certain medications. Individuals who qualify
can receive free or discounted medications for a particular period of time. Websites such as
NeedyMeds.org, RxAssist.org, and PPARX.org can be used to determine if an assistance
program is available for a given medication and what that programs’ eligibility criteria might
be. Patients who qualify may even apply for a program using these websites.
Patients can also lower costs with discount cards. Although most discount cards have similar
formatting and claims information, discount cards are not insurance cards. Offered by a
number of companies, discount cards offer savings on a variety of medications.
Unfortunately, most discount cards cannot be combined with insurance coverage. Discount
cards may hold the most utility for consumers when a particular medication is not covered by
their insurance. In this situation, a discount card may be used in place of the insurance card.
Most online medication coupons work the same way as a discount card and hold the same
limitations, but resemble a regular merchandise coupon. Medication coupons are often
specific to one medication, whereas discount cards can be applied to a variety of medications.
Advertising claims for discount cards and medication coupons can be misleading, as most
consumers do not understand the implications regarding their use.
Manufacturer assistance cards, also known as co-pay assistance cards, can be found on
manufacturer websites. Unlike discount cards or coupons, most manufacturer assistance
cards can be used with an individual’s health insurance coverage. Although benefits vary
between medication manufacturers, most manufacturer assistance cards offer a one time or
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twelve-month savings program. However, manufacturers will often set a maximum annual
savings limit and most manufacturer assistance cards must be pre-ordered or downloaded,
printed, and brought into community pharmacies by the patient. This may create some
barriers for individuals lacking access to online resources. Unfortunately, most pharmacies
do not have access to manufacturer assistance cards, but some physicians’ offices may
provide them or are willing to help patients locate them.
Uninsured patients are not the only patients who may need assistance. Underinsured
patients, who have minimal health and/or prescription insurance coverage, also may have
just as much difficulty affording medications.9,10 There are various resources available for
such patients. Families with children can go to InsureKidsNow.org to check if their child is
eligible for Children’s Health Insurance Program (CHIP).11 CHIP is jointly funded by the state
and federal government and provides health and prescription coverage to low-income
children and, in some states, pregnant women who do not qualify for Medicaid.11
Patients with Medicare Part D may qualify for low-income subsidy or “Extra Help” and can
apply online at Socialsecurity.gov/extrahelp.17 Both full and partial help is available through
the federal government, but states often offer additional programs as well. State based
programs are usually referred to as State Pharmaceutical Assistance Programs (SPAPs).5,9,10
Finally, patients can also be referred to a local State Health Insurance Assistance Program
(SHIP) office when they are in need of advice about prescription and/or health insurance or
extra assistance.
MEDICARE PART D PLAN SELECTION
One way to practice the terminology used in the previous chapter and this chapter is to look
at the Medicare plan finder. This tool helps Medicare beneficiaries compare plans and
demonstrates some of the differences between types of payer-provider relationships and
types of prescription coverage. Medicare Part D is the prescription drug benefit for all
Medicare beneficiaries. Even for patients with Medicare and Medicaid, Medicare Part D is
the first payer. This section will discuss specifically how to assist patients with comparing
options.
The Centers for Medicare and Medicaid Services (CMS) hosts a website to allow consumers
to compare Medicare Part D plans. The online tool is referred to as the “Plan Finder” and is
accessed at medicare.gov/find-a-plan. Information is maintained in this tool by CMS based
on information they receive from the insurance companies offering Medicare Part D plans.
Patients, caregivers, and advocates can search for details on different insurance plans by
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entering information about the patient. The tool will bring up a list of plans sorted in
ascending order by price, like airline flights or rental cars.
Let’s assume a male pharmacy student, Doug, is helping his Medicare-aged grandmother,
Rita. When Doug pulls up the Medicare website at www.Medicare.gov, he first has to decide
whether to do a general search or a personalized search. If the person entering information
has access to a patient’s Medicare card and their location, as Doug does, then it is best to do a
personalized search. This personalized search will allow Doug to verify Medicare’s records
regarding Rita’s coverage and any federal low income assistance benefits she receives. If you
do not have access to the information needed for a personal search, a general search can be
performed by answering as many guided questions as possible to focus the search to reflect
the patient’s current coverage.
Doug selects the personalized search option and enters: Rita’s zip code, Medicare number
(from her red, white and blue Medicare card), last name, effective date for Part A (also found
on her card), and her date of birth. When done, he selects “Find Plans.” Because her zip code
spans multiple counties, it will ask him which county she resides in. If her zip code did not
include multiple counties, then it would not show a county selection. This is because
insurance companies offering Medicare plans make network arrangements with pharmacies,
doctors and hospitals. The county a person resides in will likely impact which plans and
pharmacies are available for them.
Once this is complete, it is time to enter the patient’s medication list. At the “Enter Your
Drugs” screen you will see a review of the patient zip code and current coverage in the upper
right corner. It should look similar to Figure 5-5.
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Figure 5-5. Zip code and current coverage listing for MedicareRx Preferred

Rita has Original Medicare A and B and a Part D plan and AARP MedicareRx Preferred, a
stand-alone prescription drug plan (PDP). She does not have a low income subsidy from the
federal government (referred to as Extra Help).
If Rita had Medicare Advantage, her profile box would look like Figure 5-6. Medicare
Advantage is also referred to as “Medicare health plans,” which combines Medicare Part D
with private coverage for Medicare Parts A and B.

Figure 5-6. Zip code and current coverage listing for Medicare Complete

This patient has an AARP MedicareComplete plan, an HMO plan as indicated in parentheses
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after the name. If you were unsure if this plan had prescription drug coverage included, you
could double check by calling the company, checking their website, or by looking in the annual
CMS publication Medicare and You. This book is mailed to all Medicare beneficiaries each
year and is specific to the state they live in. Patients should be encouraged to retain this
volume each year.
Now Doug is ready to enter Rita’s medications, careful to enter the medications exactly as
brand or generic and the correct dosing. Once that is complete, he will select her preferred
pharmacy. The tool will ask which type of Medicare Part D plans are of interest.
Doug can compare three options: stand-alone prescription drug plans with Original
Medicare, Medicare health plans with drug coverage, or Medicare health plans (Medicare
Advantage) without drug coverage. An easy way to remember is that health plan means
medical benefits, like doctors and hospitals, as opposed to a drug benefit or Part D alone. Since
Rita already has Original Medicare and a prescription drug plan, that is what she wants to
compare. If Doug were to compare Medicare Advantage plans, he would need to pay attention
to the medical benefits and their network coverage, such as in-network physicians as well as
the prescription coverage details. In this search he will focus on prescription benefits.
A list of all the available plans will show up in the next screen in order of lowest estimated
annual cost, though this can be changed. The lowest estimated annual cost is an estimate of
the total cost the patient will pay for their Part D coverage. This includes premiums, the
monthly fee to maintain coverage, and the costs of their medications. The medication costs
include the amount the patient has to pay before they meet their deductibles and any co-pay
or co-insurance amounts paid until they reach their out-of-pocket maximum. Doug selects
two plans to compare with Rita’s current plan in a side-by-side comparison.
The results of this comparison are provided in Figure 5-7. The first column lists her current
plan. Please note the current plan may not always be in the same place and may change on
future searches.
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A

B

C

Figure 5-7. Plan comparison
Doug reviews this screen with Rita. He explains that the first row is the monthly drug plan
premium she will pay for her stand-alone prescription drug coverage. In the next row,
monthly health plan premium is N/A because Rita does not have Medicare Advantage.
Therefore, there is no health plan premium listed because Medicare does not list the original
Medicare premium here. The third row is the annual deductible which will take effect at the
beginning of her coverage for that year. Some plans charge a deductible and others don’t. This
amount can also vary. Plans are structured as basic or enhanced plans, which is why the plans
are not standardized.
Below the first three rows in Figure 5-7 are the estimated annual costs for Rita’s drug
premium and drug costs (taking the deductible into consideration). This image shows the cost
at two community pharmacies and the cost at the mail order pharmacy. Different pharmacies
may have significantly different costs if a pharmacy is not in network. Ensure you are looking
at the pricing for the pharmacy the patient wants to use and/or you consider the pharmacy
location in making your recommendation. A discussion of networks can be found in Chapter
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6.
Figure 5-8 shows the summary of the prescription coverage by the three plans Doug is
comparing on the “Plan Finder.” First, Doug notices that plans A and B do not have all of Rita’s
medications on the plans’ formularies. He may want to check with Rita’s doctor to see if she
can take a generic and whether generic would be covered. If he already knows she must have
brand name, then he may want to consider the overall cost of the plans in Figure 5-10. The
estimated cost will factor in the full cost of the medication not on formulary.
Next, Doug checks to see what types of restrictions exist on the medications that Rita takes.
He sees that plan B has quantity limits on the escitalopram oxalate, so she may be limited on
the number of pills she can get each month. He checks in the plan finder and sees that she is
allowed 30 in 30 days, which is the frequency that she uses the medication. He also notices
that the physician will have to complete a prior authorization for the Namenda for all three
plan options, so he will need to follow up on that when she begins her coverage. Finally, he
notices that the zolpidem tartrate requires step therapy for plan B. He makes a note to contact
the insurance company to identify what therapy must be tried first.
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A

B

C

Figure 5.8. Summary of prescription drug coverage
Now that Doug has a better understanding of the pricing and coverage of these three plans, he
looks at the two factors together. Plan B has the most restrictions but would allow her to use
her favorite pharmacists at Blackburn Health Center or cheaply at a CVS pharmacy. Plan C
does not have a deductible, which would be nice since Rita has costly heat bills in the winter.
However, it has significantly higher premiums than the other plans. Mail order is more
expensive than retail pharmacy for all three plans so there is no incentive for her to use mail
order at this time.
Doug and Rita discuss her preferences for prioritizing premiums, deductibles, pharmacies,
and restrictions. Doug remembers that there is one additional piece of information they might
find helpful: each plan receives a star rating to give consumers a quality perspective on the
plans they are selecting. Doug finds the star ratings on the Plan Finder: plan A is 2.5 stars, plan
B is 4 stars, and plan C is 3 stars.
CONCLUSION
In order to compare medical and prescription insurance coverage it is helpful to first consider
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the type of payer-provider relationship. Then understanding the details of the coverage can
allow beneficiaries to select the best coverage for them. Pharmacists can help patients and
caregivers compare prescription drug coverage and educate them about the different
insurance terms.
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GLOSSARY
Benefits
Items, services, or payments covered in full or part by the insurance company for the
beneficiary
Co-insurance
A percentage fee paid by an individual for health care services
Co-payment/Co-pay
Flat fees that must be paid by an individual for particular services, like a visit to a primary care
physician
Deductibles
A set amount that one must pay each year before the insurance company will begin to pay on
healthcare costs for an individual
Formulary
List of particular medications available for coverage by insurance companies that have been
demonstrated as safe, effective, and providing the highest cost-benefits for patients
Health Literacy
The degree to which individuals have the capacity to obtain, process, and understand basic
health information and services needed to make appropriate health decisions
Member
Individual enrolled under a particular health insurance plan
Network
Group of healthcare providers who provide services that are eligible for coverage under an
insurance plan
Out-of-Pocket Limits/Maximum
Maximum amounts a patient, also known as a beneficiary, has to pay out of their own pocket
for covered health care expenses
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Pharmacoeconomic
A branch of economics that compares pharmaceutical products and treatment strategies
through analysis of cost-benefit, cost-effectiveness, cost-of-illness, cost-minimization, and
cost-utility
Premium
What one must pay in order to have insurance coverage
Prior Authorization
Insurance requirement that physicians provide explanation and/or documentations to
support the use of a specific medication therapy in order to determine medical necessity and
appropriate therapy
Step Therapy
A treatment approach that utilizes the most cost-effective medication therapy and then
progresses to alternative therapies, which may be more expensive or lack comprehensive
research evaluating efficacy, to better control costs for insurance providers
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CHAPTER 6
PHARMACY AND THERAPEUTICS COMMITTEE
Author: Joe Jordan, PharmD, BCPS
Chapter 5 discusses access issues for patients including affordability and limits on access
such as prior authorization. This chapter explains how and why access to different
medications may be restricted on a formulary developed by a Pharmacy and Therapeutics
Committee.
While drug formularies have reportedly existed in the United States for over 200 years, their
roles and purposes have changed, reflecting the increased complexity of the medications
themselves, the healthcare systems within practice settings, and the roles and
responsibilities of stewards of these lists.1 A common name given to a group responsible for
oversight of a formulary is the Pharmacy and Therapeutics (P&T) committee. As the name
implies, this committee involves pharmacists and those involved in the therapeutic
application of these products. A typical committee is comprised of those who prescribe drugs
(e.g. physicians), those who purchase and prepare drugs (e.g. pharmacists) and those who
administer drugs (e.g. nurses), in addition to other personnel depending on setting (e.g.
finance or risk management). Membership will vary based on practice setting but is usually
representative of the primary medical services provided within that health care system. In
addition to determining formulary selection criteria, P&T committees also oversee how
products are purchased, stored, ordered, prepared/dispensed, administered, and monitored.
Any policies or protocols addressing medication use, such as adverse drug event monitoring
and reporting and approval of guidelines or care pathways, also fall under the P&T committee
oversight. In the outpatient setting, prescription drug plans have their own P&T committees
that use specific formulary management tools, such as prior authorization, step therapy, and
copayment tiers.2-3
A formulary, by definition, is a “continually updated list of medications and related
information, representing the clinical judgment of physicians, pharmacists, and other experts
in the diagnosis, prophylaxis, or treatment of disease and promotion of health”.2 The term
medication has been interpreted broadly in some settings to include all products delivered in
the context of care for diagnosis, prevention, and treatment. Given this definition, agents such
as alternative remedies (herbals and supplements), nonprescription products, blood
derivatives, and contrast media would also be included in some settings.3 While formularies
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previously operated more as inventory control, now they are intended to function as systems
to insure that drug products are used in a rational, safe, and cost-effective manner to support
affordable and sustainable drug benefits.4,5 These systems are used in hospitals, home care,
and long-term care settings, in addition to payer settings such as Medicare, Medicaid,
insurance companies, and managed care organizations.
DRUG FORMULARY EVALUATION
In order for a formulary to have the best available medications available for use, it must be
confident in the process of review of the medications.6-7 The first step for inclusion of a given
drug on a drug formulary is through evaluation of evidence. Common elements of a drug
review note the FDA approved indications and potential areas of off-label use, a review of the
differences with similar agents on formulary with respect to pharmacokinetics and
pharmacodynamics, a critique of individual trials used to support a therapeutic benefit,
analysis of potential for harm incorporating both drug and formulation characteristics, and
ultimately cost.3 Table 5-1 expands on common elements within a new drug review. A P&T
committee could simply decide to add or not add to a formulary, but more commonly will offer
recommendations for additional criteria, such as strategies for ensuring appropriate use.
Questions to consider when determining whether to add drugs to a formulary should be based
on quality of evidence and comparisons to therapeutic alternatives. One model cited in the
literature is the Formulary Leveraged Improved Prescribing (FLIP) Project.7 In this model,
five areas are addressed when reviewing a drug.
Evidence of Need – Is this Drug Truly Needed? 5
Depending on your setting of practice and the prevalence of conditions commonly treated by
your practitioners, some indications of drugs may not be relevant. For example, glucarpidase,
an antidote to methotrexate toxicity, is probably not needed in a community hospital that
mostly sees patients in need of orthopedic and cardiovascular procedures. However,
tranexamic acid, an agent used off-label to reduce postoperative blood loss, may be of interest
to this setting. It is always worthwhile to reflect on what is available on your formulary and to
describe the shortcomings of existing therapy with respect to safety, tolerability, or
effectiveness. Framing your search based on shortcomings of existing therapy will help with
discerning value, if any, of the drug you are considering.
Efficacy – What is the Evidence to Support Claims for Drug? 5
This is where being able to read, appraise, and apply clinical studies becomes particularly
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important. Depending on sources of information, claims of efficacy will be considered
differently if coming from high- or low-quality studies or those with high versus marginal
differences. For example, a single-center, uncontrolled trial showing improvement in pain
scores and decreased hospital length of stay is less generalizable than a multi-center,
randomized, active-controlled trial demonstrating these same endpoints. Similar to the
question of evidence of need, individual evidence should be assessed for relevance to the
population you treat. There may be potential for off-label use of a product and it is important
to note what evidence, if any, is available to support this since it may factor into decisions to
restrict or regulate use.
Safety – What are the Safety Issues that Should be Weighed? 5
In addition to the safety information present in the labeling of a drug (e.g. contraindications,
warnings, adverse effects), the potential for medication errors once it becomes available on
formulary should be taken into consideration. The potential for look-alike/sound-alike errors
or complicated administration or preparation requirements are a few examples of potential
safety concerns beyond the package insert. As drugs are studied in relatively small sample
sizes in relation to the size of the population they will be used, it is worth noting any safety
signals or areas under review that may become more apparent once a drug is used in a larger
population. Lastly, it is worth comparing the safety composite of the drug under review with
existing therapeutic options on formulary.
Misuse Impact Potential – What is the Potential for Misuse or Overuse? 5
This question begins to address the issues of pharmaceutical advertisements and detailing. If
a drug is heavily marketed to consumers or prescribers, there may be unrealistic expectations
leading to demand for use in areas where the product may or may not be needed. Off-label use
of drugs is very common and this is an area that a P&T committee should periodically review
to ensure that products are being used optimally based on evidence of safety and effectiveness
rather than on unrealistic expectations.
Cost Issues – Is the Drug Worth the Costs?
A common theme that arises with approval of new drugs is that while they must demonstrate
that they can have an effect in a carefully controlled trial setting, these effects may or may not
be seen in the uncontrolled real world when they are used in general practice. While a cost
may be appropriate based on perceived utility in a controlled study, these costs may be
considered excessive if a drug fails to demonstrate effect in a variety of patients in the general
population with a given disease. Additional cost factors to consider include preparation and
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storage costs, monitoring costs, and labor costs with administering product.
After preparing a review, the information gathered is commonly shared among other
healthcare professionals who would be impacted because they prescribe or would administer
the product. From a cost standpoint, it is not unusual to have a financial party assess the
relative cost-benefit of the potential impact on use of resources outside of pharmacy.
Decisions about a drug are often driven based on the final composite analysis of benefit, risk,
and cost in relation to agents on formulary. If it provides an improvement in benefit, risk, or
cost and the other variables are not impacted (or improved) then a drug will likely be added to
formulary. Similarly, if it worsens benefit, risk, or cost and other variables are not impacted
(or worsen), then a drug likely won’t be added to formulary. However, it is rare that final
analyses are this clean and there is usually some trade-off amongst these variables. When
drugs are added to formulary with potential increased risk of safety and/or cost, it is not
uncommon to have additional criteria to ensure they are used in a safe and cost-effective
manner.
STRATEGIES FOR MANAGING THE FORMULARY
Ensuring medications are used in an optimal manner often involves educational, managerial,
or regulatory strategies.3 Multi-disciplinary development of these strategies will increase the
likelihood of success instead of creating them from one practitioner’s perspective.3,7-9
Educational strategies are intended to inform or persuade healthcare practitioners to use a
medication in a particular manner. Examples of this approach could be provision of a
newsletter, preparation of consultative review documents, or one-on-one clinical
supervision or consultation. This approach is often received well by clinicians who don’t
perceive it as restrictive. A practical application of this could be providing an algorithm of
how to treat a patient with blood pressure or high cholesterol. However, this approach is one
of the least effective when trying to change behavior or practice. If a medication is not being
used optimally from a benefit versus risk or cost standpoint, this approach will likely not
result in changes in how that medication is used. For example, if a given clinician is adamant
about using a PCSK9 inhibitor (~$14,000 per year) first line in their hyperlipidemia patients,
providing an algorithm that has this class used after statin therapy won’t force them to
change.
Another approach is to use managerial strategies to guide or structure decisions. Guided
strategies allow the product to be used, but with hardwire processes so they are used in
particular way. Examples of this approach include clinical protocols or order sets, use of
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tiered or step-wise approach, procurement selection based on cost, therapeutic interchanges,
protocols converting intravenous to oral administration, and patient cost-sharing. Some
examples could include converting all ACE inhibitors to lisinopril at an equivalent blood
pressure dose (i.e. therapeutic interchange) or using an oral proton pump inhibitor instead of
an IV proton pump inhibitor (i.e. IV to PO interchange) when patients can absorb oral
therapies. This approach is less well-received by clinicians than educational strategies
because it involves barriers or requiring them to “follow the rules” if they wish to use a
particular medication or class of medications. The managerial strategy is commonly, but not
always, employed because of cost or safety concerns. If multiple medications are available to
treat a given condition and differences, if any, are considered marginal, then steering therapy
to least costly agents first is an example of a tiered approach. Another simple approach that
pharmacy can take is to procure a generic instead of a branded medication. In order to limit
formulary options or possibly save on costs, therapeutic interchanges may allow for one
medication to be used in place of another either within its therapeutic class or even out of the
same class. This is commonly seen in hospital settings and requires approval by a P&T
committee.
Lastly, a less-accepted approach, but very effective, is to introduce restrictions or limitations.
Examples of this regulatory approach could include banning certain drugs from an
institution, requiring prior authorization before use of medications, or restricting use of
medications to a certain provider. Limiting providers from writing for more than five
continuous days of ketorolac therapy or restricting daily doses of acetaminophen to <3 or 4
grams is an effective way to ensure safe use of these medications. Restricting use of an
antimicrobial to an infectious disease physician or requiring that certain criteria be met
before certain medications can be used (i.e. prior authorization) are often disliked by
clinicians but can help ensure appropriate use.
SUMMARY
A P&T committee is a multidisciplinary group of professionals within an organization that
oversee the selection and use of medications. The goal of this committee is to provide a
formulary that represents the optimal therapy for patients based on relative efficacy and
safety. As medications and healthcare systems become more complex and costly, P&T
committees are focusing efforts to ensure medications on formulary are used efficiently by
providing strategies for appropriate use.2,3
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Uses/indications

Pharmacology

FDA approved indications, other potential uses based on clinical
trials or agents with similar mechanisms of action
Summary of drug and/or drug class noting similarities or
differences within a class or versus other agents with similar
indications

Pharmacokinetics

Depth varies depending on disease state. For example, infectious
disease drugs may have more coverage in this area than a blood
pressure drug. Highlight absorption, distribution, metabolism,
elimination (ADME) of drug and note information on specific
subsets of patients (e.g. renal & hepatic dysfunction, male vs
female, pediatric vs adult vs elderly, bariatric vs normal weight)

Guidelines and/or
systematic
reviews

Review indications of drug noting prevalence of disease, current
approaches to therapy, and areas of need. Note role of current
therapy in the disease approaches, if known.

Comparative
efficacy

Review clinical trials of drug noting quality of study methods,
relevance of populations studied, applicability of outcomes
evaluated and magnitude and precision of results. Contrast
findings with other therapies available for indication

Comparative
safety

Highlight contraindications, warnings/precautions, drug interactions
and adverse reactions that a practitioner needs to be aware of to
effectively manage a patient on this drug. Note actions that a
clinician can take to mitigate risks as well as similarities and
differences with other drugs within class or drugs approved for
same indication. Contrast findings with other therapies available for
indication

Monitoring
Dosing and
administration

Recommended laboratory or other types of monitoring necessary
for patients to be effectively and safety managed
Recommended dosing regimens both for FDA indicated and
potential off-label use. Special populations such as pediatrics,
organ impairment (i.e. renal, hepatic), or obesity may have different
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dosing strategies available from the literature. Compatibility
information for parenteral products and splitting or compounding
information for oral products would go here.
Availability

How product is supplied noting specialty distribution programs,
when applicable. Some products are not orderable through normal
supply chains and are shipped directly to patients.

Pharmacoeconomic analysis

In addition to the acquisition cost of drug, presenting cost as a
function of per unit dose, per day, or per duration of therapy in
relation to other therapies. If available, note potential economic
impact on other areas such as consumption of additional
labs/supplies or ED/hospital visits.

Potential misuse
impact

If approved, is there significant education required to ensure
product is used optimally (i.e. safely and efficaciously). Are there
medication errors associated with this drug or this class and can
policies or procedures be put into place to mitigate these. Is
product likely to be used in off-label areas

Table 5-1. Common elements of drug monograph
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CHAPTER 7
BILLING AND REIMBURSEMENT FOR THE
AMBULATORY CARE PHARMACIST
Author: Jessica Wilhoite, PharmD, BCACP
Chapter 6 discusses the variety of contractual arrangements that managed care companies
make with healthcare providers such as networks, capitation fees, and salaried payment. That
chapter also introduced the concept of coordinated providers under Accountable Care
Organizations (ACOs). Medical insurers contract with physicians and hospitals through
networks, capitation and bundled payment models of reimbursement. This section will
outline how pharmacists are impacted by these payment arrangements.
Pharmacists are usually paid as hourly or salaried employees of the pharmacy chain or
independent pharmacy that employs them. It is almost always the pharmacy, hospital, or
clinic, not the pharmacist, who negotiates with third party payers such as private insurers and
pharmacy benefit managers. In the retail/community setting, claims are transmitted
electronically when the patient fills a prescription and payment for each prescription is
calculated at the point of sale. The pharmacist is removed from the contractual process but
the bottom line is impacted by each prescription rejection.
In the hospital setting, the charges for all services are added together for the patient’s stay.
This list is often referred to as the charge master, which is then billed to the insurance
company or government payer based on the contractual arrangement between that hospital
and payer. This is usually done after the patient is discharged, although a pre-authorization
may be requested to verify the patient has coverage and payment is likely. As discussed in
Chapter 6, the charges may be fee-for-service or may be submitted each day as a daily total
(per diem) or one total for the whole hospital stay (per episode).1
Hospitals and physician practices may be owned by the payer, as with a Health Maintenance
Organization (HMO). The healthcare providers in the physician practice, including the
ambulatory care pharmacist, are likely paid salary by the payer itself. In this case, a global
budget is created for hospital and administrators who are responsible for charging against a
budget and for appropriate use of funds.1 Hospital administrators who are unable to manage
budgets appropriately will likely lose their jobs. With the movement towards accountable
care and value-based payments, new contractual arrangements linking patient outcomes and
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quality measures to payment are changing reimbursement structures.
Ambulatory care pharmacy practice is one of the fastest evolving pharmacy sectors as the
profession is continuously changing to include delivery of comprehensive clinical,
consultative, and educational patient care services.2 Challenges in providing such services
still remain; pharmacists lack provider status, as they are not recognized under Title XVIII of
the Social Security Act, resulting in reimbursement ineligibility under Medicare Part B.3 One
way health care professionals generate income is through billing for their services. Because
pharmacists are not recognized as providers by many payers, including Medicare Part B,
billing for clinical pharmacy services in the outpatient setting can be complex. Billing is the
process of documenting services rendered to patients, and sending a bill for the eligible
service to the third party payer for reimbursement. Services are separated into numerical
codes, which correlate to the varying complexity of the services. Providers report these
numerical codes to third-party payers in order to receive reimbursement for their services.
Reimbursement is a dollar amount which is returned to the organization for properly
performing, documenting, and billing for services. Reimbursement amounts for the same
services can differ between payers. This means that a health care provider can be paid
different amounts for performing the same service, depending on the third party payer.
Medicare reevaluates and recalculates reimbursement amounts for outpatient services
annually and makes that data publicly available. In general, Medicaid reimburses about half
that of Medicare and private payers reimburse 20% more.4 Billing also includes cost-sharing,
which represents the patient’s copay. The next section will focus on both direct and indirect
billing methods utilized to receive reimbursement for ambulatory care pharmacy clinical
services.
PROVIDER STATUS
Provider status is granted to healthcare providers who provide patient assessments, bill for
their services, and receive reimbursement. The diversity of healthcare professionals included
in a provider network can vary between private third party payers and the Centers for
Medicare and Medicaid Services (CMS). Third party payers define a provider network to
ensure quality healthcare is delivered to patients by qualified health care professionals. A
summary of third party payer types, and pharmacist billing opportunities for each type can be
found in Table 7-1.
Medicare
Title XVIII of the social security act recognizes health care providers eligible to receive
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reimbursement from Medicare Part B. Such providers are listed in Figure 7-1. As mentioned
previously, pharmacists are not recognized as providers under Title XVIII; therefore, lack
ability to receive reimbursement for their services in the outpatient setting.3

Physician
Assistants

Nurse
Practitioners

Clinical Nurse
Specialists

Certified Nurse
Midwives

Clinical
Psychologists

Clinical Social
Workers

Physical
Therapists

Occupational
Therapists

Figure 7-1. Non-physician providers eligible for reimbursement from Medicare Part B

Additionally, Medicare Part D, which provides prescription benefits, gives variable options
for patients to choose a prescription drug benefit plan to best suit their needs. Regardless of
which plan is chosen, it is required that all plans offer medication therapy management
(MTM) services to their beneficiaries. MTM services can be provided by pharmacists or
other qualified providers and is reimbursable by Medicare Part D when the service is
provided in the community pharmacy setting.2
State Programs
Individual states have the ability to enact legislation to allow pharmacists to bill for services
and receive reimbursement. A state legislature can trump the federal social security act and
allow pharmacists to have provider status in that state. In May 2015, Washington became the
first state to sign legislation requiring pharmacists be included in health insurance provider
networks.5 At the time of this writing, 38 states designate pharmacists as providers in at least
one statute or Medicare provision.6
Private Third-Party Payers
Generally, most private third-party payers follow CMS rules and regulations; however,
pharmacists have worked directly with commercial third-party payers to create contracts for
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payment of their services. There is no obligation for a commercial payer to recognize
pharmacists as providers and it is up to their discretion whether they include or exclude
pharmacists from their provider network.
Self-insured employers are another third-party payer in which pharmacists may directly bill.
Self-insured employers are businesses where the employer pays out-of-pocket for their
employee’s healthcare expenses, handling all paperwork and payment for health claims. Selfinsured employers have the ability to recognize pharmacists as providers; however, like
private third-party payers there is no obligation to include or exclude pharmacists within
their provider network.
Self-Pay Patients
Cash paying patients always reserve the right to pay cash for services. Pharmacists may bill
dependent on the market demand of patients willing to pay pharmacists cash for their
services.
Payer Types

Can a pharmacist bill directly?

Medicaid / State
Programs

Only if an individual state passes legislature.

Medicare

Part B – No. Pharmacists are not recognized as providers.
Part D - Yes, Medication therapy management is a required
element can be provided by pharmacists or other qualified
providers.

Commercial Third Party
Payers

Only if the commercial payer includes pharmacists in their
network

Self-Insured Employers

Only if the Self-Insured Employer includes the pharmacists in
their network

Cash Paying Patients

Yes, if the patient is willing to pay

Table 7-1. Payer types24
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BILLING FOR CLINICAL PHARMACY SERVICES IN AN AMBULATORY SETTING
If a healthcare professional is not included in the provider network of a third-party payer, they
will receive no reimbursement for their services from that payer; however, there are ways in
which they can generate revenue by indirectly billing for services. Each health care
professional carries their own unique National Provider Identifier (NPI) number. An NPI
number identifies specific healthcare professionals or healthcare entities (e.g. hospitals,
nursing homes, etc.) on HIPAA standard transactions such as bills.7 Although pharmacists
are not eligible to bill Medicare Part B under their own NPI number, they can collaborate with
a physician or other recognized provider to bill indirectly under the collaborating provider’s
NPI number. To bill under another healthcare professional’s NPI number using any of the
billing methods outlined below, a collaborative practice agreement is often written and
signed by all parties. A collaborative practice agreement is a signed document granting
authority to a pharmacist (or other healthcare professional) to bill for services under a
supervising practitioner's NPI number.3 A collaborative practice agreement includes specific
practice protocols which the pharmacist must follow.
“Incident To” Billing Methods for Pharmacists
Indirect or “incident to” billing is the framework under which a non-physician practitioner
may bill under a supervising physician's NPI number, given certain criteria are met. CMS
defines “incident to” as those services that are furnished “incident to” physician professional
services in the physician’s office, separate office suite, in an institution, or a patient’s home.8
In the outpatient setting, health care professionals utilize Current Procedural Terminology
(CPT) codes to identify services rendered and International Classification of Diseases-10
(ICD-10) codes to detail the indication for those services. The indirect billing method is
utilized by ambulatory care pharmacists and other mid-level practitioners who work in
conjunction with a physician to see patients and bill for services. There are several conditions
which CMS requires in order for a non-physician provider (NPP) to be eligible to bill for
services “incident to” (Table 7-2).8
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Establish with
Physician

Physician or Medicare Part B-approved provider must perform an
evaluation or service for the same problem that is being evaluated by
the pharmacist’s service
Physician must establish a plan of care which includes future incidental
services.

Active
Involvement

Physician or Medicare Part B-approved provider must be actively
involved in the patient’s course of treatment and provide subsequent
services at a frequency that reflects their active involvement

Common
Services

Services rendered must be of a type that are commonly furnished in
the physician’s office or clinic.

Services Order

The physician or Medicare Part B-approved provider must have
provided authorization for the service and authorization must be
documented in the medical record.

Employee
Relationship

The pharmacist providing the service must be an employee, leased, or
contracted to the physician or Medicare Part B-approved provider.

Scope Of
Practice

All services rendered must be within the scope of practice for that
specific healthcare professional and medically appropriate to be given
in the provider’s office.

Direct
Supervision

A physician or Medicare Part B-approved provider must be on the
premises, but not necessarily in the same room, when services are
being performed.
Direct Physician Supervision also requires the physician must be
clinically appropriate to supervise any situation or emergency that
may arise.

Table 7-2. “Incident to” rules2
“Incident to” Billing in an Institutional Ambulatory Setting
Hospital based “incident to” billing refers to physician outpatient clinics that are financially
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tied to a hospital. To determine if a physician clinic is financially tied to a hospital, check to
see if they have similar tax identification numbers or ask the billing department for that clinic
or hospital. When a patient is seen by a Medicare Part B recognized provider, they may bill
two fees: a professional fee for the services they perform and a facility fee for the hospital to
cover facility expenses. Because pharmacists are not recognized providers under Medicare
Part B, pharmacists can only bill via a facility fee and cannot bill a professional fee. The
disadvantage of facility fee billing is the extra financial burden on the patient. For example, if
a patient sees the physician and pharmacist in the same day, they will receive two bills: a bill
for the professional fee for the physician and their facility bill, and a separate facility fee bill
that includes the services provided by the pharmacist.2
“Incident to” Billing in a Non-Institutional Ambulatory Setting
Physician clinic based “incident to” billing refers to a physician outpatient clinic that is not
financially tied to a hospital. The physician, or physician group, owns the entity in its entirety
and the clinic practices under their own business tax identification number. Unlike hospital
based “incident to” physician billing which can bill a facility fee, physician based clinics
cannot bill a facility fee and only have the option to bill professional fees. Again, because
pharmacists are not recognized providers under Medicare Part B, they must indirectly bill
“incident to” physician for their professional fees. The same CMS “incident to” rules apply
(Table 7-2). When billing “incident to” in physician based clinics, pharmacists may be
reimbursed at 100% of the physician rate, or 85% of the physician rate if a non-physician
provider (NPP) is serving as the supervising provider.9
Billing Levels
Billing for services in both hospital and physician based clinics are executed via five CPT
codes 99211-99215. CPT code 99211, or level 1 billing, is the lowest level of billing and yields
the lowest reimbursement. CPT code 99215, or level 5 billing, is the highest level of billing and
yields the highest reimbursement amount. When billing at the lowest level, 99211, there are
no documentation requirements; however, when documenting a patient visit to support a
higher level of billing, there are three main areas required: number of body systems reviewed,
number of disease states assessed, and the level of complexity of decision making.10 The level
of billing is then determined by the complexity of the visit based on the components included
in the note documentation (Table 7-3). For most regional carriers of CMS, pharmacists are
limited to the lowest billing level, 99211, when billing “incident to” because they are not
recognized Medicare Part B providers.2 For non-Medicare “incident to” billing, state
Medicaid programs and commercial third party payers may allow pharmacists to bill at
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higher levels as long as documentation supports the higher level of billing.2

Patient
History

Patient history is comprised of several components such as family history,
social history, history of present illness, chief complaint, and review of
systems. Review of systems analyzes each organ system (genitourinary,
respiratory, etc) pertinent to the patient’s chief complaint. The more systems
reviewed, the more complex the visit and the higher the billing level able to
be billed.

Physical
Exam

The physical exam is a required component of the visit. Physical exam can
range from a multi-system physical exam, to a single-organ exam. CPT code
99211 may be billed without a physical exam. The more elements involved in
the physical exam, the higher the billing level able to be billed.

Medical
Decision
Making

Medical decision making complexity is based on the three main components
of the number of diagnostic options, amount of complexity, and the risk of
decision making. A points system is utilized to categorize the level of medical
decision making and the appropriate corresponding billing level.

Table 7-3. Billing components2

MEDICATION THERAPY MANAGEMENT
Medication Therapy Management (MTM) is a medical service provided to optimize drug
therapy and improve therapeutic outcomes. Medication therapy management services are
patient-centered services, rather than product-centered services.11 In 2003, The Medicare
Prescription Drug, Improvement, and Modernization Act (MMA) created Medicare Part D
but also required insurers to cover MTM services for their beneficiaries.12 The MMA
identifies three MTM parts: education to improve patient’s medication understanding,
programs to increase medication adherence, and detection and prevention of adverse drug
reactions.13 MMA does not require that MTM services be provided by a pharmacist, but as
drug experts, pharmacists can play a vital role in improving patient’s health care quality and
reducing exacerbations.13 MTM services can be billed via CPT codes which are chosen based
on the visit length of time (Table7- 4). These CPT codes are not recognized by Medicare Part
B, because MTM is not a covered service under Part B, only Part D; therefore, these CPT codes
cannot be utilized in the physician clinic setting as Medicare Part B is the entity that covers
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services provided in the physician office (hospital-based or physician-based). These CPT
codes; however, can be utilized via contracts with prescription drug benefits plans under Part
D in a licensed dispensing pharmacy setting. MTM services can still be provided by a
pharmacist or other practitioner in the institutional or non-institutional outpatient settings;
however, billing codes utilized are those that are covered by Medicare Part B and pharmacist
billing methods are similar to other pharmacy services in these settings, as outlined
previously.

CPT Code
99605

Billed for a new patient visit for the initial 15 minutes of face-to-face MTM.

CPT Code
99606

Billed for an established patient for the initial 15 minutes of face-to-face
MTM.

CPT Code
99607

Billed for each additional 15 minutes of MTM. This code can only be used
after billing either 99605, or 99606.

Table 7-4. MTM CPT Codes25

TRANSITIONAL CARE MANAGEMENT
Transitional care management (TCM) refers to services offered during a period where a
patient is transitioning from an inpatient to an outpatient setting. This transition represents
a vulnerable time for the patient who is now required to manage changes in diagnosis,
medications, and/or lifestyle habits.14 These rapid and sometimes drastic changes can
increase the patient’s risk of exacerbation and hospital readmission if not properly
managed.14 The Centers for Medicare and Medicaid puts a strong emphasis on quality of
healthcare, and in October 2012 introduced the Hospital Readmissions Reduction Program.
Through this program hospital reimbursement rates are reduced if patients are readmitted to
the hospital within 30 days.15 In addition, effective January 1, 2013, Medicare created a new
method for reimbursement of transition-related activities. These CPT codes for TCM
services may be used to bill physician and qualified non-physician providers care
management following patient discharge. Qualified non-physician providers who may
provide TCM services include: certified nurse-midwives, clinical nurse specialists, nurse
practitioners, and physician assistants.14 TCM appointments aim to reduce hospital
99

readmissions by minimizing patient risk of new or changed medication regimens and
ensuring proper education of lifestyle habits and self-management of chronic disease. The
TCM CPT codes provide higher rates of reimbursement and combine face-to-face and nonface-to-face TCM components into one billing code (Table 7-5). The required components
for TCM billing are outlined in Table 7-6. Additional components, not required, may include:
caregiver education, managing medications, obtaining and reviewing discharge information,
reviewing pending diagnostic tests and treatments, communicating with other health care
providers, establishing referrals, arranging community resources, and assisting with follow
up with other providers or services.16-18

Visit Type
TCM
TCM

Timing
(Calendar
days)
Within 7 days
of discharge
Within 14 days
of discharge

CPT Code

Complexity

99496

High

99495

Moderate

Claim
Deadline
30 days from
discharge
30 days from
discharge

Table 7-5. Billing Codes for Transitional Care Management (TCM) Billing16-18

Interactive
Contact

Non-Face-ToFace Services

Face-To-Face
Visit

Interactive contact must be made with the patient via e-mail, telephone
call or face-to-face appointment within 2 days of the date of care
transition.
The practitioner must provide non-face-to-face services to the
beneficiary. These services may be conducted by licensed clinical staff
under the physician or NPP’s direction.
If the physician or NPP determines that non-face-to-face services are
not indicated, then they are not a required element.
A moderately complex patient must have a face-to-face visit within 14
days of the date of transition of care.
A highly complex patient must have a face-to-face visit within 7 days of
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the date of transition of care.
Medication reconciliation and management must be furnished before
or on the date of the face-to-face visit.
Table 7-6. Required components for transitional care management billing19

While pharmacists are not included in the list of qualified non-physician providers able to bill
for TCM services, these codes present an opportunity for pharmacist’s services to be
reimbursed as a part of a multidisciplinary team. The billing claim itself must be submitted
under a Medicare recognized provider and can only be billed once per beneficiary during the
TCM period (30 days post-discharge); however, the high reimbursement rates reflect the
need for involvement of multiple providers. As medication experts, the required medication
reconciliation component offers pharmacists a unique niche to become a more incorporated
part of the TCM team.
ANNUAL WELLNESS VISITS
Annual Wellness Visits (AWV) aim to provide a personalized prevention plan to reduce
patient risk of morbidity or mortality. The components of a Medicare AWV include: a health
risk assessment, establishing current providers, family history, past medical history, risk
factors for depression or other mood disorders, and functional ability.19 AWVs also include a
general checkup of height, weight, body mass index, blood pressure and any other
measurements deemed necessary based on the medical diagnoses the patient has received.19
The health risk assessment component of an AWV addresses demographic data, selfassessment of health status, psychosocial risks, behavioral risks, activities of daily living
(dressing, bathing, and walking etc.), and instrumental activities of daily living (shopping,
housekeeping, and managing finances etc.) at a minimum.19 Unlike TCM services, Medicare
Part B will reimburse for AWVs performed by a pharmacist. Additional providers recognized
by Medicare to provide AWV include: physicians, qualified non-physician practitioners
(physician assistant, nurse practitioner, or certified clinical nurse specialist), or medical
professionals (health educators, registered dieticians, nutrition professionals, or other
licensed practitioner) under the direct supervision of a physician. Pharmacists fall under the
category of other licensed practitioner; therefore, require direct supervision (as defined in
“incident to” rules) by a physician.19
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Billing for Medicare AWVs can be multifaceted, because there are time frames and
requirements to consider when billing. Optimally, AWV would be conducted on an annual
basis for each patient. The initial AWV is billed with one code (G0438) and subsequent AWVs
are billed with a separate code (G0439). An Initial Preventive Physician Examination (IPPE)
is a “Welcome to Medicare” physical and can only be performed by a physician or NPP.
Medicare will cover the initial AWV if it is 1) at least 12 months following an IPPE or 2) for
beneficiaries who are no longer within 12 months of their Medicare coverage effective date.
Subsequent AWVs cannot be billed within 12 months of the initial AWV. Medicare will pay
for one initial AWV per lifetime and one subsequent AWV per year thereafter.19

CPT Code

Type of Visit

G0402

Initial Preventive Physician Examination (IPPE) or
“Welcome to Medicare” physical

G0438

Initial Annual Wellness Visit

G0439

Subsequent Annual Wellness Visit

Table 7-7. Medicare annual wellness visit billing codes

CHRONIC CARE MANAGEMENT
Chronic conditions such as diabetes and heart failure are devastating life-long diseases, and
primary care services help to contribute to better health and quality of life for patients living
with chronic disease. Effective January 2015, Medicare began paying for Chronic Care
Management (CCM), recognizing the value primary care brings to health care.20 CCM aims
to utilize non-face-to-face interactions to decrease the risk of hospital readmission and
prevent exacerbations by educating patients on their conditions, their medications, and
providing access to care. Eligible CCM patients must have two or more chronic conditions
which place the patient at significant risk of death, acute hospitalization, or functional
decline.21 CCM chronic conditions include, but are not limited to, diabetes, heart failure,
Alzheimer’s disease, asthma, cancer, COPD, depression, and osteoporosis.21 CCM has several
required elements such as recording patient demographics, a written, patient-centered, care
plan to be documented and given to the patient, providing 24/7 access to care, and managed
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care services.21 CMS requires the billing practitioner to conduct a comprehensive evaluation
& management visit, AWV, or IPPE visit prior to billing for CCM services.21 Additionally,
healthcare providers are required to inform patients of their CCM eligibility and obtain a
written consent form before furnishing services.21 The practitioner must also explain to the
patient how to revoke CCM services and that only one practitioner may bill for CCM services
per month.21 A CCM visit provides payment for at least 20 minutes of a health care
professionals’ time per month of non-face-to-face care.
Billing for CCM is conducted on a per month basis and codes may only be submitted once per
month per patient. This prevents multiple physician offices from conducting CCM visits on
the same patient in the same month. CCM billing is not eligible to be billed in the same period
as TCM services, hospice supervision services, or certain end-stage renal disease services.17
Pharmacists may provide CCM services and bill “incident to” the billing physician or nonphysician practitioner and/or contribute to 20 minute/month time allotment, as long as they
comply with all “incident to” physician billing requirements. CMS provided an exception
under Medicare’s “incident to” rules to allow clinical staff (including pharmacists) to provide
services under general supervision of a physician or non-physician provider. Therefore, not
requiring the physician to be on the premises providing direct supervision. CCM visits are
billed using CPT code 99490. Although patient copayments or coinsurance applies to CCM
visits; CCM provides a valuable service which may prevent patient costs for more expensive
face-to-face visits in the future.
Transitional care management, annual wellness visits, and chronic care management
appointments are three unique services that are only eligible for reimbursement by Medicare
Part B, unlike “incident to” services, which may be reimbursed by Medicaid, commercial third
party payers, and self-insured employers.
DIABETES SELF-MANAGEMENT TRAINING
Diabetes Self-Management Training (DSMT) is a service provided to patients with a new
diabetes diagnosis or patients struggling to control their diabetes. Pharmacists must be a
member of a recognized DSMT program by the American Association of Diabetes Educators,
the American Diabetes Association, or Indian Health Services division of diabetes treatment
and prevention in order to provide DSMT services.22 Because pharmacists are not a
recognized Medicare provider, pharmacists may not bill for DSMT services; however,
because pharmacies are a recognized Medicare entity, a pharmacist can bill under the
pharmacy if it is a certified DSMT facility.
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DSMT services may also be billed in either a physician based or hospital based clinic. In order
for a pharmacist to bill for DSMT services the pharmacist must have a written physician's
order for DSMT services for the patients involved. During the first initial year, up to 10 hours
of DSMT services can be billed per patient in 30 minute increments in either individual or
group training.21 After the first year, up to 2 hours of DSMT services can be billed per patient
in 30 minute increments in either individual or group training.22 Subsequent years begin 12
months after the first DSMT visit. Individual visits are billed under CPT billing code G0108,
group visits of 2-20 people are billed under CPT billing code G0109.22 Individual visits
provide a higher reimbursement rate per person than group visits.22
CLINICAL LABORATORY IMPROVEMENT ASSESSMENTS – WAIVED LABORATORY
The Clinical Laboratory Improvement Amendments (CLIA) is the way CMS regulates
laboratory testing performed on humans.23 CLIA ensures laboratories are performing tests
correctly and providing accurate test results. CLIA covers blood tests such as electrolyte and
cholesterol levels, in addition to home drug tests, pregnancy tests, and any other tests
requiring bodily fluids. In order for a pharmacy to do point-of-care testing such as diabetes or
cholesterol screening, they must apply for a CLIA certificate of waiver. The entity must use
application form CMS-116 and pay a $150.00 application fee. If approved, the entity will
receive a CMS Part B Provider Identification Number (PIN). Pharmacists submit claims to
CMS by using the entities PIN on the CMS 1500 form and the proper CPT codes. Pharmacists
are allowed to bill because the claim is for the laboratory services only, and not for cognitive
services. There are numerous CPT billing codes for the variety of CLIA-waived laboratory
assessments available. The pharmacy can bill CMS for the tests performed by their
pharmacist, and the pharmacy will receive reimbursement.
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SECTION 3
QUALITY
The manufacturing and aviation industries have long used quality improvement initiatives to
remain competitive and manage public perception.1 Because cost has been the primary focus
of healthcare reform, resources allocated for improvement were focused on medical and
medication error reduction. The focus on accountable care and patient-centered care has
renewed and expanded the focus on healthcare quality. Outcomes, value, and patient
satisfaction are emphasized and impact reimbursement to healthcare providers.
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CHAPTER 8
QUALITY MEASURES AND IMPROVEMENT
Author: Carriann Smith, BS, PharmD
Through the movement from fee-for-service to managed care (see Chapter 6), payers began
to pay for performance rather than for quantity. This included paying for improving health
outcomes while containing costs. The movement to accountable care has created a similar
initiative called value-based care. New value-based structures mean that healthcare entities
must commit to delivery on many quality measures, which determine reimbursement.
Therefore, there is a new financial incentive to focus on quality to control costs.
The Institute of Medicine (IOM) defines quality as “the degree to which health services for
individuals and populations increase the likelihood of desired health outcomes and are
consistent with current professional knowledge.”1 The 2001 Quality Chasm Report by IOM
provided 6 dimensions of quality: Effective, safe, timely, patient-centered, equitable and
efficient.2
The first three dimensions, effective, safe, and timely, are the traditional items associated
with quality healthcare interventions. Effective refers to basing decisions on evidence and
scientific knowledge which is discussed in Chapter 10. Safe refers to avoiding injury from
care that is intended to help patients. Timely focuses on improving access and
communication between healthcare providers to reduce delays in treatment.
The other three dimensions, patient-centered, equitable, and efficient, are specific targets of
health care reform. Patient centered care refers to services that are respectful and responsive
to individual patient preferences, needs and values and allowing those to guide treatment
decisions. Equitable care does not vary in quality because of personal characteristics
including ethnicity and socioeconomic status. Equitable and patient centered care
personalizes care to the patient not to the preference of the provider. Efficient care avoids
waste to limit the additional cost and intrusion to patients but also to the system as a whole.
Limiting unnecessary use protects funds and availability for other patients who need to
access care. The challenge is to use evidence to determine what is necessary and unnecessary.
QUALITY IMPROVEMENT
Quality improvement (QI) is a formal method of analyzing and correcting errors. Quality
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improvement is its own career path where individuals understand the different tools
available and how to apply them to their setting. Terminology associated with measuring
quality includes quality assurance, quality control and quality assessments. Quality
assurance is planning and ensuring compliance with set standards and requirements. It may
be thought of as the “office” component to quality reviewing reports, writing policies and
procedures and reviews of processes. Quality control is the specific process for measuring
products or services against the specific standard. This may include sample testing to look
for defects, customer service audits, etc. It may also be thought of as a data collection aspect
of quality to identify the current state of quality. Quality assessments are usually the specific
standard or increment that is being evaluated. These specific measures may be a stand alone
clinical outcome or a tool that collects multiple measures. Organizations that implement
quality improvement initiatives may use the term Total Quality Management (TQM) which
incorporate all of these items.3-5
Agreement on a need to improve quality is easier than actually assessing quality and making
improvement, this is especially challenging since patients, providers, administrators and
payers may view quality differently.6,7 Several organizations referred to as quality
improvement organizations (QIOs) utilize health quality experts, clinicians, and consumers
to work together to establish quality measures and set standards.7 Some QIOs work directly
with the Centers for Medicare and Medicaid Services (CMS). There is also a federal agency
that promotes evidence-based quality, the Agency for Healthcare Research and Quality
(AHRQ). These organizations develop quality measures, patient perspectives, and detailed
outcomes measures. The Pharmacy Quality Alliance develops and recommends specific
pharmacy based performance measures. These may be used to impact reimbursement in
value based payment models.
As mentioned above, quality tools and process exist to collect quality information within an
organization and local, state and federal organizations exist to set standards and specific
measures of quality. The results of this effort may be reported and utilized in one of three
ways: accreditation purposes, report cards, and consumer ratings.7
Accreditation refers to acknowledgement by an authoritative group providing a certification
of competency or credibility to an individual, institution or other healthcare entity. The
accreditation, used by payers, consumers, or employers, confirms certain standards. For
example, the Joint Commission is the standard accrediting body for hospitals, long-term care
facilities, and other medical practices.5,7
Report cards provide details on the results of specific quality measures often referred to as
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key indicators. The National Committee for Quality Assurance (NCQA) provides report
cards for physicians and health care insurance plans. One example of data provided by NCQA
is the Health Care Effectiveness Data and Information Set (HEDIS). This data set is used by
a majority of health insurance plans to measure performance. Other examples of
organizations that report on quality initiatives include the Pharmacy Quality Alliance (PQA)
and Medicare Health Outcomes Survey (HOS).5,7
Many organizations now provide patients an opportunity to provide direct feedback via
online or phone based surveys. The data may be published or used internally for quality
improvement. A cycle of surveys followed by improvements and resurveys is often referred
to as continuous quality improvement (CQI) or total quality management (TQM). CQI or
TQM may utilize critical pathway processes to develop specific procedures to improve care
and improve efficiency in a specific location. They define key steps that are necessary quality
checks. For example, a patient is admitted to the hospital for a severe skin infection. A critical
pathway may include ordering from a list of specific antibiotics, timing of cultures, timing of
wound care, etc.7
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CHAPTER 9
INTRODUCTION TO STATISTICS AND
RESEARCH DESIGN
Author: Chad Knoderer, PharmD, FPPAG
There will be interactions that pharmacists have with other providers that will require the
pharmacist to be able to definitively and confidently support their position or perspective
with evidence, or published medical literature. Along with the ability to utilize drug
information databases and effectively searching medical literature, pharmacists must also be
able to understand and discuss research and research findings. Collectively these skills
enable the pharmacist to practice evidence-based medicine.
Not all research is the same. Understanding the different types of research will help the
pharmacist when advocating for the patient. Generally, the type of research that pharmacists
will use will be clinical research, or research that is examining questions related to clinical
practice, outcomes, or both.1 This is different from laboratory research, or basic research,
which may be experimental or exploratory in nature. Basic research is conducted in a
controlled laboratory setting and does not involve human subjects. Clinical research focuses
on applications to patient care and uses a systematic process to answer clinical questions.2
The goal of clinical research is to draw inference from the study sample to a larger population.
A population would include every person with the specific disease or illness being studied and
it’s not realistic or feasible to include everyone in a study, so instead a sample is used. A
sample is a group of subjects in the study that represent the population.
Generally clinical research will either directly involve human subjects by having humans
participate in the study or use data from human subjects. In the latter, the data already exists,
but humans aren’t actively enrolled in the study. Instead human subjects’ data is used in the
research. To highlight this difference, Fuller and colleagues implemented a chronic
obstructive pulmonary disease (COPD) clinic in a community pharmacy setting and designed
a study to determine if pharmacists can accurately perform spirometry screenings.3 Some
rationale behind the study was that if pharmacists could accurately perform the screening,
then they could improve their education of the patient about COPD risk factors and
potentially increase patient participating in smoking cessation programs. A total of 175
patients were enrolled and completed a spirometry session.3 In contrast, Chen and colleagues
conducted a study to determine the effectiveness of a pharmacist-managed telephone
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tobacco cessation clinic in a Veterans Affairs (VA) health system.4 This study looked at data
from patients who had participated in the clinic, and the data was obtained through the health
system’s electronic medical records. Both of these studies are examples of clinical research
that aimed to answer a clinical question about smoking/tobacco cessation. A difference was
that the study by Fuller actively included patients whereas the study by Chen looked at
patient data, but didn’t actually enroll a single human.
RESEARCH DESIGN
The way a study is designed is based on the question the study sets out to answer. Some
questions can’t be answered with certain study designs. Pharmacists will use information
from studies during their interactions with other providers, and a good starting place in using
the information is to determine what research question was being asked. The research
question is developed by researchers by starting with a broad idea or problem, and this might
be something observed in everyday practice. This larger idea or problem is then narrowed
down into a smaller and specific question. Sometimes several specific research questions
might come from one larger idea, and this would result in multiple studies. Once the
researchers have finalized their research question, they will rephrase the question and write
it into the study as the study objective. As pharmacists read over a study’s objective, they can
consider what the original question might have been and if the study was designed
appropriately to answer the question.
The studies by Fuller and Chen offer a look at different study designs and studies with
different perspectives. There are two perspectives a study might take. A prospective study
progresses forward in time and a retrospective study looks at data or information or events
from the past. Fuller and colleagues started at one point in time and progressively enrolled
patients and followed those patients into the future. Chen and colleagues looked back in time
at a specific time period and collected data that was obtained during that time period. There
are strengths and limitations of each perspective. Retrospective studies might be easier to
conduct and cost less, but are limited by confounding factors. Prospective studies provide the
research with more control, which will be discussed later in the chapter, but are potentially
limited by the cost or time they take. Another limitation of prospective studies is patient
enrollment, especially for studies looking at less commonly encountered conditions. It’s
important for pharmacists to understand these differences when discussing clinical research
with providers.
Other aspects of research design will be discussed throughout this chapter. Aspects such as
control types refer to what type of control, if any, is used in the study. Some studies may not
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include a control group, whereas other designs might include a placebo, historical, crossover
(where the subject serves as their own control), or active (e.g. standard of care) control.5
Studies should be designed to increase both internal and external validity. Validity relates to
how well a test is measuring what is intended to be measured.6 Internal validity, then, is how
well the study was designed to minimize errors within the study. Systematic and random
error can impact internal validity.2 Systematic errors include bias and confounding and
random errors include chance.2 Chance is what it sounds like and is the likelihood that a
finding is due to random error. Statistical tests are used to quantify or determine the level of
chance.2,5 Bias occurs when there is a systemic error in subject selection or the
measurement/collection of observations that leads to a false conclusion of association.2
Confounding is commonly heard when thinking about variables. For example, a study might
be looking to determine if a variable is a risk factor for an outcome variable. Confounding
variables are those that are associated with the predictor variable, but are also themselves
predictors of the outcome independent of the variable being studied. But, the confounding
variable is not part of the relationship between the study variable and outcome of interest.7
Pharmacists evaluate internal validity of studies by reading through the methods and
analyses and determine if they were appropriate to answer the research question. Evaluation
of the results, to determine if they are accurate based on the methods, and reading through the
conclusions to make sure conclusions are supported by the data are additional ways for
pharmacists to assess internal validity.
External validity is slightly different and refers to how the study is applied to a wider
population. External validity can be thought of as related to generalizability.2 The ability to
apply the findings from the study and make inference to a wider population is generalizability
and this is an area that is sometimes difficult to navigate in interactions with practitioners.
Issues of how easily findings from a study can be applied to a cohort within a certain practice
arise commonly and these are instances where pharmacists can be pivotal in these
conversations. Ultimately, however, if there were errors leading to a decrease of internal
validity, then there will be decreased external validity. Without internal validity, there can be
no external validity. Some methods to improve both internal and external validity include
reducing confounding variables, improve subject selection, blinding, using a control group,
and using objective data and validated measurement techniques.
Design Types
In addition to the study perspective, there are different types of study design types that could
be used to answer the research question. Broad types include observational and
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interventional studies, which are commonly referred to as clinical trials. As the name
indicates, there is no intervention in an observational study, rather events or patients are
observed either prospectively or retrospectively. Descriptive studies describe findings from
observational studies. Although statistics are commonly used to describe the findings, there
won’t be any statistical comparisons of patient groups. Analytical studies make use of
statistical tests or analysis to determine presence of any association among variables and to
make inference. There are several different designs within observational studies. A cohort
study, makes observations of a group over time. These can be retrospective or prospective
and can be descriptive or analytical. Cohort studies can evaluate independent variables (or
risk factors) for development of diseases or conditions. This design is related to exposure.
The Framingham Heart Study is a well-known and classic example of a prospective cohort
study. Investigators prospectively followed over 5000 residents of Framingham,
Massachusetts in order to get a better understanding of risk factors for cardiovascular
disease.8 Nearly 70 years and hundreds of subsequent studies later, information obtained
from the original Framingham cohort has shaped the way practitioners approach patient
care. A recent publication by Bolesta and Kong describes a retrospective and analytical
cohort study to determine the impact of the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors (also known as statins) on post-operative atrial fibrillation.9
Case-control studies are different from cohort studies in that there will be 2 distinct groups
of subjects, but the design first finds cases of subjects with the outcome of interest (the
condition or disease) and compares those subjects with a control group of subjects to
determine exposure to an independent variable (risk factor). These are retrospective and the
design starts with the disease or condition of interest. For example, a 2013 study by Barletta
and colleagues is a case-control study aimed at determining any associations between protonpump inhibitor usage and Clostridium difficile infection (CDI).10 With this design the
investigators first identified patients who had a hospital-acquired CDI. This made up the case
group. The investigators then identified patients within the same time period who did not
have CDI and used those patients to form the control group.
Cross-sectional studies collect data or make observations at a single point in time. Surveys
are a common type of cross-sectional studies. Surveys will be distributed and the collected
responses will reflect data from the respondent at a single time point. These study designs
can be efficient and relatively cheap to conduct. The designs can be used for different target
recipients (ie. patients or practitioners), but they are limited by the observations being at one
point in time. Significant consideration must be made to the development of the survey
questions and the types of response scales used in order to get the most accurate and unbiased
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information from the target sample. The biggest limitation is participation, in that subjects
may not participate. Survey response rate is important to consider when reviewing these
types of studies. Owenby and colleagues distributed surveys to VA pharmacy clinical
coordinators to characterize pharmacy services within VA emergency departments.11 In
contrast, Li and colleagues surveyed patients with recent medical visits to assess factors
related to their search of online health information.12 Both of these examples are crosssectional studies, but with different target recipients.
Clinical trials are interventional studies that are designed to evaluate the efficacy and/or
safety of an intervention. Parallel designs, where subjects receive only the study intervention
or the control throughout the study, are common. Crossover designs, where subjects serve as
their own controls may also be used. Randomized controlled trials (RCTs) are the gold
standard of clinical trials because of the degree of experimental control utilized in the study.
These are also going to be the most expensive to conduct. To pay for RCTs, researchers may
seek federal or organizational grants to pay for the study. In other situations, and
pharmaceutical or medical device company may pay to conduct the study.
To better understand RCTs, it’s important to understand all of the aspects that go into one.
Randomization is one key component of RCTs, and this is done at the beginning of the study
to make the study groups similar. The goal of randomization is to make any observed
differences in the study group due solely to chance. The group differences ultimately are
balanced through randomization. One way to think of randomization is to think of flipping a
coin. If a study has 2 study groups (also sometimes referred to as arms), a treatment and
control, then a researcher might flip a coin to randomize assignment. Subjects with heads on
the coin flip could be assigned to the treatment group and those with tails on the coin flip
could be assigned to the control group. There are many more sophisticated randomization
methods, but at the core randomization is intended to assure that subjects have an equal
chance of being assigned to each study group, and baseline confounding variables are
eliminated. Blinding is a technique used to hide group assignments. The intent is to reduce
or eliminate information bias from the participant or observer/researcher. Blinding can be
single or double. Single is where only one side is blinded (subject or researcher) and double is
where both subject and researcher are unaware of the group assignment. It can be difficult to
blind some interventions. For example, it might be difficult in a study comparing liquid
clindamycin and amoxicillin because liquid clindamycin is well known for having a bad taste
and amoxicillin is more palatable.
Understanding RCT and being able to discuss RCT findings with practitioners also requires
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knowledge of the analysis technique utilized in the study. There are two general types,
intention to treat (ITT) and per protocol (PP). Either may be used and the methods section of
the article should state which was utilized. With the ITT analysis, outcomes are compared
based on subjects’ assignments and no data is eliminated. If subjects drop out of the study or
are lost to follow-up their data is still included, but the outcome is characterized as no
outcomes. This provides a conservative estimate of efficacy difference between groups, but a
more liberal estimate of toxicity differences. Per protocol is different in that it compares
outcomes based on subjects who followed the study protocol and eliminates data of subjects
who did not complete study. This provides higher degree of efficacy difference between
groups for efficacy outcomes, but lower degree of difference for toxicity outcomes. For
example, a study comparing drug A and drug B is evaluating which drug has better treatment
success. If 20 patients are included in each study group, outcomes will be compared. Let’s say
for drug A, 15 subjects have success, 4 have failure, and 1 drops out. For drug B, 15 subjects
have success, 1 has failure, and 4 drop out. Success rates for drug A and drug B would be equal
with the ITT technique (ie. both at 75%), but would be 79% (15 of 19 completing protocol) vs.
94% (15 of 16 completing protocol), respectively, with the PP technique. The opposite would
be true if a toxicity were an outcome of interest. There are studies that will perform analyses
based on both the ITT and per protocol to evaluate if there were different findings based on
analysis strategy.
There are different types of RCT. Table 9-1 highlights some differences between superiority,
equivalence, and non-inferiority designs.13 When interacting with practitioners about
equivalence or non-inferiority studies, it should be noted that a fundamental concept in these
studies is that they are based off of a superiority RCT that has been previously conducted. It
would be important, then, to read through the original superiority RCT before discussing the
merits of the non-inferiority or equivalence study. A couple of terms will continually be noted
for both equivalence and non-inferiority studies. The delta (Δ) notes the least relevant
difference and should be considered a marker of clinical significance or importance. This will
be established by researchers and should generally be based on existing literature. The noninferiority margin is the pre-determined maximum difference between “intervention” and
“control”, and is another term for delta. The delta and non-inferiority margin will be utilized
for interpreting study results.
STATISTICAL ANALYSIS
Even the term statistical analysis has a tendency to bring out a variety of uncomfortable
responses from practitioners, but a common response is one of confusion and hesitancy.
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Type

Method

Goal

Compares investigational
treatment to control (ie. placebo,
standard of care)

Show that investigational
treatment is superior to control or
standard treatment
Show that the treatments differ
by an amount that is NOT
clinically important (ie. difference
between – Δ and + Δ)
Show that investigational
treatment is NOT clinically inferior
to control (ie. can be worse, but
no worse than – Δ)

Superiority
Equivalence

Non-inferiority

Table 9-1. Randomized controlled trial typesa
a = Table modified from reference #47, Δ = delta
Many practitioners find statistics intimidating, almost like a foreign language. Regardless of
the response, the reality is that a basic understanding of how to apply statistical analysis
techniques is needed if pharmacists are to have meaningful interactions with practitioners
and optimize patient care. The majority of pharmacists working in patient care roles won’t
be doing statistical analysis, just like they won’t be doing research. As was highlighted
previously, a good understanding of research design and all of the elements that go into doing
research will allow pharmacists to be smarter consumers leading to more effective
interactions with other practitioners and more optimal patient advocacy. This is the case for
statistical analysis as well.
The statistical analysis section of a published study may seem like a good area to pass over
quickly. Perhaps some authors may not even spend much time writing this section. Spending
some time evaluating the statistical analysis section of a published study may allow the reader
to discover that researchers used inappropriate statistical methods or potentially manipulate
the findings. Understanding statistics can help a reader connect the dots in a published study.
That stated, statistical analysis is another piece of the overall research design. It is connected
with the research design, and ultimately the research question. For example, the goal of
clinical research is to draw inference from a study sample to a larger population, but the
validity of that inference is dependent upon the appropriate design being married with the
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appropriate statistical analysis. If one of the two is not appropriate, then the study’s validity
may be called into question. If the validity is questionable, then the study findings may not be
appropriate to utilize to drive patient care decisions. All of this is complicated. Knowing
where to start and the process to use to apply knowledge of statistical analysis to patient care
situations is crucial in overcoming the intimidating barrier that can sometimes arise from
statistics.
Data Types and Scales
The type of statistics that are used depends on the type of data that is collected, and there are
different types of data and data scales for discussion. Remember that some practitioners will
use the term variables or parameters or even outcomes, but all of these terms are also terms
for data, and data can be considered either categorical or continuous. Categorical are
qualitative and can be placed into categories or buckets. Examples of categorical data include
hair color or grade level. Continuous data are quantitative and can take any range of
possibilities. Examples of continuous data include age, weight, or blood pressure. Data are
further considered on scales, and for the purposes of the medical literature there are 4 data
scales (Table 9-2).

Scale
Characteristic
Categorical or Discrete
Nominal
Unordered
categories

Statistics

Example

Counts, frequencies,
percentages

Gender, diagnosis

Ordinal

Ordered categories

Above + medians

Continuous
Interval
Ratio

Likert scales, pain
scales

Arbitrary zero
Absolute zero

Above + means,
standard deviations

Temperature (C, F)
Weight, age

Table 9-2. Data scales
The nominal data scale is the most basic data scale. Data falling onto this scale can be
classified into two or more categories that are mutually exclusive from one another and are
exhaustive. The categories are unordered and have no relation to each other. Dichotomous
data are data that can be placed into one of two categories like alive or dead, pregnant or non-
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pregnant. Dichotomous data is a specific type of nominal data. The ordinal scale includes
ordered categories with some rank and relation to another. Data derived from surveys using
Likert-scale questions (ie. strongly agree, agree, disagree, strongly disagree) or measurement
scales such as pain rating scales are examples of ordinal data. While ordinal data may be
reported as a number (ie. pain score of 7 or Likert score of 4) the number corresponds to a
category, and there is no consistent degree of difference between each category (ie. 3 is not 3
times greater than 1). Continuous variables can take on an infinite number of possibilities.
With continuous data there is both an order to the values and a consistent degree of difference
between each value. Continuous data can be placed on either the interval or ratio scale with
the difference being that ratio data has real zero (ie. heart rate) compared to an arbitrary zero
(ie. temperature on fahrenheit scale) of for interval data.14 Any continuous data could be
turned into either nominal or ordinal categorical data, but the opposite is not true.
Categorical cannot be converted to continuous data.14
Descriptive Statistics
Statistics should be considered as two broad categories, descriptive and inferential. As the
name implies, descriptive statistics describes study observations. These are very useful to
research consumers because descriptive statistics allow the reader an understanding of the
subjects that were included in the study. Data within these data scales can take on a number
of possible values, making it important to understand data distribution. The binomial and
Poisson distributions are examples of distributions of categorical data.15 The normal
distribution is a distribution of continuous data. With this, data are equally distributed
around the mean and the values of the mean, median, and mode are all equal. The next
paragraph describes mean, median, and mode. The curve of a normal distribution takes on a
bell appearance, and it’s often referred to as a bell-shaped curve. Figure 10-1 illustrates a
normal distribution curve of age that came from a dataset containing 229 patient
observations and in addition to the shape of the curve, the distribution can provide a lot of
useful information to providers. Some examples of these will follow.
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Figure 9-1. Normal distribution curve

Measures of central tendency and measures of variability are types of descriptive statistics.
Measures of central tendency include mean, median, and mode and describe the main
observations of the dataset while measures of variability are used to describe the amount of
uncertainty in the dataset. The mean is the average of the values in the dataset and can be
calculated for continuous data. The mean is highly affected by outliers making it suboptimal
to describe data that aren’t normally distributed. Because there is inconsistent degree of
difference between ordinal categories, the mean is not useful to describe ordinal data. The
median is the middle measurement (ie. 50th percentile) in a dataset and can be used for ordinal
data or continuous data that aren’t normally distributed. There are an equal number of values
above and below the median making it resistant to the influence of outlying variables. The
mode is the value occurring most often in a dataset. The standard deviation (SD) is a measure
of variability commonly used with the mean because it represents deviation from the
dataset’s mean. The SD is the square root of variance which is derived from sum of squares.
The mean of a dataset is subtracted from each data observation, and all of those deviations are
added together to make the sum of squares. Neither the variance nor sum of squares are used
commonly in the medical literature, but the SD is and knowing its origins helps make sense of
what information the SD provides practitioners. Because the mean is used in the calculation
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of the SD, this variability measure is most appropriate for normal or near normally
distributed data. Using the SD, a reader can apply the empirical rule for additional
information about the dataset. The empirical rule states that for normally distributed data,
68% of observations will fall between 1 SD of the mean, 95% of observations will fall between
2 SD, and 99% of observations will fall between 3 SD. Figure 9-2 provides an illustration.
Applying this rule to the mean and SD within Figure 10-1 and learn that 68% of the patients
had ages of 18.5 – 21.5 years, 95% were 17.1 – 23 years, and 99% were 15.5 – 24.5 years. This
type of application of descriptive statistics is particularly useful as a provider and when
discussing with other providers because it allows for some generalization. Using data from a
study where 95% of the patients were 17.1 – 23 years old wouldn’t be useful or appropriate for
providers who predominantly care for elderly patients.

Figure 9-2. Normal distribution curve with 68, 95 rule

The standard error of the mean (SEM) may be commonly confused with or used in place of
SD. However, the SEM quantifies certainty in the estimate of the true population mean where
the SD is providing an estimate of variability around a sample mean. The two are not
interchangeable, but the SEM will always be smaller leading some researchers to report it
because of the feeling that less variability is better. A reader can always determine the SD
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from the SEM by taking the SD divided by the square root of the number of observations:
(𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑆𝑆𝑆𝑆 ÷ √𝑛𝑛).

Using the data from Figure 10-1, the SEM would be calculated as:
1.499 ÷ √229 = 0.098

which is obviously smaller than the reported SD of 1.499. This equation can be used to
determine the SD when the SEM is inappropriately reported. Standard errors are used in the
calculation of confidence intervals (CI) which estimate a range of values that is likely to
contain a population value a certain percentage of time. These are commonly reported in the
literature as 95% confidence intervals. Confidence intervals will be further explained later in
the chapter. The interquartile range (IQR) represents data between the 25th and 75th
percentiles and contains the middle 50% of observations. This measure of variability is
commonly reported as 2 numbers with the highest representing the 75th percentile and lowest
representing the 25th percentile. The IQR is particularly useful for non-normally distributed
continuous data, along with the median, or for ordinal data. Other types of descriptive
statistics include frequencies and percentages or visual data displays such as histograms,
scatter plots, and box plots (Figures 9-3 - 9-5).

Figure 9-3. Histogram
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Figure 9-4. Scatterplot

Figure 9-5. Box plot
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Inferential Statistics, Hypothesis Testing, and Decision Errors
Inferential statistics are used to make a generalization about a population from the results of
a study and practitioners will use study finding to make decisions on how to manage the
patients in their care. The foundation of inferential statistics is with hypothesis testing, and
statistical tests are used in hypothesis testing. Not all studies will be testing hypotheses, so
not every study will include inferential statistics, but all studies that are reporting findings
will include some element of descriptive statistics. With hypothesis testing, statistical tests
are used to test the null hypothesis (H0) which states that there is no difference between
predictor and outcome variables. In other words, if a study were comparing two interventions
(Intervention A and Intervention B) the H0 would state that Intervention A = Intervention B.
The alternate hypothesis (H1) would then state that Intervention A ≠ Intervention B. The H1
cannot be directly tested, so it is accepted by default in instances where the H0 is rejected. The
H0 is rejected based on the results of a statistical test. In general, for studies which
pharmacists will be reading and using, hypothesis testing is two-sided. In other words, the
researcher is interested in a difference in either direction. It might be important if
Intervention A is better than or worse than Intervention B. Occasionally, inferential statistics
will be used for one-sided hypothesis testing. In a one-sided hypothesis, a direction of
difference is stated and tested. For example, the H0 might be written as Intervention A ≥
Intervention B with the H1 written as Intervention A < Intervention B.
For statistical testing, researchers determine which statistical test should be used because
there are different tests for different types of data or the number of groups being compared.
Once the researchers decide on the statistical test, the level of significance (also referred to
as alpha or α) is selected. This is generally set at 0.05 and it essentially means there is a 5%
probability of incorrectly rejecting the null hypothesis (ie. making a Type 1 error). Once the
alpha is set, a critical value will be determined based on what statistical test will be used. The
critical value corresponds to the pre-set α. A common place where statistical testing becomes
confusing for providers is what it all means. The p-value is the probability of making an
observation as extreme or more extreme than the observed if the H0 were true.17 The
statistical test is then done and the test statistic is compared to the critical value and a p-value
is calculated. P-values less than the preset alpha are considered to be statistically significant,
the H0 is rejected, and by default the H1 is accepted.
A recent study by Hammond and colleagues sought to compare the incidence of acute kidney
injury (AKI) in patients who were receiving vancomycin plus either piperacillin/tazobactam
or cefepime.18 In this example, the H0 would be AKI with PT = AKI with cefepime. This study
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had two groups (PT vs. cefepime) and the primary variable being compared was AKI which
was a nominal variable. Patients either had AKI or didn’t making this a categorical and
nominal variable. Because the researchers were comparing a nominal variable between two
groups, the chi-square test was most appropriate. More on this test will follow. The
researchers state that the pre-determined α = 0.05, which meant that the corresponding
critical value of the chi-square test = 3.84. In general, textbooks of statistical analysis will
include supplementary tables containing critical values for statistical tests, so this
information is easy to obtain. With a critical value of 3.84, any test statistic greater than 3.84
would correspond to a p-value of < 0.05 (Figure 9-6). Hammond and colleagues reported that
there was no difference in AKI between the PT (32.7%) and cefepime (28.8%) patients and
that the p-value = 0.761. The actual test statistic was not reported, and it typically is not in
medical literature, but a reader can assume from the reported p-value of 0.761 that the test
statistic resulting from the chi-square test was less than the critical value of 3.84. With this
example, because the test value was less than the critical value, the researchers could not
show a difference in AKI between the drug regimens and would ultimately conclude that
there is no AKI difference between patients receiving PT and those receiving cefepime.

Figure 9-6. Chi-square critical value and p-value
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With inferential statistics, there is always a chance of error and the two types of error that can
be encountered are Type 1 (false-positive) and Type 2 (false-negative). These errors are due
to chance variability or bias and the likelihood of encountering them may decrease with
increasing sample sizes. With a type 1 error the researcher rejects an H0 that is actually true.19
The probability of making a type 1 error is signified by pre-set alpha (α) and the p-value that
is determined from the test provides a more precise probability of making a type 1 error. A
type 2 error occurs when a researcher fails to reject an H0 that is actually not true.18 Beta (β)
is the probability of making a type 2 error and this typically ranges from 0.1 – 0.2. There are
several ways to think about decision errors so that they make more sense. One way to
consider is related to that of a jury decision.20 An innocent person did not commit a crime and
a guilty person did commit a crime. If a jury convicts the criminal and acquits the innocent,
then the correct decision was made. But, if the jury convicts the innocent person, a type 1
error has been made because the jury has concluded that there is an association when in
reality there is not. Likewise, if a jury acquits the criminal they have made a type 2 error by
concluding that there is no association when there actually is one.20 The popular belief of
those who followed or were familiar with the O.J. Simpson murder trial was that Simpson did
commit the murders although the jury acquitted him (ie. making a type 2 error).21 Contrast
that with the case of Mark Schand who spent 27 years in prison after a jury wrongfully
convicted him of committing murder (ie. making a type 1 error).22 In medicine, type 1 errors
may result in drugs or treatment being introduced to market or practice when they are truly
no different than standard treatments. Concerning are the potential downfalls of the new
treatments which likely are more expensive than standard care, but also may have more side
effects.
Power is a term that is used quite a bit by practitioners who might say that a particular study
was underpowered or that a study had adequate power. Power is the probability of correctly
rejecting the H0. This might also be considered as the probability to detect a difference when
the difference exists. The equation for power is:
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 = 1 − 𝛽𝛽

and it’s dependent upon several things. The predefined α, sample size, estimated size of
difference between outcomes (ie. the difference that researchers are trying to detect),
outcome variability, and the statistical test can all influence power. Sample size and power
are connected in that while sample size can influence power, power is also considered when
determine the required sample size. Hammond and colleagues determined that 122 patients
were needed to detect an approximate 20% difference in AKI between PT and cefepime.18
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Researchers established the α at 0.05 and β at 0.2 for a power of 80%. The sample size was
based on AKI estimates of 36.5% in the PT groups vs. 15% in the cefepime group. While
beyond the scope of this text, there are resources that would allow the reader to compute the
actual power of this particular study.
With inferential statistics, there is always a degree of uncertainty and p-values will tell one
aspect of the story, which is about statistical significance. But, the p-values themselves don’t
provide information about the clinical impact or size of any difference, if present. Confidence
intervals are useful to determine the size of the potential difference because confidence
intervals give a range of possible estimates including the observed value. All values within the
CI are statistically possible. For examples, authors report no difference in mean ± SD
vancomycin dosing (mg/kg/day) in pediatric patients with (47.5 ± 14.6) and without AKI [41.2
± 16.6) with a p-value = 0.102.23 This finding is not statistically significant, so the researchers
fail to reject the H0 that the dose in those with AKI = dose in those without AKI. But, is this
finding clinically meaningful? Some practitioners might say yes, leading to the suggestion
that dose is an important consideration with AKI, while other practitioners may disagree.
The actual difference between the doses was -6.3 mg/kg/day, but if the 95% CI of the
difference would have been included, it would have been -13.8 to 1.25. Remembering that the
CI is the range of values that could contain the true population value, one could interpret this
95% CI by saying there is a 95% certainty that the true dosing difference lies between -13.8
and 1.25 mg/kg/day. This perspective provides more clinical importance to the finding. Some
practitioners might agree that a dosing difference of nearly -14 mg/kg/day is clinically
important for this drug, but they may also to say that a difference of 1.25 mg/kg/day is not
important at all. It should be noted that within this 95% CI is 0, meaning that the true dosing
difference could be also zero. This is how CIs can also be used to test hypotheses. If the H0 is
that the dose in those with AKI = dose in those without AKI, or there is 0 difference in dose,
then the 95% CI tells a reader that the H0 should not be rejected because 0 is contained within
the CI. A more simplified approach to determining statistical significance from reading a 95%
CI is this. If estimating a difference between continuous (ie. means) or categorical variables
(ie. percentage or proportions), CIs containing zero (0) are NOT statistically significant (ie.
the p-value > 0.05), and the H0 should not be rejected. If estimating an odds ratio (OR), relative
risk (RR), or hazard ratio, CIs containing one (1) are NOT statistically significant, (ie. p-value
> 0.05), and the H0 should not be rejected.
Common Statistical Tests
Statistical tests are widely reported in both pharmacy and medical literature.24,25 Common
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statistical tests can be divided into parametric and non-parametric categories. Assumptions
for parametric tests are that the data is continuous with a normal or near-normal distribution,
data is randomly obtained, the observations are independent of one another, and the
variances between groups are equal. Parametric tests include t-tests and analysis of variance
(ANOVA) and are considered more powerful than non-parametric tests. The t-test compares
means between no more than 2 groups. These will be used to test an H0 that a mean in one
group is the same as the mean dose in another group, similar to the previous example of mean
vancomycin dose and AKI. There are different types of t-tests. A one-sample compares the
mean in a study group to that of a known population. Independent samples t-tests (also called
Student t-tests) compare means of two unrelated groups (ie. Group 1 vs. Group 2), where
paired t-tests compare the means of dependent observations (ie. measurement 1 vs.
measurement 2 in one group). A paired t-test would be commonly used in a before-after type
of study design. Analysis of variance compares means of 3 or more groups. The ANOVA is
more powerful than a t-test when there are 3 or more groups because the alpha is held
constant. There are a different types of ANOVA: one-way (ie. mean in Group 1 vs. Group 2 vs.
Group 3), two-way (ie. comparing two factors in Group 1 vs. Group 2 vs. Group 3), and
repeated measures (ie. one group but comparing the mean of Measurement 1 vs.
Measurement 2 vs. Measurement 3). With ANOVA, the test result will correspond to a pvalue that tells the researcher or reader if a significant difference exists, but the test doesn’t
signify where the difference exists. If an ANOVA yields a significant p-value, researchers
must perform further tests, called post-hoc tests, to determine precisely where the difference
lies. Pearson correlation is a parametric procedure used to examine the direction and
strength of relationship between 2 normally distributed continuous variables. The Pearson
correlation coefficient (r) ranges from -1 to +1 with values closer to 1 representing a stronger
relationship between the variables. Positive numbers indicate direct or positive relationships
with negative numbers representing inverse or negative relationships. In general r values of
< 0.3 are considered weak, 0.3 – 0.5 are moderate, and > 0.5 are considered strong
relationships.26 The coefficient of determination (r2) is the percentage of variance in the
dependent variable that is explained by the other.26 Lee and colleagues evaluated the
relationship of serum creatinine concentrations on antifactor Xa concentrations and found
an r = -0.262.27 This can be interpreted as a weak negative relationship. The r2 value = 0.0688
which means that 7% of the variance in antifactor Xa concentrations can be explained by
serum creatinine concentrations.
Non-parametric tests are used when the assumptions of parametric tests are violated. Several
analogies can be made to parametric tests. The Wilcoxan rank sum and Mann-Whitney U are
analogous to the independent samples t-tests and are used for two independent samples of
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non-normally distributed continuous data or ordinal data. The Wilcoxan signed rank test is
analogous to the paired samples t-test and would be used for data types above from related
samples. The Kruskal-Wallis test can be considered analogous to ANOVA, and would be used
for non-normally distributed continuous data or ordinal data from 3 or more groups. For
nominal data, Chi-square analysis can be used to compare proportions between 2 or more
independent groups. An assumption of the Chi-square analysis is that of sufficiently large
expected frequencies, so when this is violated (eg. when any cell has less than 5 expected
frequencies) the Fisher exact test is more appropriate. The McNemar test can be used to
compare proportions in paired samples. Lastly, Spearman correlation is analogous to Pearson
correlation and is used for continuous variables that aren’t normally distributed or for
nominal and ordinal data. Range of values from the Spearman rho (rs), which is the output
from a Spearman correlation, are negative 1 to positive 1 and interpretation is similar as
Pearson. Table 9-3 describes common statistical tests and their appropriate uses.
Regression determines how one variable predicts another variable, but it shouldn’t be
considered as establishing a cause-effect relationship. Simple regression is a relationship
between a single dependent and independent variable; multiple regression is a single
dependent with multiple independent variables. There are 2 types of regression. Linear
regression is used when dependent variable is continuous and normally distributed, and the
independent variable is continuous (simple regression) or either continuous or categorical
(multiple regression). The output from linear regression is the coefficient of determination
(r2) which explains how clearly the model describes the relationship and beta (β) which
describes the change in the dependent variable caused by a 1-unit change in the independent
variable. Logistic regression differs in that the dependent variable is categorical while the
independent variables could be continuous or categorical. The result of logistic regression is
an odds ratio that can be interpreted as previous described.
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CHAPTER 10
EVIDENCE-BASED MEDICINE
Author: Joe Jordan, PharmD, BCPS
Evidence-based medicine (EBM) has been defined as the “conscientious, explicit, and
judicious use of current best evidence in making decisions about the care of individual
patients”.1 In recent history, the EBM movement has been credited to a group of clinicians
working on new approaches to teaching medical professionals over 25 years ago.2 While
medical professionals have always relied on clinical experience when making decisions, the
original impetus of EBM was to intentionally incorporate appraisal of the best available
evidence to resolve practice issues. However, clinical expertise should not be ignored as it is
integral to balancing the patient’s clinical circumstances, relevant research evidence, and the
patient’s preferences or values when making decisions.3-4 Clinicians are now expected to not
only consult the best available evidence, but also be able to make their own independent
appraisal and application of the evidence.5 A process or step-wise EBM approach commonly
cited in literature is described below and depicted in Figure 10-1, which can be used for
resolving patient issues or practice challenges.
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Figure 10-1. Evidence-based medicine cycle

ASSESS
The EBM process starts with an assessment of a patient or practice situation. Assessment is
a skill that many first acquire in the classroom or in training programs, and then further
develop with experience. Assessing an individual patient or practice situation will likely lead
to issues that need to be resolved and resultant questions that need to be answered. These
questions that arise are often referred to as knowledge gaps. It is possible that many
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knowledge gaps may arise in a single encounter or situation necessitating a prioritization
approach to addressing and resolving them. Knowledge gaps will vary among practitioners
based on their level of clinical experience and familiarity with the current best available
evidence.5 Before proceeding, it is important to have a good idea of the clinical status and
circumstances of the patient and their preferences or values with respect to their health
goals.6-8 Without this crucial step, clinicians may not achieve optimal outcomes for their
patients. During this phase, clinicians may need to research background questions, to answer
any resounding knowledge gaps, before they pursue specific questions. If a practitioner is
unfamiliar with a given disease, intervention, or outcome, it is important to understand these
elements before pursuing specific patient questions involving these variables. For example,
before answering the question, “does tranexamic acid increase the risk of venous
thromboemboembolism (VTE) in patients with atrial fibrillation who are undergoing knee
replacement?” one may need to review background information on how tranexamic acid
works, common risk factors for VTE in general, and VTE complication rates in the orthopedic
setting. Common sources of information clinicians use to answer background questions are
tertiary sources such as review articles or textbooks.
ASK
The next step is to frame the knowledge gap into a structured question. Structured questions
are one way of finding answers using keywords that will hopefully best address the situation.5
Many databases used to search for literature utilize structured search terms that can
accommodate this strategy.
Patient specific questions usually require the practitioner to refer back to original studies or
primary literature. On occasion, pre-appraised sources of information such as guidelines or
systematic reviews may have addressed the specific question, but more commonly clinicians
have to extrapolate information from studies with similar but not identical characteristics of
their clinical situation.3,5,9 While different types of specific questions may arise in the course
of clinical work (e.g. diagnosis, prognosis, therapy, prevention), a suggested general acronym
practitioners can remember when structuring questions is PICO. PICO stands for
population, intervention, comparator, and outcome.3 In order to be efficient at evaluating a
body of literature that is expanding at exponential rates, asking a focused question using a
structured template such as PICO, can assist in yielding relevant studies. In the example used
previously, the population would be patients with atrial fibrillation who are undergoing knee
replacement, the intervention would be tranexamic acid, the comparison is inferred to be not
using tranexamic acid, and the outcome is venous thromboembolism. Occasionally, our
questions may not yield any literature hits and then we need to expand some element of our
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PICO framework. In this case, one might expand the population to patients undergoing joint
replacement and leave out atrial fibrillation under the auspices that this still may help answer
whether tranexamic acid increases risk of VTE, irrespective of atrial fibrillation.
ACQUIRE
While possessing the requisite skills to assess patients and discern what questions need to be
addressed, the process of acquiring information takes time that many practitioners do not
have.3,5,8,10 One popular approach is to consider the usefulness of information as an equation,
with relevance and validity in the numerator and work in the denominator.11-12 The relevance
of an information source refers to whether the outcome described is of value to your patient,
whether the interventions or practices described are feasible, and if the interventions would
lead to a change in practice. The validity refers to the trustworthiness of a given article, and
the work refers to the time, money, and effort it takes to obtain an answer to a clinical
question. While relying on authority or experience may require little work on the clinician’s
part, this equation reminds the clinician that information which is not relevant or valid is
useless, no matter how much effort is required. This approach also encourages clinicians to
focus on finding relevant evidence first and then apply principles for assessing validity rather
than vice versa.
Acquiring evidence can be an intimidating task because information appears to be increasing
at exponential rates.10 It is difficult to stay up to date with medical information so one must
find ways to efficiently make use of the available evidence. While many types of information
are available to practitioners today, this doesn’t mean all resources are useful. Knowing types
of resources and how they differ from each other, their strengths and weaknesses, and how to
use them is an important attribute for efficient practice.12 Studies on information seeking
behavior in literature note that this step is often not pursued when questions arise in practice
and when it is pursued, clinicians spend little time on this before either quitting the search or
going with what they were able to find.5
Strategies to ensure one is getting the best available evidence commonly vary from asking
colleagues for their expert opinion, reviewing clinical practice guidelines, searching for
systematic reviews and/or meta-analyses on existing literature, to searching databases such
as PubMed for original research studies.13 While practice guidelines or systematic reviews
may appear useful since they have already appraised the validity of information sources, the
clinician needs to be aware these can rapidly be out of date, based on the number of trials that
get published every day. Likewise, relying on experts or clinical experience to answer
questions may be perceived as an efficient way to acquire evidence, but a danger with this
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approach is that it assumes that practitioners are up to date with current literature and that
he or she is not biased by their own personal experiences. Similar to this, using general search
engines on the web can be misleading in that they provide ‘hits’ but they may not provide
information specific to your inquiry.
A traditional model in EBM is the hierarchical approach of categorizing types of resources as
seen in Figure 10-2.3 This approach implies there are some resources with more validity and
relevance than others. Study designs are ranked based upon the likelihood of providing
causality estimates. Randomized controlled trials are commonly listed at the top of these
models since the design allows the researcher control over various factors. Opinions are
commonly listed at the bottom of the pyramid because there is not a readily available way of
testing this information for validity.

Interventional
trials

Observational trials
(prospective>retrospective)

Case reports and in vitro studies

Figure 10-2. Hierarchy of study designs

Another way sources of evidence are described is based on efficiency (i.e. time required for
practitioner to find answer) as seen in Figure 10-3.2,5 In this case, resources that are preappraised for validity (e.g. practice guidelines, systematic reviews) are noted on the EBM
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pyramid as being more useful while original studies that are not pre-appraised (i.e. reader has
to do this) as less useful. However, these models do not adequately address every type of
question or resource that could arise so practitioners ultimately need to be familiar with
multiple types of resources and how to appraise them.

Practice
guidelines, metaanalyses, systematic
reviews (Filtered)

Interventional and
observational trials
(Unfiltered)

Reviews and opinion pieces
Figure 10-3. Hierarchy of resources based on efficiency

APPRAISE
After acquisition of evidence, the clinician must be able to appraise the information for
validity, or trustworthiness. Depending on the type of original question asked (e.g. diagnostic,
prognostic, therapy, etiology), some primary sources of literature are better suited than
others. While some sources of information have been pre-appraised (e.g. guidelines,
systematic reviews), it is important to determine the process of validation and be able to
confirm or agree with the information independently.14-17 Otherwise this is analogous to
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relying on authority or experts again. While prospective controlled studies by design are more
suited to answering questions of causality, this does not automatically mean observational
study designs are weaker as all studies can have methodologic flaws impacting their validity.17
Several tools are available for evaluating research evidence for validity. The EQUATOR
network (www.equator-network.org) provides reporting guidelines for a variety of study
designs in order to enhance the quality and transparency of the published article. The Centre
for Evidence Based Medicine (www.cebm.net/critical-appraisal) at the University of Oxford
provides appraisal tools to help clinicians determine reliability, importance, and applicability
of articles. While these tools can offer a checklist approach to evaluating studies, it is
important to remember that the appraisal process is just to determine whether given results
are plausible, not whether they should be used in your patient or practice setting. A common
criticism of EBM is that it implies there is a stepwise appraisal approach (i.e. cookbook
approach) to treating every practice issue. This objection is related to the loss of perception
of autonomy in decision making and is an untoward application of EBM with respect to
standardizing care and insisting on one way of doing things. However, this is not the intent of
EBM and it actually acknowledges the role of experience and intuition and the fact there are
differences in skill, is what explains variations in results at times.1-4
APPLY
After the evidence has been acquired and appraised, it must be applied back to the individual
issue, be it a patient or practice situation. This process of application should not be based
solely on the conclusions of studies written by study investigators or the opinions of experts.
A danger with relying on those with vested interest in a given intervention, could be
misappropriating what is of value both to patients and clinicians. For example, drug and
medical device companies could set research agendas to define what are relevant disease
characteristics, what test and treatments to compare (thus of value) and what outcomes will
be valuable.3 Additionally, with a lot of drug therapies available that have marginal, if any,
differences in outcome, it is important to be able to answer what is the best course of action
for this patient, in these circumstances, and at this time in their illness or condition?8,18
External evidence can inform but not replace individual expertise. This is what ultimately is
drawn upon to balance research evidence plus clinical status, and decides what applies to
whom and if it should be used in a decision. There may be tradeoffs that affect a given decision
and some recommendations may be stronger or weaker based upon these factors such as cost,
risks, and benefits. An online resource that can be used to develop recommendations based
on these factors is http://www.gradeworkinggroup.org.16 While costs are often not
necessarily the focus of EBM, certainly effective care is important, and ineffective care would
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be seen as waste from a cost standpoint. Effectiveness depends on not only whether
something can work but also on the accuracy of diagnosing a condition, compliance with
protocols, patient adherence, and coverage. Just because something can work doesn’t mean
it will be used in the right people, at the right time, if patients will take it right, or whether
people can afford it.18 Often, an overlooked area in the EBM process is an ideal way to present
information to patients so that they can make an informed decision. Keeping in mind that the
original reason to apply EBM is resolve patient issues or questions, the way this information
is communicated to patients plays a large role in achieving optimal outcomes.
ASSESS
We end where we started. That is, after applying the research evidence to the clinical
situation and taking into account the patient preferences and values, we should seek out
whether issues have resolved or whether new issues have presented. This is why this process
is sometimes referred to as a cycle.
SUMMARY
Evidence is essential, but not sufficient, for practitioners wanting to use EBM. The best
available evidence, clinical context, and patient preferences integrated with clinical
experience are what make up the hallmark of decision making.7 Without clinical experience,
practice is at risk of becoming dictated by checklists on appraisal of evidence, which may be
inapplicable to or inappropriate for an individual patient. Without the best evidence, practice
is at risk of becoming rapidly out of date, to the detriment of patients.1 It is this individual
expertise that can effectively integrate experience and evidence within context, decides
whether external evidence should be applied at all, and if so, how it should be integrated.1
Efficient EBM practice requires formulating focused questions (PICO), matching questions
to most appropriate resources, assessing confidence in estimates, and understanding how to
apply results to clinical decision making. In addition, given the acknowledgment of time
constraints, we need to ensure that management strategies are consistent with patient values
and preferences.
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CHAPTER 11
RISK EVALUATION AND MITIGATION
STRATEGIES (REMS)
Author: Annette McFarland, PharmD
The Center for Drug Evaluation and Research (CDER) and the Center for Biologic Evaluation
and Research (CBER) are the departments within the Food and Drug Administration (FDA)
responsible for evaluating drugs (or biologics in the case of CBER) to make sure they are not
only effective but safe for human use. Every prescription and over-the-counter medication is
evaluated by CDER or CBER prior to market.1 There are drugs that, although they have
substantial therapeutic benefits, carry significant risks. To ensure that the benefits outweigh
the risks, the FDA may require manufacturers to go beyond product labeling and implement
special restricted access programs.
Risk management programs have been around since the early 1990s. One of the first
medications to have prescribing and dispensing restrictions is clozapine (Clozaril®).2 This
antipsychotic significantly increases a patient’s risk for agranulocytosis, so patients must
obtain weekly blood counts to receive the drug. Physicians must monitor and submit lab
results to the manufacturer’s restricted access program in order to receive prescribing
authority. The amount of clozapine dispensed is limited to the number of days until the next
lab draw. Patients, physicians, and pharmacies must be registered with clozapine’s “no blood,
no drug” program to ensure compliance.2
Historically, such risk management programs were called Risk Minimization Action Plans
(RiskMAPs). The Prescription Drug User Fee Act (PDUFA III) of 2002 allowed the FDA to
suggest RiskMAP programs for drugs that might not otherwise be allowed on the market
because of significant safety concerns. RiskMAPs were tools “…designed to meet specific
goals and objectives in minimizing known risks of a product while preserving its benefits.”3
Examples of these tools include targeted education, reminder systems, and performancelinked access systems (eg. clozapine’s “no blood, no drug” program). Although effective, there
were limitations to the program. RiskMAPs were voluntary and the FDA could only
recommend a risk minimization program. They had no authority to require a manufacturer to
comply, nor could they require postmarking studies, labeling changes, or other safety
communications. The FDA Amendments Act of 2007 expanded the FDA’s authority
regarding drug safety. A section of the legislation now allows the FDA to require
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postmarketing studies and to mandate Risk Evaluation and Mitigation Strategies (REMS) for
drugs that have the potential to cause serious patient harm.2,4
WHAT ARE REMS?
REMS are strategies designed to mitigate a known or potentially serious risk associated with
a drug or biologic product.5 When determining whether or not a REMS is needed, the FDA
takes into consideration the number of patients who would potentially use the drug, the
seriousness of the disease or condition it’s intended to treat, the duration of treatment, and of
course, the expected benefit compared to the severity of its adverse effects.4 The FDA can
base its decision on results from clinical trials, adverse drug event reports, or post-marketing
studies.
REMS can be implemented at any stage of the product lifecycle. It can be included as part of a
license application for a new drug or new indication, or the FDA can require the
implementation of a REMS for drugs already on the market if new safety information
becomes available.6 This is why post-market surveillance is so important. The number of
people who participate in pre-market, Phase 3 clinical trials can be small compared to the
larger population who ultimately uses the drug. Therefore, continually assessing the efficacy
and safety of drugs post-market is necessary to identify any potential safety concerns not
known at the time of a drug’s approval process.
The FDA can mandate a REMS for drugs they feel need additional safety measures beyond
that of standard professional labeling. These safety measures are unique to each drug or
therapeutic class. Therefore, no two REMS are exactly alike. The following are potential
elements of a REMS:6
●
●
●
●

Medication guide
Communication plan
Elements to assure safe use (ETASU)
Implementation system

Once a REMS is approved, it is enforceable. The FDA has the authority to hold the
manufacturer accountable for not complying. If the manufacturer fails to implement a REMS,
they can be fined. The FDA can also restrict its use by preventing the sale of the drug and/or
consider it misbranded.4
REMS REQUIREMENTS
A REMS can contain any one element or a combination of elements listed above. The specific
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components of a REMS can vary based on several factors, including the severity of the drug’s
potential adverse effects and the population likely to use it.6
Medication Guides
A medication guide is a handout written in patient-friendly language by the manufacturer
highlighting important safety or efficacy information about a drug product. These are not the
same as Consumer Medication Information sheet (CMIs) which provide general information
about all aspects of a prescription drug. Unlike CMIs, which are written by organizations or
the private sector without review by the FDA, medication guides are written specifically for a
drug product by its drug manufacturer. Since each medication guide is approved by the FDA,
they are not interchangeable. Substitution of one manufacturer’s medication guide for
another is discouraged, even though the content for a generic drug may be similar to that of its
brand name equivalent.
Medication guides may be related to safety, addressing potentially serious risks patients
should be aware of prior to taking the drug or they can be about efficacy, where patient
adherence to directions for use is important to a drug’s effectiveness. The FDA determines
whether or not a medication guide is required. Although close to 300 drug products have
medication guides, only a small portion are part of a REMS. Typically, medication guides that
are part of a REMS include an Element to Assure Safe Use (ETASU), which often have more
stringent requirements.
If required, medication guides must be dispensed with every new prescription and with each
refill. They do not, however, have to be given to patients in an inpatient setting (eg. hospital,
nursing home) since the medication is being administered by a healthcare professional. The
only exception is if the patient requests one or if the medication guide is part of a REMS that
requires distribution to inpatients. In other settings where medications are dispensed to a
healthcare professional for administration to a patient, medication guides are only required
when the patient is receiving the medication for the first time or if the medication guide has
been updated with new information. Examples of such settings include dialysis centers,
physician offices, chemotherapy infusion clinics, home health care, etc.7
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Setting

Inpatient

Outpatient
when drug
dispensed to
healthcare
professional
for
administration
to patient

Patient or
Patient’s
Agent
Requests
Medication
Guide

Medication
Guide
Provided
Each Time
Drug
Dispensed

Medication
Guide
Provided at
Time of First
Dispensing

Must provide
medication
guide

FDA intends
to exercise
enforcement
discretion;
Medication
guide need
not be
provided

FDA intends
to exercise
enforcement
discretion;
Medication
guide need
not be
provided

FDA intends
to exercise
enforcement
discretion;
Medication
guide need
not be
provided

Must provide
medication
guide as
specified in
REMS

Must provide
medication
guide

FDA intends
to exercise
enforcement
discretion;
Medication
guide need
not be
provided

Must provide
medication
guide

Must
provide
medication
guide

Must provide
medication
guide as
specified in
REMS

Must provide
medication
guide

Must
provide
medication
guide

Must provide
medication
guide as
specified in
REMS

(e.g., clinic, infusion
center, emergency
department,
outpatient surgery)

Outpatient
when drug
dispensed
directly to
caregiver
(e.g., retail

pharmacy,
hospital
ambulatory
pharmacy,
patient samples

Drug is
Subject to an
ETASU REMS
that includes
Specific
Requirements
for Providing
and Reviewing
a Medication
Guide

Medication
Guide
Provided
when
Medication
Guide
Materially
Changed

Must provide
medication
guide

Must provide
medication
guide

Table 11-1. Medication guide enforcement discretion policy7
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Communication Plan
While a medication guide educates patients, a communication plan is a REMS element that
informs healthcare professionals about the safe and effective use of a drug product.
Manufacturers use communication plans to inform health care providers about the risks of a
drug. They are also used to educate them about REMS elements, such as the use of periodic
laboratory tests for medical monitoring, and encourage implementation. Communication
plans typically involve sending “Dear Healthcare Professional” letters. These are sent
directly to the health care provider, disseminated through professional organizations, or
distributed to specific practice settings. Communication Plans may also include training
materials or presentations. Health care providers are then supposed to use the information to
promote appropriate use of the drug and reinforce patient compliance.
The antidiabetic agent liraglutide (Saxenda®) is an example of a medication with a
Communication Plan.5 This REMS is required so that healthcare professionals are aware of
liraglutide’s increased risk of thyroid carcinoma and acute pancreatitis.8 The manufacturer’s
Communication Plan for this drug includes a Dear Healthcare Professional letter, web-based
information, and dissemination of a letter to professional organizations.
Elements to Assure Safe Use
The most complicated and extensive component of a REMS is the Element to Assure Safe Use
(ETASU). As defined by the FDA, they are “strictly controlled systems or requirements put
into place to enforce the appropriate use of a drug.”6 Drugs with ETASUs can be considered
potentially harmful if not used appropriately. Therefore, this REMS element allows patients
to have access to drugs known to have serious risk that would otherwise not be available.
Every ETASU is different. Medications with an ETASU may require that prescribers have
specific training, experience, or be certified before being able to prescribe that drug.9 Other
ETASUs may require special laboratory monitoring and/or enrollment of patients in a drug
registry. Still other ETASU may only allow the medication to be dispensed by a specialty
pharmacy or dispensed to patients in certain healthcare settings, such as a hospital.
One example of a medication with an ETASU is Aveed® (testosterone undecanoate).5 This
injectable product is used to treat adult males with low testosterone levels. The REMS
requires that it be administered by a trained healthcare professional in a doctor’s office, clinic,
or hospital with on-site access to equipment because of its significant safety risks. Aveed® has
the potential to cause anaphylaxis as well as pulmonary oil microembolism (POME), which is
a serious lung condition that occurs when tiny droplets of castor oil contained in Aveed®
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travel to the lungs.10 Since anyone can experience these adverse reactions with any treatment,
the ETASU requires that patients stay in the healthcare setting at least 30 minutes after
receiving the injection for observation. Additionally, the REMS requires that both the
prescriber and healthcare setting complete the REMS certification with an assessment of
knowledge before being able to prescribe or administer the drug. The education program
includes training on the proper administration of Aveed®, information on patient counseling,
and understanding of how to manage POME and anaphylaxis.11 Patients must also be aware
of the potential side effects and agree to receive the drug, despite its significant risks.
Implementation System
All ETASU include an Implementation Plan. This REMS element tells the FDA how the
manufacturer plans to monitor patients, practitioners, and healthcare settings to ensure they
are being compliant with the ETASU. It is also a way for the manufacturer to evaluate their
REMS program and make improvements, if necessary.
For example, the Implementation System for Aveed® spells out exactly how the manufacturer
will “…maintain, monitor, and evaluate” the REMS to ensure it’s meeting the program’s goals.
It includes items such as maintaining a database of all certified healthcare providers,
maintaining an informational call center and website, as well as completing an audit of
certified healthcare settings. It also includes a timetable for when the manufacturer will
submit assessments of the REMS to the FDA.12
Timetable for Submission of Assessments
Assessments are also technically considered a REMS element. They are used to evaluate the
effectiveness of a particular REMS. For example, healthcare professionals can be surveyed
regarding their understanding of the safe use of a drug. Prescriber compliance with REMS
certifications is another assessment tool. Data can also be collected on patient use of a
particular drug. Depending on the results, REMS can be modified if the assessment shows
changes are needed. REMS can even be eliminated if it has been shown that the REMS was
successful at meetings its goals.6
SHARED SYSTEM REMS
As of July 2017, there are 70 approved REMS.5 With so many REMS and each one unique to a
particular drug’s manufacturer, it has been very cumbersome for healthcare professionals to
comply, especially for drugs with an ETASU. It is time consuming for a physician to make sure
he/she has completed the required training before writing a prescription or for a pharmacist
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to verify a patient’s labs in a registry before dispensing a medication, for example. To
minimize the workload and burden on healthcare systems, the FDA has been moving towards
the development of standardized REMS. For some identical or closely related drugs (ie. drugs
within the same therapeutic class), the FDA has mandated drug companies to develop a
single, shared system REMS. Once such example is isotretinoin’s iPLEDGE program.13
Isotretinoin is a drug used for the treatment of severe acne. Studies have shown a 15-20 week
course of therapy to be effective at improving nodular acne. However, isotretinoin is
teratogenic and serious birth defects, spontaneous abortion, and premature births have been
reported.14 Therefore, the REMS for isotretinoin informs prescribers, pharmacists, and
patients about the drug’s serious safety risks and safe-use conditions with the goal of
preventing fetal exposure to isotretinoin. In the past, every manufacturer of isotretinoin,
brand and generic, had their own REMS each with different ETASU. This made prescribing
and dispensing isotretinoin extremely challenging and frustrating. To consolidate and
simplify the process, the FDA requested that all the manufacturers of isotretinoin products
work together to create one standardized REMS. This single, shared system REMS, called
iPLEDGE, includes a medication guide, ETASU, and implementation plan.14
Prescribers, pharmacies, patients, and wholesalers must all be registered with the iPLEDGE
program.14 It is a computer-based program that tracks and verifies the critical elements of the
program. Prior to receiving the medication, females must commit to 2 simultaneous forms of
birth control. They must also complete Patient Monthly Comprehension Questions and a
pregnancy test before each prescription.15 Physicians then enter the results of the pregnancy
test and the patient’s forms of contraception into iPLEDGE. The pharmacist must obtain
verification from iPLEDGE before given authorization to dispense isotretinoin to the patient.
Since patients are required to meet these same criteria every month, refills are not allowed
and only a 30 day supply can be dispensed.15
REMS FOR OPIOID PRODUCTS
There are several other single, shared system REMS including a number of class-wide
programs for opioid agents. Not only were these designed to streamline the REMS process,
but the opioid REMS are part of a larger, federal initiative aimed at reducing prescription drug
abuse, misuse, and overdose. Extended-release and long-acting (ER/LA) opioid products
were identified as a subset of opioids at high risk of abuse and misuse, while simultaneously
having a high volume of use. The misuse and abuse of this potent class of drugs led to a
significant health crisis of addiction, overdose, and death. According to the CDC, 40 people
die every day from prescription painkiller abuse. As a result, a class-wide REMS was
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introduced for all ER/LA opioid products and their generic equivalents.16
The purpose of the ER/LA Opioid Analgesics REMS is to reduce risks while maintaining
patient access.17 This potent class of drugs is intended to manage chronic pain and serious
medical conditions, so it’s important that these products continue to be available for patients
with these conditions. Unfortunately, they often lead to improper use and then abuse. One in
20 individuals age 12 and older admit to taking prescription opioids for non-medical use.18 It
is thought that prescribers are contributing to this abuse and misuse epidemic, as the number
of painkillers prescribed over the past 15 years has quadrupled.19 As a result, prescriber
education and patient awareness are the main components of the ER/LA Opioid REMS.
Currently, prescribers are not required to complete the training associated with ER/LA
Opioid REMS; however, it is “strongly encouraged”.20 In addition to educating prescribers on
proper pain management and patient selection, the REMS education program includes
patient counseling tips. Patients should be aware of opioids’ addiction potential, informed on
the proper disposal of expired or unused medications, and the need to lock them away when
not being used.21

151

REFERENCES
1. About the center for Drug Evaluation and Research. US Food and Drug
Administration website. https://perma.cc/8E2S-EYVK Accessed May 29, 2018.
2. Risk Evaluation and Mitigation Strategy (REMS) Update: Purpose and Legal
Obligations. CE Online: Pharmacist’s Letter. January 31, 2014. Therapeutic Research
Center, Stockton CA. Pharm Letter 2014
3. Food and Drug Administration. Guidance for industry: development and use of risk
minimization action plans.
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/ucm071616.pdf Published March 2005. Accessed June 1, 2016.
4. Nelson LS, Loh M, Perrone J. Assuring safety of inherently unsafe medications: the
FDA risk evaluation and mitigation strategies. J Med Toxicol. 2014; 10:165-172.
https://doi.org/:10.1007/s13181-013-0374-z
5. Approved Risk Evaluation and Mitigation Strategies. US Food and Drug
Administration website: https://perma.cc/3WXB-CV63 Accessed: May 28, 2018.
6. U.S. Food and Drug Administration. A brief overview of Risk Evaluation &
Mitigation Strategies (REMS). FDA website. https://perma.cc/K3BP-KEG2
Accessed May 29, 2018.
7. Food and Drug Administration. Guidance for industry: medication guides –
distribution requirements & inclusion in REMS. https://perma.cc/HJG7-G5NA
Published November 2011. Accessed May 29, 2018.
8. Victoza REMS Program. https://perma.cc/362F-2BLN Accessed May 29, 2018.
9. Shane R. Risk evaluation and mitigation strategies: Impact on patients, health care
providers, and health systems. Am J Health-Syst Pharm. 2009; 66(Suppl 7):S3-5.
https://doi.org/:10.2146/ajhp090461.
10. Endo Pharmaceuticals. What you need to know about Aveed™ treatment: a patient
guide. https://perma.cc/F3B3-QUNN Published February 2014. Accessed May 29,
2018.
11. Aveed™ REMS Program. https://perma.cc/WN4A-XWMW Accessed June 1, 2016.
12. Endo Pharmaceuticals Solutions Inc. Aveed Risk Evaluation and Mitigation Strategy
(REMS).
https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDet
ails.page&REMS=313 Published March 2014. Accessed June 1, 2016.
13. What are isotretinoin iPLEDGE products? Food and Drug Administration website.
https://perma.cc/69NQ-GJY7 Accessed May 28, 2018.
14. The pharmacist guide for the iPLEDGE program. https://perma.cc/25ME-EGVK
Updated February 2016. Accessed May 28, 2018.
15. iPLEDGE Committed to Pregnancy Prevention https://perma.cc/FDP4-GFTA
Accessed May 28, 2018.
16. Risk evaluation and mitigation strategy (REMS) for extended-release and longacting opioids. Food and Drug Administration website. https://perma.cc/HZX3152

6XMW Updated January 1, 2016. Accessed May 28, 2018.
17. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and
mitigation strategy (REMS) https://perma.cc/2RJ3-E4FJ Published April 2016.
Accessed May 28, 2018.
18. Substance abuse and addiction. Recovery Connection website.
https://perma.cc/WSG5-U3MA Accessed May 28, 2018.
19. Mortality data. Center for Disease Control’s National Center for Health Statistics
website. https://perma.cc/8SH4-U5XM Updated February 16, 2016. Accessed May
28, 2018.
20. The extended-release and long-acting opioid analgesics risk evaluation and
mitigation strategy. https://perma.cc/P7QE-GQTR Updated June 15, 2016.
Accessed May 28, 2018.
21. Patient counseling document on extended-release/long-acting opioid analgesics.
https://perma.cc/DH28-QJMH Accessed May 28, 2018.

153

CHAPTER 12
HOUSEHOLD DISPOSAL OF PRESCRIPTION
DRUGS
Author: Annette McFarland, PharmD
The amount of unused, unwanted, and expired medications is a growing problem that is
significantly impacting our healthcare system. Not only is it costly, but the health and safety
of patients and our environment is being affected. One recent study found that approximately
2 out of 3 prescription medications per household were unused.1 The most common reason
cited by study participants was discontinuing use because of improvement in their medical
condition and/or symptoms. Other reasons included side effects, expiration, felt it wasn’t
helping, felt they no longer needed to take it, or forgot to take it. Noncompliance is a major
contributing factor to the volume of unused/unwanted medications and it is costing the
United States about $100 billion per year in extra medical costs.2 According to a 2010 bulletin
published by the World Health Organization, only about half of the population takes their
medications correctly. Additionally, more than half of prescriptions are prescribed,
dispensed, or sold inappropriately, further contributing to household possession of excess
medications.3
Medications left unused in the home pose potential safety concerns. For example, if an
elderly patient has multiple medication bottles in their medicine cabinet they are at a greater
risk for inadvertently taking the wrong drug or duplicating therapy.4,5 Accidental ingestion is
also a concern.5 There have been over 30 reports received by the FDA of accidental exposure
to fentanyl patches, a potent opioid analgesic. Most of these involved small children less than
2 years old that resulted in hospitalization or death.6 Drug overdose is another safety concern;
it’s the leading cause of death by injury according to the CDC.7 Having excess medications
laying around the home also leads to diversion.5 When a national survey asked nonmedical
users of opioids where they obtained their drugs, more than 50% said a family member or
friend gave it to them, over 10% bought them from family or friends, and about 5% just took
them.4 Therefore, properly disposing of unused, expired, and unwanted medications is
important to help minimize the risk of accidental exposure, intentional misuse, or diversion.
Studies have found that consumers don’t always know how to dispose of medications
properly, nor do they remember receiving education on proper storage and disposal.1,8 The
majority either throw them away in the trash or use the toilet or sink for disposal.7 Such
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practices have been questioned in terms of their safety and appropriateness.9 Disposing of
medications via sink or toilet has a negative impact on rivers, streams, and supplies of
drinking water. A US Geological Survey that studied water in Minnesota found organic
contaminants in 90% of the samples tested, most of which were prescription and
nonprescription medications.10 Although not at therapeutic levels, active therapeutic
ingredients in water could be dangerous not only to humans but to wildlife as well.11 Disposing
of unwanted medications in the trash has its own set of concerns. Throwing away
prescription bottles with personal, patient information on the label can lead to identity theft.
It can also be a source of accidental exposure by children and animals or contribute to drug
diversion.
Various organizations have developed programs or guidelines on the proper disposal of
medications, including the Office of National Drug Control Policy in conjunction with the
Food and Drug Administration (FDA). These federal guidelines suggest:12
● taking advantage of pharmaceutical take-back programs in the community
● using appropriate safeguards when throwing away medications in the trash
● flushing drugs down the toilet or drain ONLY if advised by the FDA and/or instructed
by printed material accompanying the medication
COLLECTION PROGRAMS
Drug take-back programs are the preferred method for disposing medications.4,5,12 These
programs allow consumers to bring their unwanted and expired medications to a central
location for proper disposal. Collection events are designed to ensure that unused, expired, or
unwanted medications are collected anonymously and destroyed in a way that is safe, legal,
and environmentally sound.
There are various types of take-back programs available, ranging from small, one-day events
to on-going collection sites. City, county, and state sponsored take-back programs are
available. One such event is the National Prescription Take-Back Event hosted by the Drug
Enforcement Administration (DEA) twice a year, once in the spring and again in the fall.13
These events have been extremely successful. In April of 2017, the DEA, along with more than
4,000 state and local law enforcement partners, held its 13th Take-Back event which collected
over 900,000 pounds of unwanted medications across 50 states.14 The DEA’s take-back
events began in 2010 with the passing of the Secure and Responsible Drug Disposal Act which
was intended to help address the growing prescription drug abuse epidemic. According to a
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recent National Survey on Drug Use and Health, 6.5 million Americans abuse prescription
drugs.15 As mentioned previously, the majority of abused drugs are obtained from family and
friends. Therefore, it’s extremely important to get rid of unwanted, unused medications. In
the past, however, only law enforcement officials were allowed to take-back and inventory
controlled substances at collection events. This act gave the DEA authority to expand ways in
which the general public can dispose of medications, including controlled substance
prescriptions, safely and conveniently.
In October of 2014, the DEA’s revisions to the Controlled Substance Act were implemented.
The Disposal of Controlled Substances Rule now allows authorized collectors to accept
unwanted, unused, or expired prescription medications, including controlled substances, by
providing collection receptacles and/or mail-back programs.16 Medications can only be
placed in the receptacles or mailed by ultimate users which is defined as “a person who has
lawfully obtained, and who possesses, a controlled substance for his own use or for the use of
a member of his household.”17 Pharmacy staff are not allowed to do it on their behalf. So who
is considered an authorized collector? Facilities, such as retail pharmacies, hospitals and
clinics with on-site pharmacies, narcotic treatment programs, long-term care facilities with
pharmacies, manufacturers and distributors can volunteer to become an authorized collector
simply by modifying their DEA registration. Many law enforcement or police stations are
authorized collection sites as well.
Facilities that choose to have collection receptacles must follow certain requirements.
Receptacles must:16
● have tamper-evident, waterproof, tear-resistant inner liners
● be securely fastened to a permanent structure so that it cannot be removed
● be placed in a location that is not only be accessible to the public but where employees
are present
Pharmacies that choose to offer mail-back programs can sell or provide at no cost prepaid,
pre-addressed mail-back packages. Packages must:16
● be nondescript, water- and spill-proof, tamper-evident, tear-resistant, and sealable
● include a unique identifier that can be tracked
● sent to authorized collectors that destroy medications on-site
Information about take-back programs in your area can be obtained by contacting local waste
management agencies. Online resources, such as Dispose My Meds, DEA’s Office of
Diversion Control, US Environmental Protection Agency, and Recycle Indiana – Unwanted
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Medicine, are also helpful for locating pharmacies and authorized collection sites with
options for safe disposal of unwanted, unused, and expired medications.
HOUSEHOLD DISPOSAL
In the event that a take-back program or authorized collector is not available, most
medications can be disposed of in the household trash. Several agencies, including the FDA,
DEA, and EPA recommend the following steps for properly disposing of unwanted, expired,
and unused medications:5,18
1. Take drugs out of their original containers.
2. Mix the medications with a substance that is unpalatable and undesirable, such as dirt,
kitty litter, or used coffee grounds.
3. Place the mixture into a disposable container, such as a sealable bag.
4. Throw the sealed container away in the household trash.
5. Remove, cover with permanent marker, or scratch out all personal information on the
prescription label of the empty pill bottles and medicine packages to make it
unreadable before placing them in the trash.
FLUSHING
Not all medications should be thrown away in the trash if a take-back event or collection
receptacle is not available. The FDA recommends disposing of certain medications by
flushing them down the toilet or sink. There is a small list of medications that are considered
life-threatening if taken by someone other than the person for whom it’s intended.17,18 These
drugs are mostly high-potency opioid analgesics and other controlled substances that are not
only dangerous if accidentally ingested by a child or pet, but are more likely to be associated
with drug diversion and misuse. Examples include fentanyl, morphine, and oxycodone. The
most complete and up-to-date list of medications recommended for disposal by flushing can
be found on the FDA’s webpage on Disposal of Unused Medication.18
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VALUE
In the perspective of access, cost and quality, value is the balance of quality with cost. In other
words, value equals quality divided by cost. Access is assumed to remain constant for this
determination because without continued access there can be no value. Value can be
increased either by increasing the quality or decreasing the cost. In order to determine value
we must be able to measure quality.
As discussed in Section 3, health outcomes are one way to measure quality for healthcare
providers. Patient satisfaction, time off work and quality of life may be different ways
patients measure quality. Since quality can change by perspective, value changes as well. For
example, a treatment for cancer may continue to decrease the size of a tumor but the quality
of life provided during that treatment may not be worth it to the patient. In the first part of
this example, value as measured by the oncologist is determined by the decrease in tumor size
divided by the cost of the medication and any health care provider fees. In the second part of
this example, value to the patient is quality of life is divided by the cost of the medication and
any health care provider fees. There may come a point at which the patient feels the value
assessed by the health care provider, decreased size of tumor, is less than the value to them in
terms of quality of life.
Different pharmacoeconomic evaluation methods are used to measure quality and value for
patients and health care providers. Through provisions of the Affordable Care Act, the
Centers for Medicare and Medicaid Services (CMS) developed a payment option for acute
care hospitals that bill CMS for services provided to Medicare patients. This is called hospital
value-based purchasing.1-3
Value-based purchasing rewards hospitals based on the quality of care they provide to
patients, how closely recommended guidelines are followed and the extent patients are
satisfied with their hospital experiences.1 Previously hospitals were paid by Original
Medicare on a fee for service basis as explained in Section 1, Chapter 1. This means they were
paid for the quantity of services they provided (paid for each service provided). The
movement away from quantity and towards value pays hospitals on the quality of the care
they provide and the value they provide to patients. There are many criteria in which quality
and value are measured which is beyond the scope of this chapter. Hospitals can chose to
participate in these new payment models. If they do each hospital receives a score on these
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different measures. The results are compared to other hospitals and provided publically. Data
on hospitals participating in this model is provided on the CMS website.4 The score is also
used for each hospital by comparing yearly performance to a baseline score for that specific
hospital. This allows hospitals to demonstrate improvement.
The incentive for participating in the value-based program is initially financial. At the start
of this initiative CMS reduced the payments to hospitals for the care they provided to
Medicare patients. The score is then used to redistribute the money back to those hospitals
with the highest score. Therefore, the hospitals that do well receive more payment for
services than those who do not score well. An added benefit for those hospitals that don’t just
score well but who make a noticeable improvement from a patient perspective is that those
patients may refer other patients to that facility. Increasing the revenue for that hospital.
Since different patients and communities may view improvement differently, health systems
may need to consider the communities they serve. Physician practices have a similar program
to the acute care hospital value-based purchasing program. This program, currently referred
to as the Quality Payment Program (QPP), provides incentives for physicians and clinics to
be rewarded for quality and value to patients.5
While healthcare providers have always been focused on caring for individual patients, value
based changes have the potential to change how care is delivered to all the patient served in a
specific office or hospital. One example of value is electronic prescribing. Electronic
prescribing allows pharmacists to receive prescriptions quicker and often more legibly than
before. This improves health outcomes. Patients receive value because the prescription can
be sent to the pharmacy before the patient leaves the clinic and the prescription is more likely
to be ready when they get to the pharmacy. Despite the work involved in purchasing and
learning new computer software, the subsequent value associated with this change has
changed how pharmacy services are provided. Looking back at our earlier example, if all
practitioners changed how they viewed value for cancer therapies it might change how we
approach cancer therapy especially in end of life decisions. Therefore, value based changes
made by multiple offices or hospitals can lead to changes for an entire population of people.
POPULATION HEALTH
The education of healthcare providers is focused on preparing providers to serve the needs of
individual patients. However, sometimes the needs of one patient may be applied to multiple
patients within an institution or practice. If this need impacts the community as a whole, a
public health concern might arise. This is especially important if the condition impacts
others either because it can be easily transmitted to others or it uses significant financial
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resources. The connection between public health and healthcare delivery is hundreds of
years old.6 Initially, focused on communicable diseases, public health means so much more
today and is sometimes referred to as population health. However, population health usually
relates to large efforts by an institution such as a health systems or health care payer whereas
public health is more general. As mentioned above, as quality and value are improved for
patients, facilities, and communities, the impact continue to expand to new populations.
These initiatives and innovations can impact a single state or in the case of the value-based
program the entire United States population.
While the value-based program is one example of a population-based initiative, many
different population-based local, state, and federal initiatives are taking place. The use of
healthcare information technology is one source of information for population health
initiatives. This includes patient care electronic medical records, insurance based electronic
claims transmissions, and pharmaceutical and device company data collection. The analysis
and use of these large databases of information are often referred to as data analytics. For
example, data collected primarily from health insurance claims allows payers for health care
to determine how best to spend their money.
Expanding the view of healthcare beyond the patient-provider relationship, expands our
discussion of value. Payers must consider value for the health care they purchase. Medicare
was the payer in the value-based program mentioned earlier but state Medicaid programs and
private insurance companies are also interested in establishing payment based on value. As
more payers seek value, healthcare providers will need to continue to justify value in their
daily operations. This perspective can be applied to pharmacy practice as well.
Brian is a 55 year old patient with multiple sclerosis. Because of his condition, he requires a
high cost injectable medication that has side effects. Brian gets this medication from
specialty pharmacy X. His medication is paid for by insurance company Y. The medication is
made by pharmaceutical manufacturer Z. Because of the high cost of the medication, the
value of paying for this medication has to be determined by insurance company Y. If the
medication keeps Brian, and others like him, from incurring other medical expenses, there is
likely a value for insurance company Y to pay for Brian’s medication, as long as the cost does
not outweigh the benefit. The insurance company however does have to consider that the
more medications it covers, even if they all add value to their patients. This means it will add
cost to the plan which will likely result in increased premiums or co-insurance rates for all
patients being served by that insurance company. All the patients served by that insurance
company would be the “population” served by their insurance company.
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Pharmaceutical manufacturer Z has to be able to demonstrate that value, determined by the
payer, to justify the price they place on their medication. This could change the strategy of
pharmaceutical manufacturer Z; not only do they need to show that their medication is
effective but they need to show that the medication produces appropriate value. Assuming
that manufacturer Z is able to demonstrate value to insurance company Y, then the patient
will be able to order the medication from the specialty pharmacy X.
When Brian begins treatment and obtains the medication from the specialty pharmacy,
specialty pharmacy X must demonstrate that they are providing Brian the medication in a
timely manner, without interruption, and that they are supporting Brian through his
treatment, such as answering questions and addressing side effects. The reason that the
specialty pharmacy needs to demonstrate this is because the payer and the manufacturer
have a role in determining which specialty pharmacy will supply the medication to the
patient. If the specialty pharmacy wants to maintain that business, they need to demonstrate
their value to the payer and manufacturer.
If the patient is not adherent or successful on the medication due to preventable causes, such
as delay in receiving treatment or misjudging a potential side effect, the money that has
already been spent on that medication was wasted. This wasted money reduces the amount
of money available to be spent on other patients in the population of that insurance company.
In the case of wasted dollars, money for no value.
ADVOCACY, PUBLIC POLICY, POPULATION HEALTH AND VALUE
Every day that pharmacists care for patients, they advocate for their success. This may
include discussing a medication change with the prescriber based on a new study, negotiating
coverage with the insurance carrier based on patient experience, or providing advice on
proper medication disposal. The development of policies for a practice site may include
establishing guidelines for antibiotic use or setting prescribing guidelines for a new
formulary agent. When, these policies extend beyond individual advocacy they serve as
advocacy of the site population. When multiple advocates seek for higher level population
changes, such in the form of laws or regulations, this is referred to as public policy.
Public policy development involves the creation of laws and regulations as well as identifying
the necessary budgets and resources necessary to make them a reality.7 For example, Section
1: Chapter 3 discusses the growth in ambulatory care, the need for provider status and the
importance of billing for services. Different legislation and regulation is needed at the federal
and state level to support provider status to allow pharmacist to be recognized as health care
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providers who can bill for their services. Without the approval of federal funds to support
payment to pharmacists, which is based on the demonstrated value of pharmacists, the
proposed legislation would not be implemented.
The process of public policy development can be divided into three phases: 1) formulation,
which involves deciding what to focus on, 2) implementation, which involves executing the
policies, and 3) modification, which involves reviewing current policies and identifying areas
for improvement.8 At each stage different special interest groups may demonstrate a voice.
For healthcare policy, these may include employers, payers, providers, consumers, etc.
Public policy efforts initiated by volunteers or members of an association that are advocating
for themselves is often called grassroots efforts. Public policy efforts initiated by paid
individuals is called lobbying and these “lobbyists” register with the government entity they
serve. For example, state and national pharmacy associations are involved in many kinds of
advocacy and policy development. The participation of their members is considered
grassroots but they may also hire paid lobbyists to assist with the cause.
The target of public policy may be legislators or one of many government agencies that make
decisions on health policy. Locally, this may include the state department of health, board of
pharmacy, department of insurance, etc. At the federal level, regulatory agencies include the
Department of Health and Human Services (DHHS), Centers for Medicare and Medicaid
Services (CMS), Food and Drug Administration (FDA), National Institutes of Health (NIH),
Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and
Quality (AHRQ), etc. In addition to government agencies, several non-government (private)
groups are influential in setting health care policy. These include the Institute of Medicine
(IOM), The Joint Commission (JTC) and the American Medical Association (AMA).7
Policy decisions are often supported by data collected by individuals who do health services
research. These researchers examine the influence that pharmacists and other health care
providers have on patients and the health care system. This is a robust field in the current
environment of frequent health care reform.8
CONCLUSION
The authors of this text expect that many changes will continue to happen with healthcare
reform in the United States over the next several years. While the authors cannot predict
these changes, the fundamentals of health care reform presented in this book are likely to
remain: the focus on access, cost, and quality. And specifically, the renewed focus of value will
continue to evolve the health of patients and populations.
164

REFERENCES
1. Hospital Value-Based Purchasing. Department of Health and Human Services.
Centers for Medicare and Medicaid Services. CMS website. https://perma.cc/TYC3U627 . Published September 2015. Accessed May 28, 2018.
2. McLaughlin D. Productivity and Quality. In. Responding to Healthcare Reform.
Chicago, IL: Health Administration Press; 2011: p27-8.
3. Joshi MS, Ransom ER, Nash DB, Ransom SB. Organizational quality infrastructure.
In. The Healthcare Quality Book: Vision, Strategy, and Tools. 3rd ed. Chicago,IL:
Health Administration Press; 2014:p525.
4. Hospital Compare. Centers for Medicare and Medicaid Services. CMS website.
https://perma.cc/29B8-WHAQ . Publishes October 19, 2016. Accessed May 28, 2018.
5. Quality Payment Program. Centers for Medicare and Medicaid Services. CMS
website. https://perma.cc/F5P9-TRDG Accessed May 28, 2018.
6. Hanson A, Hurd P, Levin B. Public Health. In: Plake, Schafermeyer, McCarthy eds.
Introduction to Health Care Delivery: A Primer for Pharmacists. 6th ed. Burlington,
MA: Jones and Bartlett Learning; 2017: p160-1.
7. Askin E, Moore N. Policy and Reform. In: The Health Care Handbook. 2nd ed. St.
Louis, MO: Washington University Press; 2014: p139-140.
8. Begley C, Lairson D, Morgan R, et.al. Applying Health Services Research in Policy
Analysis. IN: Evaluating the Healthcare System. 4th ed. Chicago, IL; 2013: p200

165

